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5Je zal maar dertien zijn en weten dat je alles wat gezonde leeftijdsgenoten kunnen niet kunt, 
zoals fietsen, voetballen, rennen en met vrienden buiten spelen. 
Altijd hulp moeten vragen, als je bv iets wilt lezen, als je uit bed wilt en je wilt aankleden, 
maar je moet toch wachten op hulp, want alleen kun je het niet. 
Dat er altijd mensen zijn die je niet goed kunnen verstaan en niet de tijd voor je nemen om 
je wel te verstaan en je daarom erg kinderlijk behandelen en denken dat je dom bent. 
Je zal maar dertien zijn en later ook motor willen rijden en weten dat je dat NOOIT zal kunnen. 
Zo zijn er tal van dagelijkse handelingen, die voor ons ZO normaal zijn maar voor 
deze kinderen steeds weer een dagelijkse vermoeiende strijd is. 
Je zal maar dertien zijn en voelen dat je steeds minder kan en weten dat je vroeger 
veel van het voorafgaande wel kon
© Frans van Meir
Augustus 2008
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GENERAL INTRODUCTION AND AIMS OF THE STUDy
1General introduction and aims of the study
Ataxia-telangiectasia (A-T) is a rare complex autosomal recessive multisystem disorder 
occurring worldwide. The condition was recognized as a separate disease entity in 1957.1 The 
disorder is characterized by progressive, ultimately severe neurodegeneration, primarily of the 
cerebellum, and by oculocutaneous telangiectasia (Figure 1). The first symptom is usually ataxic 
gait, which is most often noted when the child begins to walk. Early in childhood the majority 
of patients also show extrapyramidal signs, i.e. choreoathetosis, dystonia and myoclonic jerks. 
Generally, the patient becomes wheelchair-bound around the age of ten. Non-neurological 
disease characteristics include immunodeficiency, affecting both cellular and humoral immune 
responses, respiratory failure, growth retardation in the second decade of life, diabetes mellitus 
type 2 in young adulthood, and an increased risk of malignancies. Laboratory hallmarks of A-T 
are chromosomal instability and radiosensitivity, and an elevated level of serum α-fetoprotein. 
Most patients die in the second or third decade of life due to progressive respiratory failure or 
malignancies.1 
To date, more than 400 different mutations have been described along the entire coding 
sequence of the responsible A-T mutated (ATM) gene (Leiden Open Variation Database). The 
encoded ATM protein is involved in cell cycle control and DNA repair. Unfortunately, there is no 
curative therapy for this severe and relentless disease.
Background to the study
During recent decades it has become increasingly clear that some A-T patients present with less 
severe neurological features and at an older age.2,3 The presentation in such patients is often 
designated as “variant AT”. The exact clinical and genetic differences between these patients 
with a milder course and those with classic A-T are not clearly defined in the literature. 
A proper insight into the variety of clinical presentation is needed for the purpose of early 
diagnosis and for appropriate patient care. A better understanding of the genetic and 
phenotypic variability, their relationship and the underlying pathophysiological mechanisms 
of A-T is necessary for the development of therapeutic interventions.
Aims of the study
The aims of the present thesis were: 
O  to describe the phenotype of A-T patients with a milder case of the disease and those with 
classic A-T. Concerning the latter group, we focused particularly on the neuromuscular 
abnormalities, neurocognitive and language performance, pulmonary problems and 
granulomas,
O  to assess the genotype-phenotype relationship for the various mutations of the ATM gene. 
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Outline of the thesis
The thesis starts by focusing on the non-cerebellar neurological features of A-T. 
Chapter 2.1 deals with the neuromuscular abnormalities. We studied motor neuron disease, 
which has been observed previously in patients with variant A-T, in patients with classical A-T 
and we were able to classify the polyneuropathy in children as well as adults with classical 
A-T.
In Chapter 2.2 the neuropathological findings of two classic patients and one patient with 
variant A-T are compared, paying special attention to the anterior horn cells. 
In Chapter 2.3. we study the cognitive function of classic A-T patients, by using a specially 
adapted test battery that takes into account confounding effects present in A-T patients, such 
as speech abnormalities, oculomotor disturbances and difficulties with motor coordination. 
The prominent non-neurological features of A-T are outlined in the second part of the thesis. 
In Chapter 3.1. the clinical course and outcome of three classic A-T patients who died at the 
ICU are evaluated, and the possible pathogenesis of observed restrictive pulmonary function 
is discussed.
Figure 1: characteristic ocular telangiectasia in an A-T patient 
Telangiectasia generally develop between the age of two and eight years old. Initially, telangiectasia 
are noted bilaterally in the angles of the bulbar conjunctivae and spread horizontally. Telangiectasia 
may also appear in sun-exposed skin areas. Most often, cutaneous telangiectasia are observed on 
the butterfly area of the face, the external ear and the neck. 
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Chapter 3.2 consists of descriptions of skin granulomas in four A-T patients and a systematic 
review of the literature on skin granulomas in patients with A-T and other primary 
immunodeficiencies. The aim of the study was to find a common immunological denominator 
for these lesions. 
In the last part of the thesis we assess the genotype-phenotype relationship for A-T. 
In Chapter 4.1 the genotype and phenotype of adult patients with classical and variant A-T is 
evaluated. The principal aim of this study was to outline the variant A-T phenotype and so to 
improve clinical recognition of affected patients.
In Chapter 4.2 the clinical and laboratory data of all 51 genetically proven A-T patients who live 
or have lived in the Netherlands are described, and the phenotype, genotype, presence of ATM 
protein and the amount of ATM-kinase activity are compared.
Finally, Chapter 5 provides a general discussion on the main conclusions of this thesis and offers 
a guideline for the diagnostic evaluation and follow-up of patients with A-T.
22451_Mijke Verhagen binnenwerk.indd   13 10-07-2012   11:45:14
22451_Mijke Verhagen binnenwerk.indd   14 10-07-2012   11:45:14
Neurological abnormalities 
in Ataxia-Telangiectasia
Pa
rt
 I
22451_Mijke Verhagen binnenwerk.indd   15 10-07-2012   11:45:16
22451_Mijke Verhagen binnenwerk.indd   16 10-07-2012   11:45:16
2.1 |  Neuromuscular abnormalities 
in ataxia telangiectasia
   A clinical, electrophysiological and muscle ultrasound study
M.M.M. Verhagen1, N. van Alfen2, S. Pillen1,2, C.M.R. Weemaes1, J.L. yntema1, J.A.P. Hiel3, 
H. Ter Laak4, M. van Deuren5, A. Broeks6, M.A.A.P. Willemsen7.
Department of Pediatrics1, Clinical Neurophysiology2, Pathology4, Internal
Medicine5, and Pediatric Neurology7, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands.
Department of Neurology3, Máxima Medical Centre, Veldhoven, The Netherlands.
Department of Experimental Therapy6, The Netherlands Cancer Institute,
Amsterdam, The Netherlands.
Neuropediatrics. 2007;38(3):117-121.
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CHAPTER 2.1
Abstract
Thirteen classical ataxia telangiectasia (A-T) patients, varying in age from 1 to 25 years, 
were studied clinically, electrophysiologically as well as by muscle ultrasound to chart the 
development and spectrum of neuromuscular abnormalities in A-T. The most prominent finding 
was a progressive axonal sensorimotor polyneuropathy, apparent by electromyography and 
muscle ultrasound from the age of 8 years and becoming clinically discernible around 12 years 
of age. Before the age of 8 years decreased tendon reflexes and slightly slowed sensory nerve 
conduction velocities could already be observed. With routine electrophysiological techniques 
the severe polyneuropathy precludes conclusions about the presence of anterior horn cell loss 
in older patients.
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Introduction
Ataxia telangiectasia (A-T) or Louis-Bar syndrome is an autosomal recessive multisystem 
disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, 
increased serum α-fetoprotein, variable immunodeficiency, chromosomal instability, and 
radiation hypersensitivity.12,13 The responsible gene, ATM, is located on chromosome 11q22-23 
and is involved in cell cycle control and DNA repair.
The clinical picture of A-T is dominated by neurological abnormalities. Children appear 
healthy at birth, but when they begin to walk, instability of gait due to cerebellar ataxia is 
noticed. Besides cerebellar ataxia, other neurological features such as oculomotor apraxia, 
choreoathetosis and dystonia, as well as neuromuscular features gradually become apparent 
in A-T. Due to slow but relentless progression of the neurological abnormalities, most patients 
are confined to a wheelchair by the age of 10 years.12,13
With regard to the neuromuscular abnormalities in A-T, both axonal polyneuropathy and 
anterior horn cell disease have been described.1, 2, 4, 5, 7, 8, 12, 15 Muscle ultrasound studies in A-T 
patients have not been reported before. With ultrasound it has been found possible to detect 
structural muscle changes, like fibrosis or fatty infiltration, caused by both neuropathies and 
myopathies, with high sensitivities and specificities.9 These changes are visible on ultrasound 
as increased muscle echo intensity.10 Especially in children, ultrasound is the technique of 
choice to visualize the muscle, as it requires no sedation or ionizing radiation.
To gain more insight in nature and evolution of neuromuscular system involvement in A-T we 
evaluated the clinical, electrophysiological and ultrasonographic findings in 13 patients with 
ages from infancy into adulthood.
Methods
Subjects. Thirteen A-T patients (8 male and 5 female) were studied, with ages ranging from 1 to 
25 years. Cases 1 and 3 were siblings. All patients are classical A-T patients, showing cerebellar 
ataxia, ocular telangiectasia, increased α-fetoprotein levels, and immunodeficiency. Mutation 
analysis of the ATM-gene was performed in all patients, using the methods as previously 
described.3 The patients underwent neurological evaluation at the same time when nerve 
conduction studies and electromyography (EMG) were performed. In the nine youngest 
patients ultrasound was performed. In one patient (case 10), who died at the age of 22 years, 
autopsy was performed.
Electrophysiological studies. Nerve conduction studies (NCS) were performed using Medelec 
Synergy (Oxford Instruments Medical, Old Woking, UK) equipment and software (version 10) 
and surface recording electrodes (TECA 6030 TP; Oxford Instruments Medical, Old Woking, 
UK). Recordings were performed with the standard settings (0.2 ms stimulus duration, a 1-Hz 
stimulus frequency, 3 Hz - 3 KHz frequency bandwidth, and a sensitivity of 20 μV/division) and 
according to standard techniques.6
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Age-appropriate reference values were used for interpretation.14 Before performing NCS, skin 
temperature was measured with a skin surface infrared thermometer (KM812; Comark Ltd, 
Stevenage, UK). We ensured a temperature of 30°C or higher by warming the hands and feet 
in a bath of heated water (38°C). During the NCS an infrared lamp was used to maintain the 
temperature. The myogram was performed using disposable concentric needle electrodes 
(TECA; Oxford Instruments Medical, Old Woking, UK).
Ultrasound imaging. In the nine youngest patients (case 1-9) we performed ultrasonographic 
imaging of the skeletal muscles (Sonos 2000 Phased Array Imaging System; Hewlett-Packard 
Company, Andover, Massachusetts, USA). Four muscles were examined in the transverse plane: 
biceps brachii, forearm flexors, quadriceps femoris, and anterior tibialis muscle. Muscle was 
measured with electronic calipers during the examination. The mean muscle echo intensities 
(EI) were determined using a computer-assisted grey-scale analysis. The muscle thickness was 
corrected for weight and compared to normal values for children established in a previous 
study; muscle echo intensity is independent of age, weight and gender and therefore required 
no correction.11 All values were transformed into z-scores (number of standard deviations from 
normal) to make comparison between different muscles possible.
Results
Clinical studies. In all patients, the onset of the disorder was between 1 and 2 years of age. 
The presenting symptom was ataxic gait. Progressive neurological features were observed in 
all patients, and the clinical picture was variably complicated by mild to severe oculomotor 
apraxia, chorea, dystonia, and peripheral neuropathy during the course of the disease, as 
would be expected for a series of A-T patients. By the age of 10 or 11 years the children were 
confined to a wheelchair. The four oldest patients died early in the third decade of life, and 
patients 6 and 8 died at the age of 13 years. Mutation analysis of the ATM-gene proved the 
diagnosis in 10 patients, while investigations of patient 7 (both alleles) and patients 11 and 
Table 1. Mutations in the ATM gene in patients with classical A-T
Patient  Mutation (allele 1 / allele 2)
P1  c.7875_7876delTGinsGC (homozygous)
P2  c.6082 C>T (homozygous)
P3  c.7875_7876delTGinsGC (homozygous)
P4  c.484 C>T / c.1898+2 T>G
P5 c.790_790delT / c.1563_1564delAG
P6  c.2467+1551 del 97kb (homozygous)
P7  in progress
P8  c.2921+5G>A (homozygous)
P9  c.3576 G>A (homozygous)
P10  c.1027_1030delGAAA / c.1660_1660delA
P11  c.8633T>G / in progress
P12  c.7875_7876delTGinsGC (homozygous)
P13  c.5762-2 A>T / in progress
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13 (one allele) are still in progress (Table 1). All mutations are reported in the ATM database 
(http://chromium.liacs.nl/lovd/). Neuromuscular symptoms became evident from the second 
half of the first decade of life with a decrease in tendon reflexes (Table 2). Subsequently, patients 
developed progressive muscle weakness and atrophy as well as sensory abnormalities, with a 
distal-proximal gradient, starting early in the second decade of life.
The peripheral nervous system findings of our patients are summarized in Table 2. Post mortem 
examination of the spinal cord in a female patient (case 10) who died at the age of 22 showed 
only minimal signs of anterior horn cell degeneration (data not shown).
Electrophysiological studies. All 13 patients underwent nerve conduction studies (NCS). In all 
patients, except patients 1 and 3 and patient 10 at the age of 18, needle EMG has also been 
performed. Results are shown in Table 3. NCS showed a decline of the sensory nerve amplitudes 
in the upper and the lower limbs from the age of 8 and 10 years old respectively. Sensory nerve 
amplitudes became unrecordable around the age of 12 in the lower limbs and around 14 in 
the upper limbs.
Additionally, slightly decreased sensory nerve conduction velocities of the sural nerve have 
been found in all but one patient (case 2) as early as the first year of life. This slowing remained 
stable until the sensory nerve amplitudes became unrecordable. Motor nerve conduction 
velocities were within normal ranges in all investigations. In patients over 10 years of age 
motor amplitudes started to decrease in the lower limbs. In the upper limbs the motor 
amplitudes were only slightly decreased in patients over 20 years. The first neurogenic changes 
became visible in the myogram of distal leg muscles. Severe neurogenic changes including 
denervation, spreading to the more proximal leg muscles were found from the age of 16 years. 
In patients over 20 years neurogenic changes became visible in the myogram of distal arm 
muscles.
Table 2. Neurological findings in thirteen patients with classical A-T
Patient p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 p11 p12 p13
Sex F M M M M M M F F F M F M
Age (years) 1 3 5 8 10 12 12 12 13 18 22 21 25
 
Tendon reflexes
 biceps + + +/- - + +/- +/- +/- - - - - -
 triceps + + +/- - + +/- +/- +/- - - - - -
 patellar + + + +/- + +/- + +/- - - - - -
 achilles tendon + +/- +/- - +/- - - - - - - - -
 
sensory deficit - - - - - + - + + + + + +
 
muscle atrophy - - - - - - - + + + - + +
 
muscle weakness - - - - - - - + + + - + +
M = male; F = female
+= present; +/- = borderline or decreased; - = absent
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Ultrasound imaging. The results of ultrasound imaging of skeletal muscles of the nine youngest 
patients (aged 1 -13 years) are shown in Table 4. All patients younger than 8 years had a normal 
ultrasound. In all older patients (6 patients) increased muscle echo intensities were found 
in at least one muscle (Figure 1). More severe abnormalities were seen in patients 6 and 8, 
both 12 years of age. The leg muscles were generally more affected than the arm muscles. 
Muscle thickness was diminished in two patients, both of whom had severely increased echo 
intensities (above 4.5 SD in three or more muscles).
Figure 1. Ultrasound of the tibial anterior muscle of an age-matched control subject and an A-T 
patient
The left figure shows the normal ultrasound of the tibial anterior muscle from an age-matched 
control subject. The right figure shows the tibialis anterior muscle of patient 6. Note the increased 
muscle echointensity in the A-T patient, indicating structural changes in muscle architecture such as 
infiltration of fat and fibrosis. TA = tibial anterior muscle, T = tibia, F= fibula, arrows = subcutis.
Table 4. Muscle ultrasound imaging in 9 patients with A-T
Patient   P1 P2 P3 P4 P5 P6 P7 P8 P9
Age (yrs)   1 3 5 8 10 12 12 12 13
Muscle Thickness biceps brachii -0,8 1,7 0 0,2 -1,2 -1,5 -1,8 -3,2 -0,3
  flexors forearm -0,1 1,3 -0,1 1,1 -0,4 -1,2 3,1 -2,7 1,7
  quadriceps -1,9 -1,4 0,2 -1,9 -1,7 -4,6 -1,6 -3,5 -0,8
  anterior tibial -0,4 -1,4 -0,1 1,3 0,4 -1,3 0,7 -0,2 -0,3
     
Echo Intensity biceps brachii 0,2 -1 -0,1 0,3 1,8 1,1 1,1 6,2 -0,3
  flexors forearm -0,7 -1 0,3 -0,8 -0,1 6,1 1,2 5,9 0,4
  quadriceps -0,5 0,6 1,6 2,6 2,8 9,2 1,8 4,5 2
  anterior tibial -0,3 -0,6 0,7 0,5 2,5 6,3 3 5 0,2
Muscle thickness and echo intensity are expressed in z-scores (number of standard deviations from normal). 
Muscle atrophy was only found in 2 patients. All patients above 8 years showed increased muscle echo 
intensities, especially in the distal muscles (the biceps brachii was normal in all but one patients), indicating 
structural changes like fibrosis and fatty infiltration in these muscles.
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Discussion
In this relatively large case series comprising patients from every age group with classical A-T, the 
most prominent neuromuscular feature was a progressive axonal sensorimotor polyneuropathy. 
In patients up to 8 years only a slight decrease of tendon reflexes was noticed. Additionally, 
slightly decreased sensory nerve conduction velocities of the sural nerve were found as early 
as the first year of life. This slowing remained stable, until the sensory nerve amplitudes became 
unrecordable around the age of 12 in the lower limbs and around 14 years in the upper limbs. 
At the age of 8 years the first signs of axonal sensorimotor polyneuropathy became visible on 
EMG recordings. This was in concordance with ultrasound results, which showed increased 
muscle echo intensities indicative of fibrosis or fatty infiltration in the leg muscles in children 
over 8 years of age. Muscle weakness and atrophy was first noticed clinically at the age of 12 
years. Further clinical implications of the progressive axonal polyneuropathy in older patients 
are difficult to estimate because of the numerous other neurological abnormalities developing 
in A-T patients over time. The polyneuropathy became both clinically and electrophysiologically 
discernible around the time when the patients became wheelchair-bound. The progressive 
sensorimotor polyneuropathy precludes conclusions about the additional presence of anterior 
horn cell loss in our older patients using these ‘routine’ electrophysiological techniques. 
However we found only minimal anterior horn cell degeneration in the lumbar region in a 
single post mortem spinal cord specimen from a 22 year-old female patient (patient 10).
Muscle ultrasound is a relatively new tool to evaluate neuromuscular disorders. Quantitative 
measurement of echo intensity is a sensitive method to detect neuromuscular disorders.9 
Increased echo intensity is caused by fatty infiltration or fibrosis and not by disuse or central 
motor impairment.9 Therefore, the axonal polyneuropathy is most likely responsible for the 
ultrasound abnormalities found in these patients. Moreover, most changes were found in the 
leg muscles, rather than the biceps brachii muscle, which was in concordance with the distal-
proximal gradient that was also clinically apparent, although the ultrasound changes were 
visible before clinical muscle weakness or atrophy was present.
The presence of a polyneuropathy in A-T has been previously reported.1, 5, 7, 8, 14 The present case 
series, however, allowed following the development of this abnormality over time. Additionally, 
to our knowledge the selective but nonprogressive slowing of sensory nerve conduction 
velocities has not been reported before.
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Abstract
Ataxia telangiectasia (A-T) is classically characterized by progressive neurodegeneration, 
oculocutaneous telangiectasia, immunodeficiency and elevated α-fetoprotein levels. 
Some patients, classified as variant A-T, exhibit a milder clinical course. In the latter patients 
extrapyramidal symptoms, instead of cerebellar ataxia, tend to be the dominating feature 
and other classical disease hallmarks, like telangiectasia, appear later or even may be absent. 
Some patients with variant disease have clinically pronounced anterior horn cell degeneration. 
Neuropathological studies of genetically proven A-T patients are lacking. The aims of our study 
were to describe the neuropathology of 3 A-T patients, in two of them the diagnosis was 
genetically confirmed. The neuropathological findings were compared with those of all known 
published autopsy findings in A-T patients up to now. Two classical A-T patients of 19 and 22 
and a 33-year old patient with variant disease were autopsied. In line with previous reports, our 
patients had severe cerebellar atrophy, less pronounced degeneration of the dentate nucleus 
and inferior olive, degeneration of the posterior columns and neurogenic muscular atrophy. 
In addition, all three had anterior horn cell degeneration, which was most prominent at the 
lumbar level. Compared to the literature, the degenerative changes in the brain stem of the 
variant A-T patient were somewhat less than anticipated for his age. Degenerative changes in 
the cerebellum, and spinal cord were comparable with the literature. Progeric changes were 
lacking. In conclusion, compared to classical A-T, the variant A-T patient showed essentially 
the same, only slightly milder neuropathological abnormalities, except for more prominent 
anterior horn degeneration.
Keywords: ataxia telangiectasia, variant, spinal cord, neuropathology 
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Introduction
Ataxia telangiectasia (A-T), recognized as a separate disease entity in 1957, is a complex 
autosomal recessive multisystem disorder, with severe neurodegeneration as an important 
feature. 
Neurologic signs include cerebellar ataxia, oculomotor apraxia, extrapyramidal symptoms, 
polyneuropathy and anterior horn cell degeneration.1 Other identified disease characteristics 
are oculocutaneous telangiectasia, variable immunodeficiency, endocrine abnormalities, 
respiratory failure, predisposition to malignancies, increased serum α-fetoprotein levels, 
chromosomal translocations and radiosensitivity.1 However, since the ATM gene has been 
identified in 1995,2 it became apparent that the clinical spectrum of A-T is variable. Some 
patients with an atypical clinical course – those with slower disease progression, predominant 
extrapyramidal symptoms or later disease onset – appeared to have A-T.3,4 The milder A-T 
phenotype, now classified as variant A-T, is associated with missense mutations and splice 
site mutations leading to residual ATM-protein expression and residual ATM-kinase activity. 
The severity of the phenotype depends on the amount of residual kinase activity.4 Elevated 
α-foetoprotein (αFP) levels and cytogenetic abnormalities are excellent disease markers of 
both the classical and the variant A-T phenotype.4 
The majority of the neuropathology studies in A-T dates from the 1960-ies. Recent post mortem 
studies are sparse. More importantly, only one study was published after the discovery of the 
ATM gene,5 but autopsy results have never been described in genetically confirmed A-T cases.
To gain more insight in the neuropathology of A-T, we evaluated nervous system findings of 3 
autopsies of A-T patients: two patients with classical A-T who died at ages 19 and 22 old, while 
one patient of 33 years suffered of variant A-T. Diagnosis was genetically confirmed in one 
of the two classical A-T patients and in the variant A-T patient. In addition, we reviewed the 
literature for CNS-autopsy results of A-T patients and compared our data with those published 
in the era before identification of the genetic defect.
Patients and Methods 
Patients
The main clinical and laboratory findings of the patients are tabulated in Table 1. 
Patient 1: This boy’s early childhood psychomotor development was normal. However, 
since the age of 2 years his gait became progressively ataxic. There was IgA deficiency. 
Pneumoencephalography showed cerebellar atrophy. Electromyography and a muscle biopsy, 
at that age, were normal. 
At the age of 19 years he was found to be small, cachectic and severely dyspnoeic. Neurological 
investigation revealed cerebellar ataxia and dysarthria, distal paresis with amyotrophy, and 
dystonic posture of the hands and fingers. Deep tendon reflexes were absent. Proprioception 
was mildly affected. He died one week after presentation, in 1981 at age 19. Three sibs of the 
22451_Mijke Verhagen binnenwerk.indd   29 10-07-2012   11:45:19
30
CHAPTER 2.2
patient also suffered from A-T. Autopsy findings of one of his brothers have been published 
previously.6 
Patient 2: This girl suffered in her early childhood from recurrent upper respiratory tract infections. 
Motor development was delayed. When she started to walk at the age of 18 months, the gait was 
ataxic. Increased αFP level, humoral and cellular immunodeficiency, typical rearrangements of 
chromosomes 7/14 and radiosensitivity turned out to be present. Electrophysiological studies 
revealed severe and progressive axonal sensorimotor polyneuropathy since the age of 14.7 At 
age 16, a B-cell non-Hodgkin lymphoma was diagnosed in the epipharynx. Treatment with 
vincristine, methotrexate, doxorubicine and prednisone in mitigated dosages, resulted in 
complete remission. However, since that time B-cell lymphopenia and agammaglobulinaemia 
persisted, necessitating gammaglobulin substitution. In addition, a deterioration of 
neurological functions was seen after chemotherapy. She developed pedes equines, claw 
Table 1. Clinical and laboratory findings in 3 A-T patients
 Patient Pt 1 Pt 2 Pt 3
gender  M F M
phenotype classical classical variant
genotype NA c.1027_1031del5/  c.7838_7839dupGA/
  c.1660delA c.8494C>T
died at age (yrs) 19 22 33
cause of death respiratory failure intractable urinary tract bronchopneumonia/
  bleeding/respiratory  hepatocellular
  failure carcinoma
Disease onset 
presenting symptom cerebellar ataxia cerebellar ataxia cerebellar ataxia and
    myoclonic jerks
since the age of (yrs) 2 1.5 6
Wheelchair-bound since the age of (yrs) NA 10 18
Extrapyramidal symptoms + + +
Oculomotor apraxia NA + -
Neuromuscular symptoms 
weakness + + +
atrophy + + +
sensory deficit + + +
absent deep reflexes + + +
Non-neurological features 
ocular telangiectasia since the age of (yrs) 6 7 -
malignancy - + +
Laboratory findings 
increased α-foetoprotein level NA + +
immunodeficiency + + -
chromosomal instability NA + +
radiosensitivity NA + +
NA = data not available; + = present; - = absent
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position of the hands, contractures of both knees and hips, severe muscle weakness and 
atrophy, while the choreiform movements of her limbs and head became worse. Pulmonary 
function tests revealed a severe and progressive restrictive pulmonary function from the age 
of 17 years onwards. She developed diabetes mellitus type 2. She died in 2005, at age 23 of an 
intractable urinary tract hemorrhage and respiratory failure.
Patient 3: Part of the medical history of this boy was published previously.8 His psychomotor 
development was normal until the age of 6 years. Thereafter he developed progressive 
cerebellar symptoms and myoclonic jerks. He became extremely obese.
Clinical examination at age 22 showed distal amyotrophy, paresis and areflexia. Gnostic 
and vital sensation was distally impaired. Cerebral imaging revealed pontocerebellar 
atrophy. Nerve conduction studies and electromyography revealed a progressive axonal 
sensorimotor neuropathy. Neither oculocutaneous telangiectasia nor oculomotor apraxia nor 
immunodeficiency were observed. He developed diabetes mellitus type 2. Laboratory findings 
included an elevated αFP level, chromosomal instability and increased radiosensitivity of 
DNA synthesis. At the age of 33 the patient was diagnosed with metastasised hepatocellular 
carcinoma. He died one week thereafter of a bilateral bronchopneumonia in 1993. 
Molecular genetic studies
Mutation analysis of the ATM gene and measurements of ATM-protein expression and ATM-
kinase activity were performed as previously described.9,10
Pathological analysis
The brains and the spinal cords were examined macroscopically and fixed in 10 % formalin for 
several weeks. After the CNS was sectioned, blocks were taken from the cerebral neocortex 
from each separate cerebral lobe, hippocampus, cingulated gyrus, amygdala, basal ganglia, 
thalamus, hypothalamus, cerebellum, midbrain, pons, medulla oblongata, and the spinal cord 
at cervical, thoracic and lumbar levels. These blocks were embedded in paraffin. Sections from 
these blocks were stained with hematoxylin-eosin, luxol fast blue-cresyl violet or luxol fast 
blue-hematoxylin. Additional silver impregnations were performed. Immunohistochemistry of 
spinal cord sections was performed using the immunoperoxidase technique with antibodies 
against ubiquitin (DAKO pAB Z0458), AT8 (Innogenetics), phosphorylated TDP43 (Protein Tech 
pAB 10782-2-AP) and unphosphorylated alpha-synuclein (syn211, NeoMarkers, Fremont, CA.)
Literature search 
The paper of Sedgwick and Boder1 was indicated as key paper on the neuropathology of A-T. 
All referred articles of this study were critically reviewed and autopsy studies of ‘A-T patients’ 
CNS findings were retrieved. Additional papers were searched, using the PubMed database of 
the US National Library of Medicine, with the key words: ataxia telangiectasia AND autops*, 
ataxia telangiectasia AND neuropatholog*, ataxia telangiectasia AND histopathology*, ataxia 
telangiectasia AND nervous. Relevant articles were identified from the reference lists.
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Results
Molecular genetic studies:
From patient 1 no material was available for molecular studies.
Patient 2 was compound heterozygous for two truncating mutations: c.1027_1031del5 in exon 
10, leading to a frame shift in the protein at position Glu343, and c.1660delA in exon 13 causing 
a frame shift at Thr554. Cell lines from patient 2 showed no ATM-protein expression or ATM 
kinase activity.
In patient 3 ATM mutation analysis revealed a truncating mutation in exon 55, c.7838_7839dupGA 
(p.Pro2614fs), and a missense mutation in exon 60, c.8494C>T (p.Arg2832Cys). Cell lines showed 
some ATM-protein expression, with residual ATM-kinase activity.
Neuropathological studies 
The main neuropathological findings of the patients are tabulated in Table 2. 
Patient 1: Except for a slight pallor of the myelinated structures in the pallidum the supratentorial 
structures were almost normal. Both the hemispheric and the vermian  cerebellar cortex were 
atrophic, more so dorsally than ventrally, with severe loss of the Purkinje cells, slightly more 
than the loss of internal granular neurons. The nuclei of Goll and the bulbar olivae were severely 
degenerated Also, fibrillary gliosis was found in the median raphe and in the spinal radix of the 
spinal radix of the trigeminal nucleus . The gracile fascicle (Fig 1a, b and c) showed severe loss 
of myelinated fibers and important fibrillar gliosis, most severely so at the cervical level and 
with a ventral to dorsal gradient within each level. At the lower thoracal and lumbal levels, a 
paramedian region corresponding to the descending fibres of the posterior funicles remained 
relatively spared. The cuneate fascicle was less involved. The tractus semilunaris was also better 
spared than the ascending tracts of the posterior funiculus. In the lateral cords, astrocytes with 
large irregular nuclei were found. The anterior horns (Fig 2a and b) showed some fibrillar gliosis 
and there was some neuronal loss with proliferation of astrocytes and microglia and some 
neuronophagia in the lumbal cord. In the nucleus of Clarke a few neuroaxonal spheroids were 
present. 
Muscle biopsies of the triceps surae and the biceps femoris muscles, taken at 6 years age, 
already showed signs of neurogenic atrophy. There were no signs of mitochondrial disorder. 
The cervico-brachial plexus, lumbal plexus and sciatic nerve showed some signs of axonal 
degeneration but no signs of segmental demyelination at light microscopical examination, EM 
was not available. 
Patient 2: Supratentorial examination did not reveal any significant lesion. The cerebellum, the 
nuclei of Goll and the inferior olivary nuclei showed important degeneration. Severe, to almost 
complete loss of myelinated fibers in the gracile fascicle was seen at all levels of the spinal cord 
(Fig 1d, e and f ). The only regions with almost normal remaining myelination of this fascicle 
were found in the paramedian zone at the lumbal level and in subpial locations. Moderate 
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to severe loss of myelinated fibers in the cuneate fascicle was noted. The tractus semilunaris 
was better preserved. There was mild loss of myelinated fibers in the lateral corticospinal tract 
and in the spinocerebellar tracts. In the anterior horns some neuronal loss, one ballooned 
neuron and several neurons with chromatolysis were found. This was complemented by mild 
astrocytosis and swollen axons. The anterior horn lesions (Fig 2c and d) were most prominent 
in the lumbar segments and almost absent at the cervical level. Some neuronal loss, a sporadic 
neuron with central chromatolysis and a few neuroaxonal spheroids were seen in the Clarkes’ 
columns. 
The anterior tibial muscle showed in the same section both normal appearing areas and one 
severely abnormal area with signs of advanced denervation atrophy. The iliopsoas muscle 
Table 2. Neuropathological autopsy findings in 3 A-T patients
 Patient Pt 1 Pt 2 Pt 3
sex  M F M
phenotype classical classical milder
died at age (yrs) 19 22 33
Supratentorial structures
venous congestion + - -
thalamus, hypothalamus, putamen and caudate - - -
nucleus abnormalities
degeneration and demyelinisation in the pallidum mild - -
internum
Cerebellum
cortical atrophy severe severe moderately severe
loss of the internal granular layer important loss moderate - severe light - severe
Purkinje cell loss severe slight - moderate moderate - severe
dislocation of Purkinje cells +   +
empty baskets + + + 
hypertrophy of the Bergman glia + + +
degeneration of the dentate nucleus  mild mild mild
Brainstem
degeneration and gliosis in the nuclei of Goll +   +
degeneration of the bulbar olivae severe mild moderate
neuronal loss in the substantia nigra - - -
Spinal cord
posterior column demyelination and degeneration severe severe severe
paramedian sparing of the myelinated fibers in + + +
the gracile fascicle
cuneate fascicle less involved compared with the + + +
gracile fascicle
lateral cord degeneration mild mild mild
anterior horn cell degeneration  slight slight slight - moderate
degeneration of the Clarkes column mild mild moderate
Muscles
neurogenic atrophy slight no - severe severe
Nerves
axonal degeneration slight  -
segmental demyelination -  -
NA = data not available; + = present; - = absent
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displayed several small or atrophic fibers, intermingled with normal sized fibers. On average, 
type II fibers were smaller than type I fibers and some atrophic type II fibers were noted. The 
quadriceps muscle appeared quite normal except for a relative increase in the number of 
type 2 fibers, but no signs of denervation atrophy. Nerve specimens were not available for 
examination.
Patient 3: An old hemorrhage, with a gliotic reaction, resided in the white matter of the precentral 
gyrus, in conjunction with a few microscopic old necrotic cortical lesions. There was cerebellar 
atrophy with mild to severe loss of the internal granular layer, sometimes more pronounced 
at the top of the folia, and moderate to severe loss of Purkinje cells. The inferior olives showed 
moderate gliosis. A few focal microglial nodules were seen in the pes pontis. There was mild 
pallor of the locus coeruleus. The olivocerebellar tracts were gliotic. There was severe to almost 
complete loss of myelinated fibers in the gracile fascicle (Fig 1g, h and i). Also, moderate to 
Figure 1.
Loss of myelinated fibers in the posterior funicles is more pronounced at the cervical level (a,d,g) 
than at the thoracal (b,e,h) and lumbal (c,f,i) level. Patient 1 (a,b,c) and patient 2 (d,e,f ) with classical 
type A-T show more severe loss than patient 3 (g,h,i) with variant type A-T. Inserts in b,e and h: rela-
tively more spared short descending fibres of the posterior columns at the thoracal levels (HE-Luxol 
fast Blue, bar = 1mm)
Figure 1  
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Figure 2. 
Anterior horn at the lumbal level of patients 1 (a,b) and 2 (c,d) with classical A-T and of patient 3 (e,f ) 
with variant A-T. There is some diffuse loss of neurons with small groups of gliotic cells (asterisks) in 
all patients (a,c,e). Degenerating neurons (arrows) are more easily found in the variant A-T patient (f ) 
than in the classical A-T patients (b, d) (HE, bar = 100 µm)
Figure 2  
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severe loss of myelinated fibers occurred in the cuneate fascicle, with the most severe loss in 
its cervical part, and increasing loss from ventral to dorsal. Some loss of myelinated fibers in 
the corticospinal tract and in the spinocerebellar tracts was observable. At the spinal lower 
thoracic levels relative sparing of a paramedian layer in the gracile fascicle was noted. Slight 
to moderate neuronal loss of motor neurons in the anterior horn was observed (Fig 2 e and f ), 
with some of the remaining neurons showing central chromatolysis, while some swollen axons 
and sometimes small groups of glial cells were present. A gradient of severity of anterior horn 
cell loss from cervical to lumbar levels existed. In the Clarkes’ columns moderate neuronal loss, 
sporadic chromatolytic neurons and some axonal spheroids were observed. Compression of 
the spinal cord was seen at upper thoracic level by an epidural tumor (length 3 cm x width 2 cm 
x thickness 0.5 cm) which turned out to be a metastasis of a hepatocellular carcinoma.
Muscle biopsy at age 22 showed severe chronic neurogenic atrophy with fiber type grouping. 
Electron microscopic examination of a biopsy of a branch of the fibular nerve at age 22 showed 
a loss of thick myelinated axons without segmental demyelination and without signs of acute 
axonal degeneration.
Immunohistochemical study
In none of the three patients abnormal inclusions were found with tau, ubiquitin and alpha-
synuclein in anterior horn neurons. With TDP-43, the nuclei of the anterior horn neurons stained 
normal and no cytoplasmic TDP-43 inclusions were present.
Literature data
Twenty-seven of the 28 reviewed autopsy reports in the neuropathology chapter in Sedgwick 
and Boder1 and five additional papers with detailed neuropathological data, traced by Pubmed 
search, were retrieved5;11-14 (Table 3). Two papers were excluded because of the highly atypical 
presentation of the patients in the absence of cytogenetic or genetic abnormalities that 
would support a diagnosis of A-T.12,13 In none of the patients αFP serum concentrations were 
mentioned, while radiosensitivity was reported in one paper,5 and chromosomal instability 
in two patients.15,16 ATM gene mutation analysis has never been reported in any of the by us 
identified studies. 
Discussion
Ataxia telangiectasia (A-T) is a disease characterized by severe histological CNS abnormalities 
and a relative homogenous but still variable clinical presentation. The present study describes 
CNS-autopsy results of 3 A-T patients, two of whom were confirmed genetically. Previously 
described post-mortem results have never before been supported by molecular genetic 
testing. All previously reported 24 autopsy reports, 23 of which were published before the 
discovery of the genetic defect in 1995, lack this genetic information. Therefore, it is difficult 
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to determine whether the previously reported patients were diagnosed correctly and whether 
they had the classical or variant phenotype. 
The gross neuropathological findings in our patients, i.e. cerebellar degeneration, particular 
of the cortex and with relatively well-preserved deep cerebellar nuclei and inferior olives; 
degeneration of the posterior columns, specially of the gracile fascicle; and axonal degeneration 
of the peripheral nerves with subsequent muscle atrophy, are in line with the literature.5,6,11,14-31 
However, some interesting differences are found in the 33 years old patient with variant 
A-T (patient 3) who displayed some residual ATM-kinase activity. In addition, the finding of 
abnormalities in other parts of the spinal cord is of interest (Table 2).
Table 3. Summary of neuropathologic autopsy findings in the literature
Authors Pt Age Sex Cerebrum Cerebellum Brain Spinal  Anterior Peripheral Muscle
  (yrs)    stem cord* horn nerve
Boder et al.17 1†,‡ 10 F - + NA - NA NA NA
Centerwall et al.21  1 12 M + + + NA NA NA NA
Biemond et al.19  B 12 F + + + NA NA NA NA
 C 12 M       
Bowden et al.11  1 15 F - + - - NA NA NA
Ostetowska et al.35  1 7 F  + + + NA NA NA NA
Dunn et al.23 2 17 F - + - + NA NA ±
Strich29 1 15 M ± + + + - + +
 2 11 F ± + + + - + +
 3 12 F ± + + + - + +
Sourander et al.28  1 14 F - + - + + NA NA
Centerwall et al.20  2 23 M - + - + NA NA -
Thieffry et al.32  1 3 F - + - NA NA  NA NA
Solitare et al.27  1 13 F - + - + - NA ±
Hassler24  1 17 F - + - + NA NA +
Aguilar et al.18  1 21 M - + + + + NA NA
 2 10 F - + + + + NA NA
 3*1 10 F - + + + + NA NA
 4 19 M NA NA NA + + NA ±
 5 ? M - + - NA NA NA NA
Solitare31  1 22 F - + - + - - +
Itatsu et al.25  1 10 F + + + - NA + NA
Terplan et al.30  1 18 F + + + + + NA NA
Navarro et al.6  1 9 M + + + + + + +
De León et al.22  1 17 M + + + + + NA +
Agamanolis et al.15  1 31 M + + + + + + +
Amromin et al.16  1‡ 32 F + + + + + + +
Casaril et al.36  1 26 M + + NA NA NA NA NA
Perry et al.26 1 25 M - + + + + NA NA
Monaco et al.14  1 26 M + + + + + NA NA
Opeskin et al.5  1 34 M + + NA + + NA +
*spinal cord: general spinal cord findings; † the same patient; ‡ sibs
NA = data not available, - = no abnormalities, + = abnormalities, ± minimal abnormalities described
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Previously published studies confirmed the clinical observation that neuropathological 
abnormalities become more advanced and severe with increasing age.1 However, there is 
considerable individual variation.22,29 In general, cerebellar atrophy, degenerative changes of 
the Clarkes’ columns and inferior olives, loss of myelinated fibers of the posterior columns, 
degeneration of the dorsal root ganglia, axonal degeneration of the peripheral nerves and 
muscle atrophy are already visible in patients who die around the age of 10 years (Table 
3). By advancing age, the abnormalities progress and extend, and new lesions appear. 
In older patients, gliosis of the posterior columns in the spinal cord is more common, loss 
of myelinated fibers in the spinal cord extends to the spinocerebellar and corticospinal 
tracts.14,15,16,18,19,20,21,26,32 Furthermore, with advancing age progressive anterior horn cell 
degeneration develops.5,14,15,16,18,22,26,28,30 In the brainstem degeneration of the cranial 
nerves,15,16,22,33 depigmentation of the locus caeruleus14,15,22 and degenerative changes in the 
substantia nigra have been described.14,15,16,21,22 
Table 4. Anterior horn cell findings in the literature
Authors Casus  Age (yrs) No No Neuronal Ghost Gliosis
   information lesions loss cells
Boder et al.17 1 10 + 
Bowden et al.11  1 15  +† 
Ostetowska et al.35 1 7 + 
Dunn et al.23  2 17 + 
Strich SJ. 29  1 15     -
 2 11   -
 3 12     -
Sourander et al.28  1 14   +
Centerwall et al.20  2 23 +
Thieffry et al.32  1 3 +
Solitare et al.27  1 13   +
Hassler24 1 17 +
Aguilar et al.18 1 21     + + +
 2 10    +
 3 10    + +
 4 19     + +
Solitare31  1 22 + +
Itatsu et al.25  1 10  +†
Terplan et al.30 1 18         +
Navarro et al.6  1 9     + + +
De León et al.22  1 17     + + +
Agamanolis et al.15  1 31   + + +
Amromin et al.16  1 32     +   -
Casaril et al.36  1 26 +
Perry et al.26 1 25     +
Monaco et al.14  1 26     +   +
Opeskin et al.5  1 34     +
†Spinal cord findings have only been described as normal
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The neuropathological findings in our A-T patient with the milder phenotype (patient 3), who 
displayed some residual ATM-protein expression with minimal ATM-kinase activity, are in 
general comparable with those reported from patients who survived into the fourth decade. To 
what extent the epidural tumoral mass in patient 3 influenced the neuropathological changes 
especially in the long tracts is difficult to estimate, but the tumor was fast growing and the 
findings were quite symmetric and in line with findings in the other patients. 
Progeric changes – such as Lewy bodies, Alzheimer plaques, neurofibrillary tangles and 
gliovascular abnormalities – have been described in older A-T patients,5,14,15,16,26 but were 
not present in our patients. In addition, the lesions in the brain stem were less widespread 
and somewhat milder in our milder A-T patient, than in previously described age-matched 
patients. The neuronal degeneration in the anterior horn were somewhat more pronounced 
in the latter case than in the 2 other patients with classical A-T, but the patient was also more 
than 10 years older. Occasionally cerebral glial nodules and gliosis of the white matter of the 
gyrus precentralis were observed in our patient with the milder phenotype. However, these 
small cortical anoxic lesions, the old small scar with hemosiderin in the white matter of the 
gyrus precentralis, and the few distributed foci of neuronophagia in the ‘griseum pontis’ are 
most likely due to the respiratory distress. Glial nodules were also observed in four other A-T 
patients, with ages between 11 and 17 years, who died due to respiratory problems.22,29 
Clinical signs of anterior horn cell disease have also been described in A-T patients who 
survived into the third decade of life.33,35 However, descriptions of neuropathological 
findings of the anterior horn cells are sparse (Table 4). Loss of anterior horn neurons due to 
an interfering disease such as ALS, tauopathy, or alpha-synucleinopathy could be excluded 
by immunohistochemistry in our patients. The precise role of anterior horn cell disease in 
(younger) classical A-T patients is difficult to establish: the severe signs of the progressive 
sensorimotor polyneuropathy precludes conclusions about the additional presence of anterior 
horn cell disease.7 In variant A-T patients, anterior horn cell degeneration is clinically more 
pronounced and could be the presenting and predominating feature of A-T.4,34
The first signs of anterior horn cell involvement have already been described in the lumbar 
levels in a 9-year old boy (the brother of patient 1).6 In the patients described in the present 
paper, the anterior horn involvement became more widespread by advancing age. In the 22-
year old female (patient 2) and 33-year old male (patient 3), anterior horn cell degeneration 
was also visible at the cervical level. The extent and severity of the neuropathological findings 
in the anterior horn cells of the patient with the milder phenotype were comparable with those 
of classical A-T patients. Neurogenic muscle atrophy was present in all and more pronounced 
in the distal muscles whereas peripheral nerve biopsies revealed signs of axonal degeneration. 
Thus, anterior horn cell degeneration and axonal sensorimotor polyneuropathy, are disease 
features of both classical and variant A-T. It may be assumed that the muscle weakness due to 
anterior horn cell degeneration is clinically more impressive in milder A-T patients, as compared 
to classical patients in whom the earlier and more pronounced cerebellar and extrapyramidal 
symptoms may partly mask the weakness.
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The longest tracts appear to be most severely affected in A-T. The gracile fascicle is more severely 
affected than the cuneate fascicle, with the most severe abnormalities at the cervical level. In the 
gracile fascicle a slight ventral to dorsal gradient of loss of myelinated fibers was observed. The 
short descending fibres of the posterior funicles remained relatively more spared at the different 
levels: the tractus semilunaris at the cervical level and the oval field of Flechsig at the low thoracal 
and lumbal levels. Interestingly, at the lumbar level the anterior horn cell degeneration is more 
prominent. The present study does not allow to differentiate the changes secondary to the 
polyneuropathy in these patients from changes due to neuronal loss e.g. in the nucleus of Goll.
As in all previous studies5,6,11,14-31, 37, 38, also in our patients the cerebellar Purkinje cells are 
crucially affected. Demonstration of abnormal arborization of Purkinje cells and the presence 
of displaced Purkinje cells in the molecular layer of the cerebellum, as we also observed in 2 
patients, suggested that Purkinje cells are affected as early as during the midgestational period, 
but after they are fully developed.37,38 ATM has been found to be concentrated in the nucleus 
of Purkinje cell neurons in the normal juvenile human brain and is absent in the cerebellar 
Purkinje cells from A-T patients.39 This is consistent with the hypothesis that, as in all other cell 
types examined, also in fully differentiated Purkinje cells a major function of ATM may be to 
detect and repair nuclear DNA damage. If this mechanism also plays a role in anterior horn 
cells remains open to research, as detailed information on the presence of ATM in anterior horn 
cells is lacking. It remains also unclear which other factors play a role as ATM expression is not 
limited to neuronal cell types that are affected in A-T patients.39 
In conclusion, we describe the neuropathological findings of DNA proven A-T patients. In line with 
the literature the main neuropathological abnormalities are cerebellar atrophy, degeneration 
of the posterior columns and an axonal sensorimotor polyneuropathy. With advancing age, 
the abnormalities progress and become more advanced and prominent. Anterior horn cell 
degeneration seems to occur already in young A-T patients, and to progress with advancing age, 
and is more prominent at the lumbar level. Residual ATM-kinase activity, which is associated with 
a milder clinical phenotype, leads to similar but somewhat less pronounced neuropathological 
abnormalities than in patients without any ATM kinase activity at all.
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Abstract
Objective: To describe cognitive and speech-language functioning of patients with ataxia 
telangiectasia (A-T) in relation to their deteriorating (oculo)motor function. 
Design: Observational case series.
Methods: Cognitive functioning, language, speech, and oral- motor functioning were 
examined in eight individuals with A-T (6 boys, 2 girls), taking into account the confounding 
effects of motor functioning on test performance. 
Results: All patients, except the youngest one, suffered from mild to moderate/severe 
intellectual impairment. Compared to developmental age, patients showed cognitive deficits 
in attention, (non)verbal memory, and verbal fluency. Furthermore, dysarthria and weak oral-
motor performance was found. Language was one of the patients’ assets.
Conclusion: In contrast to the severe deterioration of motor functioning in A-T, cognitive 
and language functioning appeared to level off with a typical profile of neuropsychological 
strengths and weaknesses. Based on our experiences with A-T, suggestions are made to 
determine a valid assessment of the cognitive and speech-language manifestations.
 
Keywords: Ataxia telangiectasia, cognition, speech language, child neurology, 
neuropsychologie
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Introduction
Ataxia telangiectasia (A-T) is a rare autosomal recessive multisystem disorder, belonging to the 
family of DNA repair disorders. This disease is characterized by progressive neurodegeneration, 
oculocutaneous telangiectasia, pre-disposition for malignancies, variable immunodeficiency, 
and pulmonary abnormalities.1 The main neurological findings in these patients are progressive 
cerebellar ataxia with onset in early childhood, extrapyramidal symptoms (i.e. chorea, dystonia, 
and myoclonus), oculomotor apraxia, and a progressive axonal sensorimotor polyneuropathy 
with onset around the age of 8.1,2 During their life, A-T patients become progressively disabled 
due to their neurological problems. Classically, patients become wheelchair-bound around the 
age of 10 years. 
Surprisingly, there has only been limited attention for the cognitive functioning of A-T patients 
in the past decades. In the 1960s and 1970s, it was described that ~30 to 50% of the A-T patients 
had a below average intelligence.3 In those years, IQs of many A-T patients were mentioned in 
reports, with values varying between 37–115.4-16 Other researchers have found a tendency to 
‘level off’ at a mental age around 10, which leads to an increasing disparity between chronologic 
age and mental age, mainly on tests involving visual-motor co-ordination.1,4,5 Intellectual 
deterioration is only rarely reported.8,9 Otherwise, adults with A-T who have completed regular 
education have been mentioned.1 In addition to the reported generalized below-average 
intelligence, a specific cognitive deficit in perceptual timing (investigated by a test of judgment 
of duration) may be present in individuals with A-T.17 
Neurocognitive testing is complicated by the speech abnormalities, difficulties with motor 
coordination and timing, as well as striking oculomotor abnormalities. Furthermore, a valid 
interpretation of the test scores is challenging, because of these confounding factors. To the 
authors’ knowledge, there has been no investigation on the neuropsychological and speech-
language profile in children with A-T taking into account their complex movement disorder 
and oculomotor impairments.
This study sought to determine 1) whether A-T patients show global intellectual impairment, 
2) whether these patients show specific deficits and assets in cognitive and speech-language 
functioning and 3) whether the deficits, if present, show a progressive course.
The current report presents observations in eight patients with A-T who were studied in order 
to address these questions. The authors performed neurocognitive and speech-language 
testing using a test battery with minimal fine motor and oculomotor demands, to gain better 
insight in the cognitive function of A-T patients. 
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Methods 
Participants
Eight patients diagnosed with A-T with a classical phenotype (6 boys, 2 girls) who are currently 
known in our hospital were investigated. In all patients the diagnosis was confirmed at the 
molecular level by demonstration of mutations in the ATM gene and absence of ATM kinase 
activity. At the time of assessment these children were between 3 and 15 years of age 
(mean=11;2, SD=4;5), see Table 1. All patients lived in the Netherlands. One patient (patient 
1) was growing up in a bilingual (i.e., Turkish-Dutch) environment. Patient 8 was too young 
to be assessed with the neuropsychological test battery, therefore only the general cognitive 
outcome was determined. 
Procedure
All patients were tested by the same persons of the research group. Data were obtained by a 
paediatric neuropsychologist (AV) and an experienced speech-language pathologist (MvG). 
Data collection took place at the Department of Paediatric Neurology of the Radboud University 
Nijmegen Medical Centre in Nijmegen, The Netherlands. The individual neuropsychological 
assessment consisted for most children of one session with a total duration of 3.5 to 4 hours. 
After a break, the speech and language functioning of the children was tested. 
The experimental procedure of this study was approved by the Committee on Research 
Involving Human Subjects (CMO Regio Arnhem–Nijmegen) of the Radboud University 
Nijmegen Medical Centre. 
Measurements
Intellectual outcome and neurocognitive functioning
For this patient group, the verbal intelligence scale of the Dutch version of the Wechsler 
Intelligence Scale for Children-3rd version18 was considered to be the most reliable estimation 
of general cognitive functioning, since the sub-tests of this scale are not negatively affected by 
the fine motor and oculomotor impairments. Therefore, the verbal intelligence quotient (VIQ) 
was used to determine the developmental age of the patients.
The WISC-III was not age-appropriate for the youngest patient. Instead, the SON-R 2.5-7, a 
nonverbal intelligence test, was chosen.
To gain more insight into the neurocognitive functioning of the A-T patients, an assessment 
consisting of different sub-tests of four test batteries was administered (Wechsler-Intelligence 
Test, WISC-III; Kaufman-ABC, K-ABC; and Revised Amsterdam Kinder Intelligence Test, RAKIT; 
Test of everyday attention for children, TEA-CH).18-21 The assessment battery intended to 
examine the following neurocognitive functions: 
O  Attention: assessed by the sub-test ‘Tel Mee’ of the TEA-CH; children have to attend to 
auditory stimuli (e.g., a beep) and count them. 
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O  Perception: assessed by the sub-test Gestalt Closure of the K-ABC; the child mentally ‘fills in 
the gaps’ in partially completed ‘inkblot’ drawings and names the object or action depicted 
on the drawings.
O  Visuo-spatial skills: Triangles of the K-ABC; for most items, the child assembles several 
identical foam triangles (blue on one side, yellow on the other) to match a picture of an 
abstract design.
O  Verbal memory: Word Order of the K-ABC and Digit Span of the WISC-III were assessed. In 
the sub-test Word Order, the child touches a series of silhouettes of common objects in the 
same order as the examiner said the names of the objects. In the sub-test Digit Span, the 
child repeats a series of numbers in the same sequence as the examiner said them, with 
forward and backward series with increasing lengths. 
O  Non-verbal memory: The sub-tests Hand Movements and Spatial Memory of the K-ABC were 
used to examine non-verbal memory. Hand Movements: The child copies the examiner’s 
precise sequence of taps on the table with the fist, palm, or side of the hand. Spatial Memory: 
The child has to point out the placement of pictures on a page that was exposed briefly.
O  Working memory: The sub-test Arithmetics of the WISC-III was administered. The child has to 
solve verbally framed math problems without paper.
O  Fluency: The sub-test Verbal Fluency of the RAKIT was administered. Children have to name 
up words belonging to a certain category (such as ‘drinks’ or ‘things you can buy’).
Speech and oral-motor performance
The severity of dysarthria was scored using the ‘Dysarthria Score’, which is an English 
translation and adaptation of the nationally used Dutch ‘Nijmegen Dysarthria Scale’ (NDS). It 
evaluates the main physiological speech systems (respiration, phonation, resonance, prosody, 
articulation, and lips/ tongue/ jaw movements) and assesses the effectiveness of speech during 
Table 1. Clinical findings in eight A-T patients
Patient 1 2 3 4 5 6 7 8
Sex; age (years) F; 15 M; 15 M; 14 M; 13 M; 11 M; 8 M; 6 F; 3
Age of diagnosis A-T (years) 9 7 12 2 7 5 3 0.5
Neurological findings
Cerebellar ataxia age of onset (years;  5;0 1;0 1;9 1;6 1;3 1;3 1;6 1;0
months)
Non-ambulatory at age (years) 9 11 15 10 10 - - -
          
Ocular apraxia + + + + + + + - 
 
Nystagmus + + - + + + + - 
 
Extrapyramidal signs + + + + + + + +
Polyneuropathy + + + + + - - +
M = male; F = female; + = present; – = absent
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communication in daily life. The NDS scoring system is a Dutch revision of Therapy Outcome 
Measure.22 
The type of dysarthria was determined by clinical judgment of the aspects of speech as 
mentioned above. Furthermore, oral-motor performance, feeding and swallowing were 
clinically assessed. 
Language 
O  Receptive vocabulary: The Peabody Picture Vocabulary Test was used for the assessment of 
the receptive vocabulary.23 
O  Receptive language: One sub-test of the validated Dutch language test for children (‘Taaltests 
voor Kinderen’) was used for children above 7 years.24 To assess language comprehension in 
younger children, an adapted and standardized Dutch version of the Reynell Developmental 
Language Scales was used.25
O  Expressive vocabulary: To test the word finding capacity, the Word Finding Vocabulary Test of 
the Renfrew Language Scales and the Word Developmental Test of the Schlichting Test for 
Language Production were used for younger children.26 The Boston Naming Task for Dutch 
Children was used for older Children. 
O  Expressive language was assessed with the Sentence Development Test of the Schlichting 
Test for Language Production for the younger children26; a sub-test of the Dutch language 
test for children (‘Taaltests voor Kinderen’) measuring sentence construction was used for 
the older children.24 
Data analysis
To get more insight into the neurocognitive functioning of the children, the concept of 
developmental age was applied as method to avoid floor effects on the standardized tests, 
as these render interpretation of results difficult or impossible. This approach allowed us 
to determine whether an observed level of performance of an individual with A-T on a 
particular cognitive function is above or below that expected given the child’s general level 
of intellectual functioning. Thus, in order to examine the cognitive profiles of the patients, first 
VIQ scores were converted to developmental ages. The developmental age was determined by 
a comparison of the raw sum score of the VIQ scale to the corresponding average intelligence 
level (which means VIQ around 100) of a particular age norm group. This age equivalent to 
the raw VIQ scores was considered as an estimation of the level of intellectual functioning of 
the child, further referred to as ‘developmental age’. Then, this developmental age was used 
to determine the standardized norm score of all other cognitive and language sub-tests. The 
standardized scores were converted to z-scores to be able to compare the diverse scaling of 
tests administered. 
An important advantage of this method is that all sub-tests measuring cognitive functions 
scored within ±2 SD from the tests’ norm score at that particular developmental age, which 
provides a valid assessment and better differentiation of the patients’ neurocognitive profile 
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than if chronological age was applied. One sample T-tests were performed to investigate 
whether the means of the neuropsychological sub-tests differ from the reference distribution. 
Data analyses were performed using SPSS version 16.0 and test results considered statistically 
significant at p<0.05. 
Results of receptive and expressive language functions were converted to age equivalents. 
Statistical analyses were not feasible for the language tests because –according to the particular 
age of the patient–different tasks were used to examine the language domain. 
Results
Clinical and neurological features of the patients with A-T
Table 1 outlines the most relevant clinical features of the patients with A-T. All patients presented 
with an ataxic gait in early childhood. Progressive neurological features were observed in all. 
During the course of the disease the clinical picture was variably complicated by mild-to-
severe oculomotor apraxia, chorea-athetose, dystonia, and peripheral neuropathy with onset 
in childhood. Four of five children were non-ambulatory around the age of 10. The other 
patient (patient 3) was non-ambulatory at age 15, 1 year after performing neurocognitive and 
speech-language testing. In all patients ocular telangiectasia, elevated α-fetoprotein levels, 
and immunodeficiency were present since early childhood. 
Intellectual functioning
Table 2 shows the data of intellectual outcome for the patient group. The youngest patient 
who was tested with a non-verbal intelligence test performed within the normal range (SON-
IQ 111). For the other patients, VIQ values ranged from 57–83 (mean=71.86, SD=10.6), 1–3 
SD below the average test norm score of the particular chronological age and, thus, varying 
from mild (three of eight patients) to moderate/severe impairment (four of eight patients). 
T-tests revealed a statistically significant deviation from the age appropriate mean (t(6)= –7.02, 
p<.001). The developmental ages are also presented in Table 2. Compared to chronological 
age (mean=11;08, range 6;9–15;8 years), the mean developmental age was much lower with a 
mean of ~8;4 years (range=6;0–10;11), corroborating the degree of mental retardation. There 
seems to be a tendency of the older children displaying lower verbal IQs.
Neuropsychological functioning
Summary data regarding the presence or absence of neuropsychological deficits are presented 
in Table 2. One should take into account that the developmental age was used to determine 
the standardized norm score of all other cognitive and language sub-tests. 
Statistical analyses revealed significant impairments for the attention domain (t(6)= –4.11, 
p=0.009), for one sub-test of the verbal memory domain (t(6)= –3.97, p=0.007), for non-verbal 
memory (for sub-test Hand movements: t(6)= –2.65, p=0.038; for sub-test Spatial Memory: 
t(6)= –2.47, p=0.049), and word fluency (t(6)= –4.13, p=0.006). On the other cognitive functions 
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(perception, visuo-spatial skills and working memory), patients performed within the average 
of the (developmental) age-appropriate norm of the test. An investigation of the individual 
patients showed this profile of strengths and weaknesses, even in children with mild general 
cognitive impairment (patients 4, 5, and 6). 
Speech, oral- motor performance and swallowing
In all participants dysarthria was found (see Table 3). The dysarthria was a mixture of the ataxic 
and the hyperkinetic type. In most patients, the speech was moderately-to-severely affected. 
In two participants the intelligibility was frequently a problem. None of the children used 
alternative forms of communication in daily life. According to the parents, speech problems 
became more evident during a period of 3–5 years; the caregivers of the child were increasingly 
complaining about the intelligibility.
Regarding the oral-motor functioning it is evident that there are problems in strength, rate, 
and range of movements. Planning of the right movements with tongue and lips is intact. Four 
children were often coughing on thin liquids and their drinks had to be thickened; chewing 
problems were found in four children. The implications for daily life were that soft solids 
had to be given and tough food had to be mashed or cut in very small pieces. Problems in 
chewing and swallowing seem to aggravate during the years. Severe drooling necessitating 
the use of napkinds was only found in one patient. It was evident that eating and drinking was 
additionally hampered by the complex movement disorder in these children, resulting in poor 
body posture and hand function (e.g. action myoclonus).
Language
For the language domain, again, the age equivalents of all tests are shown in Table 4. The 
age equivalents are similar to or even higher than the developmental age, as determined 
earlier, except for patient 7 (a patient known to have a delay in language development prior 
to diagnosis of A-T). The mean age equivalents for receptive vocabulary was 8;11 (range 2;7–
12;9), for receptive language 7;8 (range 2;11–10); for expressive vocabulary 8;5 (range 2;10-12), 
and for expressive language 7;4 (range 2;10–10). 
Table 3. Speech and oral-motor functioning
Patient Age Sex Speech Oral-motor Eating and
   Type of Dysarthria Severity performance drinking
1 15;8 F Ataxic/Hyperkinetic 2 2 2
2 15;6 M Ataxic/Hyperkinetic 2 2 3
3 14;6 M More Ataxic than hyperkinetic 2/3 3 3
4 13;6 M Ataxic 2 2 2
5 11;6 M Hyperkinetic-Hypokinetic 2 3 3
6 8;3 M Ataxic/Hyperkinetic 2 2 2
7 6;9 M Hyperkinetic 3 3 5
8 3;6 F Ataxic/Fonology 2 3 4
0 = very severe; 1 = severe; 2 = moderate/severe; 3 = moderate; 4 = mild; 5 = normal
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The assessment of the sentence production test was difficult due to tiredness of the children. 
However, an impression of expressive language functioning can be given based on the 
sentences produced during the first part of the test session and during spontaneous situations. 
Most of the children produced accurate but rather short sentences. Only two children had 
difficulties in producing correct sentences.
Based on two observations, it was conclude that language does not seem to deteriorate during 
the years. First, no differences were found between the performances of older patients and 
younger children. Second, seven patients had been tested by the same speech-language 
pathologist previously during the past three years. Comparison of the results of the present 
study with previous test results showed slightly lower scores in two children, better scores in 
three, while in two children the results were the same across the two test moments.
Additional information of the developmental course of three patients
Patient 3. For this patient, a mild retardation of the motor development became evident at 
the young age of 3 years. The results of a psychological examination at that age revealed a 
mild cognitive retardation (3 years; 1 month): his developmental age was 2 years; 6 months. At 
the age of 5 years, the developmental delay was more prominent and a discrepancy between 
verbal and performance intelligence was found (Verbal IQ=77, Performance IQ=63 assessed 
by the WPPSI). Similar results on verbal intelligence were found at the age of 12 years (Verbal 
IQ=70 assessed by the WISC-III). 
Patient 4. At the age of three years a psychological examination had taken place. Results 
revealed that the boy performed above average on a Dutch developmental test (Developmental 
Index=130 on the Groninger Intelligence scale). To the authors’ knowledge, no other 
assessments have been done. 
Patient 5. Patient 5 had been tested three times before our assessment took place. At the 
age of 5;11 years an average development was found. At the age of 6;6 similar overall results 
Table 4. Receptive and expressive language functions
Patient Sex Age Dev.  Receptive Receptive Expressive Expressive
   Age vocabulary language vocabulary  language
1 F 15;8 8;0-8;3 11;6 >101 7;43 nt
2 M 15;6 9;0-9;3 11;6 101 124 66
3 M 14;6 10;0-10;3 11;9 101 <104 106
4 M 13;6 10;8-10;11 12;9 101 >124 >10
5 M 11;6 9;4-9;7 11;3 7;21 >124 >106
6 M 8;3 6;8-6;11 6;0 6;61 7;03 nt
7 M 6;9 6;0-6;3 4;4 4;102 4;45 5;17
8 F 3;6 3;6 2;7 2;112 2;105 2;107
nd= not determined.
1 Dutch Language Test (Taaltests voor kinderen- Test voor Verzwegen Betekenis); 2 Reynelltest for Language 
Comprehension; 3 Renfrew Word Finding Vocabulary Test; 4 Boston Naming Test; 5 Schlichting Test for Language 
Production (Word Development); 6 Dutch Language Test (Taaltests voor kinderen- Zinsbouw Productietest); 
7 Schlichting Test for Language Production (Sentence Development); nt= not testable.
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were found, but a discrepancy between two test scales (Performance Scale=84, Logical 
Thinking Scale=99, as assessed by the Dutch (non-verbal) SON-R 5½–7 IQ test). An extensive 
neuropsychological examination at the age of 10 revealed again a discrepancy in the cognitive 
profile (Verbal IQ=75, Performance IQ<55 on the WISC-III).
Discussion 
The current paper describes the intellectual, neuropsychological, speech-language, and oral-
motor functioning of children with A-T. To the authors’ knowledge, no recent descriptions of 
both similar extensive cognitive function tests and speech language examination of children 
with A-T are available. The current study adds to the existing knowledge a comprehensive 
investigation of the profile of strengths and weaknesses, taking into account the confounding 
effects of fine motor and oculomotor impairment, and helps to interpret cognitive functioning 
in a broader view.
With respect to global intellectual functioning it was found that all patients, except the 
youngest one, showed an impairment varying from mild (three of eight patients) to moderate/
severe (four of eight patients). Further analyses of the neuropsychological profile showed, in 
addition to the general cognitive impairment, specific and statistically significant deficits in 
attention, (non)verbal memory, and word fluency. On all other cognitive functions assessed in 
the project (perception, visuo-spatial skills, and working memory), patients performed within 
the average of the (developmental) age-appropriate norm of the test. 
In relation to developmental age and the cognitive profile, language functioning was one of 
the strengths of the patients, as also described previously in literature.4,5 Speech, oral-motor 
performance, and swallowing were affected in most patients and were aggravating with 
increasing age. In the recent period of 3–5 years, more adaptations had to be used to cope 
with eating and drinking problems. The motor problems in the oral and pharyngeal phase are 
influencing the swallowing process negatively. In the oral phase, the tongue movements to 
form a bolus and to transport the bolus to the oropharyngeal area are reduced. Choking on 
thin liquid is a signal of incoordination of the pharyngeal movements and airway closure. Also 
the poor body posture aggravates these problems. 
Follow-up data on three patients showed that, in contrast to the severe progressive motor 
disorder in A-T, cognitive and language deficits appear to level off but not to deteriorate during 
the course of the disease. This finding is in line with the global impression from the available 
literature, as well as our clinical experiences with other A-T patients during the past decades. 
Overall, this study found, in line with the literature, no arguments for cognitive deterioration, 
in school-aged children with A-T. The authors, therefore, feel that it is justified to reassure 
patients and their parents that, although A-T is a severe neurodegenerative disorder, acquired 
intellectual and language skills are relatively preserved, however levelling off is a disease 
feature in children with A-T.
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Another important finding concerning the neuropsychological assessment is that motor and 
oculomotor problems alone cannot explain the specific cognitive profile. Taking into account 
the global intellectual impairment, attention and memory problems as well as weak verbal 
fluency are most prominently affected. The question remains whether these findings can 
be explained mainly by cerebellar involvement, which is of course evident in A-T, since the 
cerebellum is increasingly recognized as cerebral structure with an important role in higher 
cognitive functions. 
Clinical implications
A valid assessment of neuropsychological and language functioning of A-T patients should 
carefully take into account their complex movement disorder including oral motor impairments 
and oculomotor impairments. 
More insight into cognitive outcome and the profile of neuropsychological and speech-
language functioning is a pre-requisite for providing appropriate support concerning school 
environment. From a developmental psychological perspective, this is of particular importance 
with respect to the increased risk of the development of social-emotional and adaptational 
problems and adequate treatment focusing on the specific needs of these patients. For this 
reason, children with A-T should be monitored with respect to cognitive and speech language 
functioning from an early age on. Crucial other time points for an assessment in the child’s 
development are starting kindergarten, starting school, and entering secondary education. 
What this paper adds:
1)  In contrast to the severe deterioration of motor functioning, cognitive and language deficits 
appear to level off in A-T.
2)  Patients show below average intelligence, with attention and memory problems as well as 
verbal fluency being most prominently affected.
3)  Assessment of neuropsychological and language functioning should carefully take into 
account the complex movement disorders and oculomotor impairments.
4)  Patients and their parents might be reassured that, although A-T is a severe neurodegenerative 
disorder, acquired intellectual and language skills won’t be lost.
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Abstract
Ataxia telangiectasia (A-T) is a rare autosomal recessive multisystem disorder with a short life 
expectancy. During adolescence pulmonary complications are common in A-T patients, and 
respiratory failure is the most important cause of death. Therefore mechanical ventilation 
is often considered in these patients. In this study we retrospectively evaluated the clinical 
characteristics and ICU course of three consecutive adolescent A-T patients who were 
mechanically ventilated for respiratory failure. None of these patients had a history of respiratory 
infection. In all patients volume-pressure ratios indicated severe restrictive lung dysfunction. 
This was supported by data on pre-admission lung function testing. All three patients died of 
hypercapnic respiratory failure during ICU admission. The study shows that severe restrictive 
lung function is a common finding in adolescent A-T patients which may seriously complicate 
ventilator treatment. Preadmission lung function testing is essential for the optimal medical 
management of these patients.
Keywords: Ataxia-telangiectasia, respiratory failure, mechanical ventilation, restrictive lung 
dysfunction
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Introduction
Ataxia telangiectasia (A-T), an autosomal recessive multisystem disease, is characterized by 
progressive cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, elevated 
α-fetoprotein levels, rearrangement of chromosomes 7 and 14, and increased radiosensitivity.1 
A-T is a rare condition with an incidence in the Netherlands of ~1 :200.0000 (1 new case a 
year). The gene responsible for A-T, the A-T Mutated gene, is localized on chromosome 11 
(11q22-23) and its protein is involved in cell cycle control and DNA repair.2,3 In patients with 
A-T the life expectancy is relatively short, due to enhanced risk of malignancies and infections.4 
Pulmonary complications are common and respiratory failure is the most frequent cause of 
death.1 Therefore, mechanical ventilation is a therapeutic option that is often considered in 
these patients. However, in A-T patients invasive ventilatory support is not without risk and 
may be associated with adverse outcome. Procedural ventilation related respiratory failure in 
A-T patients has been reported (M.Taylor, Birmingham, personal communication).
In this case report we describe our experience with three patients with classical A-T who died 
of respiratory failure because of severe restrictive lung function without having a history of 
serious recurrent respiratory infections.
Methods 
Over the period 1999-2006 the clinical outcome of three consecutive patients with classical A-T 
who were mechanically ventilated for respiratory failure was evaluated. The overall compliance 
of the respiratory system (Crs) – i.e. lung and chest wall compliance - was calculated using 
volume-pressure ratios during ICU admission. The patients were ventilated by pressure regulated 
volume control (PRVC, servo 300â, Siemens). Because in pressure-regulated ventilation the 
peak inspiratory pressure (PIP) equals the plateau airway pressure (PAP), PIP was used to assess 
the compliance of the respiratory system (Crs). Crs was calculated as follows: The ratio Tidal 
Volume / [Peak Inspiratory Pressure – Positive End-Expiratory Pressure] (VT/[PIP – PEEP]) from 
a representative expiratory tidal volume. Lung-function was measured according to standard 
ATS/ERS criteria with the patient seated. Vital Capacity (VC) and Forced Expiratory Volume in 
1 second (FEV1) were determined with a dry spirometer (Jaeger, Wurzburg, Germany). Total 
Lung Capacity (TLC) was measured by the Helium dilution method. At least one recent chest 
X-ray was available for each patient.
Case Reports
Patient A 
A 26-year-old A-T patient was admitted with an acute respiratory syncytial virus (RSV) 
pneumonia. He had no history of respiratory infections. Preoperative lung function testing at 
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the age of 20 was indicative of restrictive pulmonary dysfunction (Table 1) and therefore it was 
decided to cancel a planned corrective operation.
On admission his chest X-ray showed a small bell-shaped thorax, a mild kyphoscoliosis and 
only moderate infiltrative shadowing in the left lower quadrant. Over the subsequent days 
he became progressively dyspnoeic and tachypnoeic (respiration 30 – 40/ min). On day 5 he 
was intubated and ventilated for respiratory failure. From the start of mechanical ventilation 
(Pressure Regulated Volume Control (PRVC), Servo 300â, Siemens) severe restrictive lung 
function was observed. High Peak Inspiratory Pressures (PIP; 45 - 50 cm H20) were required to 
achieve acceptable ventilation (PaCO2 6 – 8 kPa) and correlated with low tidal volumes (TV) (200 
- 220mL). Calculated Crs (at PEEP 5 cm H20) was extremely low: 4.4 - 5.5 mL/cm H20 (Normal 
values > 50 – 100 mL/cm H20). Supportive therapy with restrictive fluid management, broad 
spectrum antibiotics, immunoglobulin substitution and corticosteroids was not effective. 
His pulmonary function gradually deteriorated and he died 53 days after start of mechanical 
ventilation of hypercapnic respiratory failure.
Patient B
In this patient a B-cell non-Hodgkin lymphoma in the epipharynx had been successfully treated 
with mitigated dosages of vincristine, methotrexate, doxorubicin and prednisone at the age 
of 16 years. Following treatment, complete agammaglobulinaemia persisted. Intravenous 
immunoglobulin substitution was started and no respiratory infections were observed over 
Table 1. Results of pulmonary function tests of the three classical A-T patients (%; values as percentage of 
reference value for gender, age and height)
patient A B C
gender M F M
age (yrs) 20 17 20 21 10 12
BMI 18,9 15,4 18 17,5 12 11,2
 
volumes 
TLC-He (L)     1,86 1,96
 TLC-HE as % of predicted     44 46 
VC (L) 1,12 1,17 1,34 1,21 0,56 0,55
 VC as % of predicted 47 42 43 38 36 22
RV (L) 1,25   0,51 0,76 
 RV as % of predicted 53   51 66 
FEV1 (L) 0,85 0,95 1,09 1,21 0,41 0,5
 FEV1/VC max(%) 76 81 81 100 73 91
 
pressures
MEP (kPa)     2,8 3,63 
 MEP as % of predicted     33 43 
MIP (kPa)     3,6 4,43 
 MIP as % of predicted     57 70 
TLC-He = total lung capacity determined with helium, VC = vital capacity, RV = residual volume, FEV1 = forced 
expiratory volume in the first second, MEP = maximal expiratory mouth pressure, MIP = maximal inspiratory 
mouth pressure
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subsequent years. Because of the observed severe restrictive lung function in patient A, we 
evaluated her lung function (Table 1). From the age of 17 pulmonary function tests had shown 
progressive restrictive pulmonary dysfunction (Table 1). At the age of 22 she was seen at 
Emergency Department with haemorrhagic shock due to extensive bleeding from the urinary 
bladder. After intubation and volume resuscitation she was admitted to the ICU. The chest 
X-ray showed a small bell-shaped thorax, mild kyphoscoliosis and no pulmonary infiltrates. 
Pulmonary mechanics during ventilation (PRVC) showed severe pulmonary restriction: 
calculated Crs (at PEEP 8cm H2O) was 6.3 – 8.1 mL/cm H20 (TV 235 – 260 mL; PIP 40- 45 cm 
H20). Despite extensive pro-coagulant therapy and coiling of both internal iliac arteries, 
the bleeding from the bladder persisted. She developed progressive hypercapnia and died 
of respiratory failure 10 days after admission. At autopsy, histology of the lungs showed no 
micro-organisms, mild diffuse interstitial fibrosis and areas of non-necrotizing granulomatous 
inflammation.
Patient C
In this boy, lung function was assessed at the age 12 and showed severe restrictive 
pulmonary dysfunction (Table 1). The same year an EBV-positive lymphoma was diagnosed 
and successfully treated with rituximab. When he was 13 years old, he developed a B-cell 
lymphoma in the nasopharynx causing severe upper airway obstruction. Treatment with 
prednisone and rituximab resulted in a decrease of tumour size and relief of the inspiratory 
stridor. Subsequently however, progressive pulmonary dysfunction developed and ventilatory 
support was indicated. The chest X-ray showed minimal kyphoscoliosis, no pulmonary infiltrates 
or signs of ARDS. Because of his known restrictive lung function non-invasive positive pressure 
ventilation was started (Bipap® Vision, Respironics) in an attempt to avoid intubation. However, 
on day 2 he had to be intubated because of progressive respiratory distress. From the start of 
mechanical ventilation (PRVC, Servo 300, Siemens), volume pressure ratios indicated severe 
restrictive pulmonary function; high peak pressures (35 – 40 cm H20) correlated with low tidal 
volumes (TV 225 - 250 mL). Calculated Crs (at PEEP 5 cm H20) was 6.4 – 8.3 mL/cm H2O. He 
progressively developed hypercapnia and died on day 6 after admission to ICU for respiratory 
failure.
Discussion 
This report shows restrictive lung dysfunction to be a common finding in A-T patients and 
a major risk factor for adverse outcome after start of mechanical ventilation. In adolescent 
wheelchair-bound A-T patients preadmission lung function is rarely assessed, because 
pulmonary dysfunction may not be clinically evident and lung function testing is difficult to 
perform in patients with neuromuscular dysfunction. In all patients in this study, ventilator 
volume-pressure ratios were compatible with severe pulmonary restriction. The estimated Crs 
values are only indicative as they were calculated from PRVC ventilator settings. Restrictive 
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pulmonary dysfunction was supported by data on pre-admission lung function testing (Table 
1). Recently, reproducible lung function testing was shown to be feasible in adolescent A-T 
patients by McGrath-Morrow and co-workers.5 In line with our findings they found decreased 
vital capacity (VC)% predicted values in most A-T adolescents. It was hypothesized that this 
could be explained by expiratory muscle weakness. In our study however, severe restrictive 
lung function was also observed in sedated A-T patients on high ventilator settings when 
neuromuscular dysfunction is only minimally involved in respiratory mechanics. 
Our observations, combined with those previously reported1-6 indicate that the aetio- 
pathogenesis of restrictive lung function in A-T is not fully understood. First, none of our 
patients suffered from recurrent or severe lung infections. Second, none of the chest 
Figure 1. Growth curves of patient A and patient B
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radiographs showed signs of ILD. Third, histology of the lungs in patient B revealed only mild 
fibrosis, not characteristic for A-T. In this patient a side effect of earlier cytostatic therapy 
cannot be excluded, although drugs with known toxicity in A-T were avoided. Pulmonary 
restriction in A-T patients may be multifactorial and can be caused by a variety of disorders 
involving the extracellular matrix of the lung, its vascularization, or the tissues that surround 
the lung. In addition mechanical factors that lead to decreased chest wall compliance such as 
scoliosis, stiffening of the intercostal muscles and neuromuscular weakness, may contribute 
to restrictive pulmonary function. The patients in our study, however, had only mild scoliosis. 
Remarkably, they all had the small sized bell-shaped thorax known to be associated with a fixed 
maximal inspiratory position of the ribs and decreased chest wall compliance. Interestingly, the 
growth curves of all our adult patients with classical A-T lacked a puberty-associated growth 
spurt (Fig 1). This is in line with data of Schubert and co-workers who showed decreased IGF-
1 and IGFBP3 levels reflecting impaired somatic growth in A-T patients.7 Taken together, we 
hypothesize that development of a small bell-shaped thorax with restricted rib expansion 
may play an important role in restrictive lung dysfunction in A-T patients. Severe pulmonary 
restriction in these patients may be of decisive importance in the choice of treatment and the 
ultimate course of the disease. Mechanical ventilation is a major risk for a complicated course 
and unfavourable outcome and may not be an option in certain adolescent A-T patients. 
Therefore, invasive diagnostic procedures or surgery in A-T patients, requiring mechanical 
ventilation, demand individual tailored and careful consideration. Unfortunately, to the best of 
our best knowledge, there are no data in the literature referring to mechanical ventilation and 
outcome in A-T patients. If mechanical ventilation is unavoidable, forced weaning and early 
extubation is imperative. Using this approach, several young adolescent A-T patients (n=3) 
in our institution were successfully extubated after procedural mechanical ventilation (n=12 
episodes; total time on mechanical ventilation 30 min - 2 hr).
In conclusion, this series of three patients demonstrates that severe restrictive lung dysfunction 
is a common finding in adolescent A-T patients and a serious risk factor for adverse outcome 
after the start of mechanical ventilation. Preadmission lung function testing is essential for the 
optimal medical management of these patients.
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Abstract 
Background: Non-infective cutaneous granulomas with unknown pathogenesis, occur in 
various primary immunodeficiencies (PIDs) including ataxia telangiectasia (A-T). 
Objective: To find a common immunological denominator in these cutaneous granulomas.
Methods: The dermatological and immunological features of 4 patients with A-T and cutaneous 
granulomas were described and the literature on skin granulomas in A-T and in other PIDs is 
reviewed.
Results: All 4 A-T patients had progressive granulomas on their limbs and showed decreased 
IgG and IgA concentrations with normal IgM levels. They had a marked decrease of B-cells and 
naïve T-cells coinciding with the appearance of the cutaneous granulomas. Reportedly, similar 
B- and T-cell abnormalities were described in patients with other PIDs with skin granulomas.
Conclusions: We hypothesize that the pathogenesis of these skin granulomas is related to 
immune dysregulation of macrophages due to the absence of naïve T-cells with an appropriate 
T-cell receptor repertoire in the presence of γδ T-cells and/or NK-cells.
Keywords: Ataxia telangiectasie, Cutaneous Granulomas, Immunodeficiency, B-cells, T-cells, 
NK-cells.
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Introduction 
Systemic granulomas develop in response to infections like Mycobacterium tuberculosis 
and Schistosoma mansoni, to foreign material or in the context of non-infectious diseases 
like sarcoidosis and Wegener’s granulomatosis. Cutaneous granulomas with unknown 
etiology not related to infectious or systemic diseases, occur uncommonly in various primary 
immunodeficiencies (PIDs).
Ataxia telangiectasia (A-T), is caused by a mutation in the A-T Mutated gene, localized 
on chromosome 11 (11q22-23) and its protein is involved in cell cycle control and DNA-
repair.1 A-T is characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, 
immunodeficiency, predisposition toward malignancy, elevated α1-fetoprotein levels, 
rearrangement of chromosome 7 and 14, and increased radiosensitivity. In addition A-T patients 
may display a wide range of humoral and cellular immune system abnormalities and variable 
lymphopenia.2 Here we describe four A-T patients who developed cutaneous granulomas and 
review the literature of all (n=17) reported A-T patients with skin granulomas. In addition, we 
review the literature on cutaneous granulomas in all known other PIDs. Based on the obtained 
data we propose that unexplained cutaneous granulomas in PID patients can be considered as 
a manifestation of dysregulation in wound healing and tissue repair explained by the immune 
defects inherent in to these PIDs.
Material and methods
Medio 2010 there were 52 patients known in the Dutch A-T registry. In all, the diagnosis was 
confirmed by chromosomal analysis. Cutaneous granulomas developed in 4 (8%) of these 
52 patients. Unfortunately, one patient was lost to follow up. In this article, we discuss the 3 
Dutch A-T patients and included one Icelandic A-T patient with cutaneous granulomas who 
shared the same immunological profile. We also reviewed existing literature on cutaneous 
granulomata in patients with A-T3-12 and in patients with other PIDs. To this end a search was 
done in Pub-Med with the MeSH words: granuloma, skin, cutaneous and all known PIDs as 
reported by the International Union of Immunological Societies Expert Committee on Primary 
Immunodeficiencies13. Included were all primary publications published in English, German 
and French. Eleven primary reports were found describing cutaneous granulomas in A-T3-12 
and a series of articles reporting skin granulomas in other PIDs 14-26. For Common Variable 
Immuno Deficiency (CVID), often associated with granulomas in various organs, only the 
recently published article of Ardeniz et al.23 dealing with skin granulomas was included.
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Case reports
Patient 1
An 8 yrs old girl of Moroccan ancestry presented with a one year history of tender lesions on 
the left leg appearing after a fall. It started as an ulcer, which progressively enlarged to involve 
her entire lower leg. She had been diagnosed with A-T at 2 yrs of age on the basis of cerebellar 
ataxia, elevated α- fetoprotein (αFP), recurrent sinopulmonary infections with low IgG, deficient 
IgA (<0.10 g/L) but normal IgM (1.18 g/L) (Table 1). At the time of appearance of the granulomas, 
she had almost absent CD19+ B-cells, extremely low naive (CD3+CD4+C45RA+) T-cells, and 
normal NK-cells in her peripheral blood (Table 1). Clinical examination revealed multiple tender 
ulcers on the left anterior shin and below her knee. The ulcers had irregular ragged edges 
with clean fibrinous bases. The surrounding skin was erythematous, atrophic and had surface 
telangiectasia (Figure 1). A biopsy from the lesions showed palisading granulomas consisting 
Figure 1. Ulcer on the leg 
with surrounding erythema, 
atrophy and telangiectasia 
of  Patient 1
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of histiocytes and polynuclear giant cells with necrosis. Alcian blue stain, Ziehl-Neelsen 
(ZN) and periodic acid-Schiff (PAS) stain were negative as were cultures for microorganisms. 
The lesions continued to deteriorate despite topical tacrolimus, topical corticosteroids, oral 
antibiotics, tuberculostatics and increment of the dosage of intravenous (IV) immunoglobulin. 
Slight improvement was noted when she was on oral corticosteroids given for her interstitial 
lung disease. She suffered from recurrent chest infection and succumbed due to respiratory 
failure at 14 yrs of age.
Patient 2
Patient 2, the son of consanguineous Dutch parents, was diagnosed as A-T at age two based 
on cerebellar ataxia, ocular telangiectasia, recurrent upper respiratory tract infections and low 
IgG, absent IgA and slightly increased IgM (1.93 g/L) (Table1). At the age of 6 yrs he developed 
progressive lesions on arms and legs. Clinical examination at 8 yrs old showed erythematous 
atrophic plaques on his right hand and left leg associated with surface telangiectasia (Figure 
Table 1. Immunological characteristics of the 4 described A-T patients with skin granulomas at time of diagnosis 
of A-T and at time of diagnosis of granulomas
At time of diagnosis of AT
 Normal value Patient 1 Patient 2 Patient 3 Patient 4
Age in months  24 24 12 24
Mutation   c.2921+5G>A c.2467+1551 del 97kb c.5188C>T c.2554C>T
IgG (g/L) 4.0-11.0 2.27 2.34 0.50 0.30
IgA (g/L) 0.1-1.80 <0.10 <0.10 <0.10 <0.10
IgM (g/L) 0.5-1.80 1.18 1.93 0.90 0.83
CD19+ B-cells (x109/L) 9-15m: 0.6-2.7  0.4 0.16 0.16 0.07
 15-24m:0.6-3.1
CD3+ T-cells (x109/L) 9-15m: 1.6-6.7 1.6 0.83 1.04 0.68
 15-24m: 1.4-8.0
CD4+ T-cells (x109/L) 9-15m: 1.0-4.6 1.0 0.72 0.45 0.30
 15-24m: 0.9-5.5
Naïve T- cells (x109/L)  0.4 0.10 0.02 Not available
Effector T-cells (x109/L)   1.0 0.57 0.40 Not available
CD8+ T-cells (x109/L) 9-15m : 1.0-4.6 1.2 0.21 0.21 0.56
 15-24m : 0.9-5.5
NK-cells (x109/L) 9-15m: 0.2-1.2 1.1 0.15 0.50 0.51
 15-24m: 0.1-1.4
At time of diagnosis of granulomas
 Normal value Patient 1 Patient 2 Patient 3 Patient 4
Age in years  8 8 7 8
B cells x109/L 0.2-1.6 0.01 0.03 0.07 0.01
CD3+ T-cells (x109/L) 0.7-4.2 0.34 0.90 1.50 0.65
CD4+ T-cells (x109/L) 0.3-2.0 0.28 0.70 0.50 0.31
Naïve T-cells (x109/L)   0.03 0.02 <0.01 <0.01
Effector T-cells (x109/L)  0.24 0.68 0.24 0.15
CD8+ T-cells (x109/L) 0.3-2.0 0.24 0.13 0.43 0.31
NK-cells (x109/L) 0.09-0.9 0.33 0.04 0.41 0.36
γδ T-cells (x109/L) 0.06-0.6 0.02 0.11 0.61 0.05
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2) and shallow tender ulcers on his right wrist and left foot. At that time, he had markedly 
decreased CD19+ B-cells, low CD3+CD4+CD45RA+ naive T-cells and low but detectable NK-
cells in his peripheral blood (Table 1). On histology, granulomatous inflammation was seen in 
the deeper half of the dermis consisting of epitheloid histiocytes and polynuclear giant cells 
surrounding a necrotic center. Small amount of mucin were demonstrated in the center of the 
granuloma. Culture for microorganisms, ZN stain and PAS stain were negative. The histological 
and immunohistochemical features of his granulomas were published previously27. Notably, 
the intra-lesional CD4+/CD8+ ratio was low (0.28). The lesions did not respond to topical or 
intralesional corticosteroids or topical and systemic antibiotics. Although some improvement 
was noted with topical tacrolimus, the plaques on his limbs persisted. At age twelve, he 
developed a pre-malignant B cell lymphoma which regressed with rituximab. Unfortunately, a 
year later, he was discovered to have nasopharyngeal carcinoma and passed away.
Patient 3
Patient 3, a girl of Afghan ancestry, was diagnosed with A-T when she was one year old on the 
basis of positive family history (two siblings had A-T) and investigations revealing elevated 
αFP, low IgG, deficient IgA, and normal IgM (Table 1). At 7 yrs old, she presented with two 
discrete well-demarcated plaques on her left lower leg, which appeared after an insect bite. 
Clinical examination showed a 5 by 2 cm dusky-red, scaly, well-demarcated plaque with central 
crusting on her left lower leg and another similar plaque on her right forearm. The lesions were 
Figure 2. Erythematous atrophic plaques associated with telangiectasia  on the leg of Patient 2
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not tender. At that time, she had almost absent CD19+ B-cells, very low CD3+CD4+CD45RA+ 
naïve T-cells and normal NK-cells in her peripheral blood (Table 1).
Patient 4
From the age of six months, this Icelandic girl suffered from recurrent otitis media and 
pneumonia. When she was sixteen months old, immunological investigations revealed IgG and 
IgA deficiency with normal IgM (Table 1). She was started on immunoglobulin substitution and 
prophylaxis for Pneumocystis jirovecii pneumonia. She developed cerebellar ataxia at eighteen 
months. At 8 yrs old, she developed, without distinct triggers erythematous indurated plaques 
in her face, thighs and legs. The lesions on her face measured between 0.5 to 4 cm. They were 
non-tender, not ulcerated, erythematous, slightly indurated but not fixed to the underlying 
structures. A biopsy showed granulomatous inflammation. Alcian blue, ZN and PAS stains 
were normal and repeated cultures and polymerase chain reaction (PCR) for microorganisms 
were negative. At the time of diagnosis of the granulomas, she was found to have significantly 
decreased number of CD19+ B-cells, low CD4+ T-cells but normal NK-cells in her peripheral 
blood (Table 1). Treatment including topical and intra-lesional steroids, topical tacrolimus, 
oral antibiotics, oral anti-fungal and etanercept were unsuccessful. With oral steroids, the 
granulomas decreased significantly but relapsed after withdrawal. Control of the granulomas 
was again obtained with reintroduction of steroids that were maintained at low doses.
Review of the literature
We traced in the literature 17 reported A-T patients with cutaneous granulomas3-12 (Table 2 ). 
There was a female preponderance (13 females, 4 males) compared with equal sex distribution 
in A-T patients in general. The age at presentation of the cutaneous granulomas ranged from 
1.5 to 31 yrs. The duration of skin lesions before diagnosis varied from 11 months to 5 yrs. 
Table 2. Immunological characteristics of A-T patients in general and in patients reported in the literature with 
skin granulomas 
 Number Age  IgG IgA IgM IgG2 B-cells CD3+  CD3+ CD3+  γδ T- NK- 
 of in      cells CD4+ CD8+ cells cells
 patients years       cells cells
Ataxia Telangiectasia (classical)  N QQQ N QQQ N-Q N-Q N-Q N-Q N N
Fleck 19863 1 8 Q QQQ qqq
Paller 19914 8
Joshi 19935 1 7 N QQQ q
Götz 19946 1 13 N QQQ q QQ    q
Drolet 19977 1 6.5 N QQQ N
Murakawa 19988 1 8
Sentürk 19989 1 12 QQQ Q N
Corbisier 199910 1 2 QQQ Q qqq
Mitra 200511 1 4 Q QQQ  QQQ
Folgori 201012 1 3 QQ QQQ N QQQ QQ Q QQ Q  N
N = normal, QQQ= deficient
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Interestingly, in 4 of the reported patients, the onset of granulomas antedated the diagnosis 
and the classical cutaneous features of A-T. All patients presented in literature, including ours, 
had lesions on the limbs. The second most common site was the face, while only a quarter of 
the patients had lesions on their trunk.
In the reported patients, the granulomas were described to be well-defined erythematous 
indurated papules and plaques, which slowly enlarged and became scaly. They were usually 
small, less than 5 cm in diameter though lesions up to 10 cm were reported. Most had central 
atrophy with occasional ulceration and surface telangiectasia. The lesions healed with 
hyperpigmentation. Tenderness was noted in 3 of the 17 reported patients whereas 2 of our 4 
patients had significant pain.
Immunoglobulin levels were measured in only 8 of the 17 reported patients. Five had IgG 
deficiency; 3 had normal total IgG although in one, IgG2 was low (IgG-subclasses were not 
measured in the other 2 patients). All 8 patients in which immunoglobulin levels were reported 
had markedly decreased IgA levels and normal or elevated IgM. Only in one patient data on 
B-cells, T-cells and NK-cells were available.12 In this 3 yrs old boy, B-cell count was decreased 
(0.04x109/L), T-cells (CD3+) were low (0.30x109/L) with a marked predominance of T-cells with a 
memory phenotype (CD3+CD4+CD45RO+)12, and NK-cell numbers were normal. Interestingly, 
T-cell rearrangement excision circles in this patient were extremely low for both CD4+ and 
CD8+ T-cells with oligoclonal expansion in most peripheral CD4+ and CD8+ T-cells. Also, the 
T-cell receptor (TCR) repertoire in the skin biopsy was skewed.12
No treatment was shown to be effective. Topical steroids and oral antibiotics did not alter the 
course of the disease though topical steroids decreased the erythema and scaling of lesions 
in two patients.3,4 Oral steroids in combination with oral antibiotics resulted in slow control in 
one patient in the literature, however, the lesions relapsed after cessation of steroids.11 Similar 
control and relapse with the discontinuation of oral steroids was also noted in our fourth 
patient. Intra-venous immunoglobulin therapy had no effect in three patients while in another 
patient, it was reported to induce regression of the lesions.6,10 Local recurrence and enlargement 
occurred after excision in one patient.4 Paller et al.4 proposed a trial of topical corticosteroid 
for granulomas in A-T patients that are not ulcerated, while application of topical mupirocin 
or nonadherent dressings is most appropriate for ulcerated lesions. For A-T patients with 
debilitating granulomas, she proposes administration of systemic steroids, to be undertaken 
with caution in view of their tendency towards progressive sinopulmonary infections.
Our literature search on the occurrence of skin granulomas in other PIDs revealed description 
of cutaneous granulomas in Nijmegen Breakage Syndrome (NBS)14,15, severe combined 
immunodeficiency (SCID) caused by deficiency of RAG16, Artemis17 and JAK318, TAP deficiency 
syndrome19-21, Griscelli syndrome22 and common variable immunodeficiency (CVID)23(Table 
3). Three studies on skin granulomas were cancelled: two studies describing lesions in a 
patient with X-linked Hyper-IgM24 and IgA deficiency25 because from the decription the lesions 
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appeared sarcoid-like not resembling the skin granulomas in A-T, and one study on a man with 
X-linked agammaglobulinemia (XLA)26 because the paper was published in 1991 before the btk 
gene analysis became available and the description of the patient did not fit to what is now 
known for XLA.
In NBS, a condition caused by a DNA repair defect resembling the defect in A-T, which is 
characterized by microcephaly, a special face and combined immunodeficiency, 2 patients with 
skin granulomas have been described.14,15 Skin granulomas have been reported also in SCID 
caused by RAG deficiency16 (2 patients), Artemis deficiency17 (1 patient) or JAK3 deficiency18 
(1 patient). In Griscelli syndrome, characterized by partial pigmentary dilution or albinism, 
frequent infections and neurological abnormalities, defective NK- and T-cell cytotoxicity and 
Table 3. Immunological characteristics of patients with other PIDs and skin granulomas
PID Number Age  IgG IgA IgM IgG2 B-cells CD3+  CD3+ CD3+  γδ T- NK- 
 in years       cells CD4+ CD8+ cells cells
         cells cells
NBS   N-Q QQQ N QQQ N -Q N -Q N -Q N -Q N N
yoo 200814 1 7 N QQQ   Q Q
Vogel 201015 1 9 QQQ QQQ QQQ   Q
RAG deficiency   QQQ QQQ QQQ QQQ QQQ QQQ QQQ QQQ N N
Schuetz 200816 2 3 QQQ QQ QQ  QQQ QQQ QQQ Q N N
  7 QQQ QQ N  QQ QQ QQ low N N N
Artemis deficiency   QQQ QQQ QQQ QQQ QQQ QQQ QQQ QQQ N N
IJspeert 201117 1 6 N - Q QQ Q  QQ Q Q N N N
Jak3 deficiency   Q Q Q  N - Q QQ    QQQ-Q
Gregoriou 200818 1 6 QQQ QQQ Q    QQQ N  QQQ
HLA Class I deficiency (TAP  N N N  N  N Q
deficiency)
Moins- 5 adult       N QQ qq qq
Teisserenc 199919  adult       Q N qq qq
  adult       QQ qq qq q
  27       Q N qq qq
  36       Q Q qq qq
Mertens 200020 1 34        QQ  qq
Villa Forte 200821 1 20     N   Q q N
Griscelli Syndrome   N N N  N N    ab- 
            nor- 
            mal
Eyer 199822 1 3
Common variable    QQ N- N- QQ N-QQ N-QQ N-QQ  N N
immunodeficiency    QQQ	 QQQ
Ardeniz 200923 7 14 QQQ QQQ QQQ  N
  16 QQQ QQQ Q  QQ
  22 Q QQQ QQQ  QQQ
  27 QQQ QQQ QQQ  Q
  37 QQQ QQQ Q  QQ
  44 Q Q N
  59 QQQ QQQ Q  Q
N = normal, QQQ= deficient
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uncontrolled lymphocyte and macrophage activation, 1 patient has been described22. In 
patients with HLA Class I deficiency (TAP deficiency)19-21 and in patients with common variable 
immunodeficiency (CVID) cutaneous granulomas are reported more frequently. Granulomas in 
various other organs (lung, liver, lymphnodes, gastro-intestinal tract) are a well known feature 
of the subgroup of CVID-patients with a defective B-cell class switch and low T-cells.28
Discussion
The principal finding of the current study is the observation of non-infectious dermal 
granulomas in A-T patients. A-T is a PID associated with defective DNA-repair. In B- and T- 
cells, this defect causes a restricted repertoire of the B-cell receptor (BCR) and T-cell receptor 
(TCR).29 Approximately 10% of A-T patients has a deficiency of IgG and IgA and unaffected or 
even slightly increased IgM levels, which is indicative for a defective CD4+Th2-cell dependant 
switch of B cells in the germinal center. All our 4 A-T patients with granulomas had this hyper 
IgM phenotype. Indeed, switched memory B-cells, determined in two of them, were absent 
(Driessen et al, in preparation). Further, we noticed that by the time of diagnosis of the 
cutaneous granulomas in our A-T patients, they all had a markedly reduced number of CD19+ 
B-cells and CD3+CD4+CD45RA+ naïve T-cells (Table 1). This immunological profile is distinct 
from that observed in our patients at an earlier stage, and also differs from that reported in the 
literature for A-T patients without skin granulomas.30 Interestingly, the same immunological 
disturbances were mentioned in the A-T patient of Folgeri12 (Table 1) and in the patients with 
cutaneous granulomas associated with RAG deficiency16 and Artemis deficiency17 (Table 2). 
CVID patients, particularly those with B and T-cell lymphopenia and reduced switched memory 
B-cells are also more prone to granulomatous disease.28,31 Resolution of cutaneous granulomas 
in RAG deficiency and Artemis deficiency have been noted after hematopoietic stem-cell 
transplantation.16,17
In none of the A-T patients with skin granulomas an infective cause was demonstrated. 
Cultures and staining for microorganisms in all 17 reported patients as well as in all our 4 
patients were negative. In several patients, the granulomas developed after minor injuries. 
The propensity for granulomas to appear on the limbs (trauma prone area) may be related 
to impaired wound healing and tissue repair in these immunodeficient patients. The marked 
decrease of B-cells and naïve T-cells in our A-T patients coinciding with the appearance of the 
cutaneous granulomas (Table 1) suggests that the immunopathology of these skin lesions may 
be secondary to impaired B-cell or T-cell mediated immune regulation.
Dermal wound healing is a complex sequential process that involves the integration of 
chemotaxis of inflammatory cells, migration of keratinocytes and remodeling of scar tissue. 
T-cells, B-cells and various key growth factors and enzymes work in synergy to orchestrate 
the healing process.32 CD19 is a positive-response regulator of B-cells, which play a critical 
role in wound healing as is shown by the observation that CD19 deficiency in mice inhibits 
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wound healing.33 Macrophages exert different roles at diverse stages of the repair response 
and they orchestrate the natural sequence of repair phases in skin, which are essential to 
restore solid tissue homeostasis and integrity postinjury.34 Macrophages are activated in 
response to various cytokines, including interferon-γ (IFNγ)35 that is produced by NK-cells36 and 
by T-cells. The crucial role of IFNγ in the induction of granulomas is illustrated by the inability 
of patients with a defective IFNγ signaling pathway to form mature granulomas in response 
to mycobacterial infections.37 The importance of NK-cells is illustrated by the occurrence of 
granulomas in patients with TAP deficiency who lack, by the absence of HLA class I molecules, 
the ability to turn off NK-cell activity and thus NK-cell derived IFNγ production.19,38 In A-T 
patients, the amount of intracellular IFNγ in NK-cells is not different from controls30 and NK-cell 
numbers were normal in our A-T patients and also in patients with RAG deficiency and Artemis 
deficiency (Table 1 and Table 2). However, in the patient with JAK3 deficiency and granulomas 
NK-cells were absent.
An appropriate on-off T-cell response requires proliferation of naïve T-cells with a normal, 
unrestricted T-cell receptor (TCR) repertoire.39 In A-T, TCR repertoire is skewed as it was in 
the patient with skin granulomas reported by Folgori et al.12 Similarly, an abnormal TCR 
repertoire has been reported in the patients with RAG deficiency and in patients with CVID 
who display granulomas. Specific CD4+ Th1-lymphocytes recognize via their αβ TCR complex, 
peptide antigens presented by macrophages on major histocompatibility (MHC) class II 
molecules.40 Although most T-cells bear the TCR αβ complex, a small subpopulation of about 
5% have a distinct T-cell receptor composed of γ and δ subunits. For non-peptide antigens, 
as encountered in Mycobacterium infections, IFNγ comes mainly from these γδ T-cells which 
recognize antigens that are not presented in the MHC II context.41 T-cells bearing γδ-receptors 
are present in patients with A-T42, NBS, RAG deficiency and Artemis deficiency. In the patient 
with JAK3 deficiency the presence of γδ T cells was not investigated, however γδ T-cells were 
demonstrated in other patients with this defect.43 In patients with TAP deficiency γδ T-cells are 
elevated and autoreactive NK- and γδ T-cells were demonstrated.38 Both NK-cells and γδ T-cells 
have been reported to be important in the development of cutaneous granulomas.37,38,40,44-46
IL-10 is a cytokine, derived from Th2-cells, that inhibits Th1 derived IFNγ production.47,48 Thus, 
whereas granuloma induction requires IFNγ, the resolution of granulomas needs IL-10. This 
means that appropriate activation of both specific Th1-cells and Th2-cells are crucial for an 
appropriate induction and cessation of a granulomatous response.
We propose that in patients with immunodeficiencies like A-T, NBS, deficiencies of RAG, Artemis 
and CVID, macrophages cannot function appropriately due to the lack of naïve (CD4+CD45RA+) 
T-cells with functional unrestricted TCR-repertoire on CD4+ Th1- and Th2-cells. Whereas NK-
cells and/or γδ T-cells will continue to activate the macrophages in the skin, this activation 
cannot be downregulated due to the absence of a counterregulatory IL-10 production by a 
specific CD4+ cell population.
In conclusion, we report that a subset of A-T patients with deficiencies of IgG, IgA and normal 
or even increased levels of IgM (the so-called hyper IgM phenotype), is more likely to develop 
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cutaneous granulomas. We postulate that the etiology of these granulomas is related to 
immune dysregulation as suggested by a marked reduction of peripheral CD19+ B-cells, a 
low number of CD3+CD4+CD45RA+ naïve T-cells in the presence of normal NK-cells and γδ 
T-cells.
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Abstract 
Objective: To describe the phenotype of adult patients with variant and classical ataxia 
telangiectasia (A-T), to raise the degree of clinical suspicion for the diagnosis variant A-T, and 
to assess a genotype-phenotype relationship for mutations in the ATM gene.
Methods: Retrospective analysis of the clinical characteristics and course of disease in 13 
adult variant A-T patients of nine families and six unrelated adults with classical A-T. Mutation 
analysis of the ATM gene and measurements of ATM protein expression and kinase activity.
Results: Variant A-T patients were only correctly diagnosed in adulthood. They often presented 
with extrapyramidal symptoms in childhood, whereas cerebellar ataxia appeared later. Four 
variant A-T patients developed a malignancy. Both classical and variant A-T patients had 
elevated serum α-fetoprotein levels and chromosome 7/14 rearrangements. 
The mildest variant A-T phenotype was associated with missense mutations in the ATM gene 
that resulted in expression of some residual ATM protein with kinase activity. Two splicing 
mutations, c.331+5G>A and c.496+5G>A, caused a more severe variant A-T phenotype. 
The splicing mutation c.331+5G>A resulted in less ATM protein and kinase activity than the 
missense mutations. 
Conclusions: A-T should be considered in patients with unexplained extrapyramidal 
symptoms. Early diagnosis is important given the increased risk of malignancies and the higher 
risk for side effects of subsequent cancer treatment. Measurement of serum α-fetoprotein and 
chromosomal instability precipitates the correct diagnosis. There is a clear geno-phenotype 
relation for A-T, since the severity of the phenotype depends on the amount of residual kinase 
activity as determined by the genotype.
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Introduction
Ataxia telangiectasia (A-T), an autosomal recessive multisystem disease, is characterized by 
neurodegeneration – primarily of the cerebellum – and oculocutaneous telangiectasia. Other 
characteristics include a variable immunodeficiency, endocrinopathy, respiratory failure, high 
risk for malignancy, increased serum α-fetoprotein levels, radiosensitivity and chromosomal 
instability.1 The responsible A-T mutated (ATM) gene on chromosome 11q22-23 encodes the 
ATM protein.2,3 This protein is a key player in the cellular response to DNA damage.4
A-T patients classically present with an ataxic gait at the time they begin to walk and are 
wheelchair-bound at approximately the age of 10 years. Death occurs in the second or third 
decade of life due to malignancies or respiratory failure. Some patients, however, designated 
as variant A-T patients, exhibit milder clinical features and have an extended life span.5-10 It has 
been suggested that variant A-T is associated with mutations that leave some residual ATM 
kinase activity whereas ATM kinase activity is fully absent in classical A-T patients.4
The clinical features of genetically proven variant A-T have only been described in reports on 
single cases or on two families maximally,6-8,11-17 while four other studies described primarily 
the genotypes of relative large series of variant A-T patients.9,10,18,19
We analyzed the clinical spectrum and genotype of a relative large series of 13 adult variant A-T 
patients and compare them with six classical A-T patients who survived into adulthood. Aims 
of the study were to assess a possible genotype-phenotype relationship for mutations in the 
ATM gene and to facilitate early diagnosis by enhancing awareness of variant A-T. 
Methods
All six classical A-T patients (c1-c6) who were known in our hospital during the last 30 years and 
who reached adulthood and thirteen adult patients with variant A-T (v1-v13) were included. All 
patients lived in the Netherlands. Data were retrospectively collected from the medical records 
at our hospital. Information on patient v6, v9, v11 and v13 was obtained from questionnaires 
completed by their attending physicians in other hospitals. Some data on patient v1-3 and v12 
have been published previously.15 The study was approved by the local ethical committee.
Molecular genetic studies and cytogenetic studies were performed using methods as 
previously described.20-22
Results
Demographic features (table 1)
Classical A-T: three men and three women (c1-c6), age range 21 to 38 years, from six families 
were included. Five died at ages between 21 to 27 years. One patient (c6) is alive at age 38.
Variant A-T: the 13 patients (v1-v13), age range 23 to 51 years, from nine families included 5 
men and 8 women. Two (v3, v6) died at the age of 51 and 23 years. Eleven patients are alive at 
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Table 1. Epidemiologic features and results of ATM mutation analyses of 6 classical and 13 variant A-T patients
pt sex year died at  ATM mutation protein change  mutation type
  of age   
  birth (yrs)
classical A-T
c1 F 1979 21 c.7875_7876delTGinsGC  p.Asp2625_Ala2626delinsGluPro exon 55 double
      missense mutation
    c.7875_7876delTGinsGC p.Asp2625_Ala2626delinsGluPro exon 55 double
      missense mutation
c2 F 1983 23 c.1027_1031del5  p.Glu343fs exon 10 frameshift
    c.1660delA p.Thr554fs exon 13 frameshift
c3 M 1980 26 c.8633 T>G p.Ile2878Arg exon 61 missense 
      mutation
    unidentified
c4 M 1972 27 c.5762-2 A>T p.Arg1921_Ser1974del52 exon 41 splice
      acceptor defect
    unidentified
c5 F 1962 27 c.7875_7876delTGinsGC  p.Asp2625_Ala2626delinsGluPro exon 55 double
      missense mutation
    c.8578_8580delTCT p.Ser2860del exon 60 deletion
      Serine 2860
c6 M 1970   c. 1564_1565delAG  p.Glu522fs exon 12 frameshift
    unidentified  
variant A-T
v1 M 1963   c.3136 C>T p.Leu1046Phe exon 23 missense 
      mutation
    c.7622 T>G p.Leu2541Arg exon 53 missense
      mutation
v2 M 1962   c.3136 C>T  p.Leu1046Phe exon 23 missense
      mutation
    c.7622 T>G p.Leu2541Arg exon 53 missense
      mutation
v3 M 1957 51 c.3136 C>T p.Leu1046Phe exon 23 missense 
      mutation
    c.7622 T>G p.Leu2541Arg exon 53 missense
      mutation
v4 M 1975   c.331+5G>A   exon 6 splice donor
      defect
    c.331+5G>A  exon 6 splice donor 
      defect
v5 F 1972   c.331+5G>A   exon 6 splice donor
      defect
    c.331+5G>A   exon 6 splice donor
      defect
v6 M 1969 23 c. 2909 T>G p.Leu970Arg exon 21 missense
      mutation
    c.6908dupA p.Glu2304fs exon 49 frameshift
v7 F 1975   c. 2909 T>G  p.Leu970Arg exon 21 missense
      mutation
    c.6908dupA p.Glu2304fs exon 49 frameshift
      
v8 F 1974   c.5932 G>T  p.Glu1978X exon 42 nonsense
      mutation
    c.8147 T>C  p.Val2716Ala exon 57 missense
      mutation
22451_Mijke Verhagen binnenwerk.indd   88 10-07-2012   11:45:49
89
CLINICAL SPECTRUM OF ATAXIA-TELANGIECTASIA IN ADULTHOOD
4.1
ages between 32 to 51 years. There was one family with three affected sibs (v1-v3); two families 
had two affected sibs (v4-v5 and v6-v7). 
Neurological features (Table 2)
Classical A-T: in all patients an ataxic gait was the first symptom and started between the age 
of 1 and 5 (median 1.5) years. All patients were wheelchair-bound at ages between 8 and 11 
Table 1. Continued
pt sex year died at  ATM mutation protein change  mutation type
  of age   
  birth (yrs)
v9 F 1971   c.8147 T>C p.Val2716Ala exon 57 missense 
      mutation
    unidentified
v10 F 1962   c.8147 T>C  p.Val2716Ala exon 57 missense 
      mutation
    unidentified
v11 F 1958   c.717_720delCCTC  p.Leu240fs exon 9 frameshift
    c.8147 T>C p.Val2716Ala exon 57 missense 
      mutation
v12 F 1958   c.2922-1G>A  p.Val2716Ala exon 22 splice 
      acceptor defect
     c.8147 T>C  exon 57 missense 
      mutation
v13 F 1960   c.496+5G>A  p.Arg111_Glu166del55insLys exon 7 splice donor
      defect
    c.7875_7876delTGinsGC p.Asp2625_Ala2626delinsGluPro exon 55 double 
      missense mutation
Mutations in bold have previously not been reported
Table 2. Neurological features in 6 classical and 13 variant A-T patients
  classical  variant
cerebellar ataxia 6/ 6 12/ 13
 mild/ moderate 0/ 6 12/ 13
 severe 6/ 6 0/ 13
wheelchair-bound 6/ 6 5/ 13
 age of 8 - 12 years 6/ 6 0/ 13
 age of 15 - 21 years 0/ 6 3/ 13
 age of 42 - 43 years 0/ 6 2/ 13
nystagmus 4/ 4 5/ 11
oculomotor apraxia 6/'6 7/'11
dysarthria 6/ 6 13/ 13
chorea-athetosis 5/ 5 9/ 13
dystonia 3/ 3 8/ 11
resting tremor unknown 8/ 12
 mild/ moderate
 severe  4/ 12 4/ 12
polyneuropathy 4/ 4 6/ 10
neuronopathy of anterior horn cells unknown 7/ 8
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(median 10.5) years. All suffered from cerebellar dysarthria and oculomotor apraxia. Chorea-
athetosis was noted in five (c2-c6), nystagmus in four (c2-c5), dystonia in three (c3, c4, c6) and 
myoclonus in two patients (c3, c4). 
In four patients (c1-c4) electrophysiological studies were performed, showing progressive 
axonal sensorimotor polyneuropathy.23 
Cerebral imaging studies were available of four patients (c1-c3, c6) and demonstrated cerebellar 
atrophy without other abnormalities.
Variant A-T: the presenting signs were variable (Table 3). Seven patients (v4-v8, v10, v11) 
presented with slowly progressive chorea-athetosis since early childhood (range 0 to 4 years). 
A resting tremor was the presenting symptom in five patients (v1-v3, v9, v12) at age 12 to 34 
years. Patient v13 experienced primarily distal muscle weakness of the lower extremities from 
the age of 6 years. Twelve patients (v1-v8, v10-v13) suffered from mild to moderate, slowly 
progressive, cerebellar ataxia with a median age of onset of 27 (range 6 to 39) years. Five patients 
(v4, v5, v10, v11, v13) were confined to a wheelchair between ages of 15 and 43 (median 21) 
years, after a disease duration of 9 to 43 (median 20) years. Since childhood dysarthria was 
noted in four patients (v6-v9). In adulthood dysarthria was noted in all, chorea-athethosis in 
Table 3. Initial symptoms and suspected diagnosis of 13 variant A-T patients
pt age of  presenting feature first diagnosis (age in years) age of 
 onset    diagnosis 
 (yrs)    (yrs)
v1 26 resting tremor resting tremor of unknown cause (28) 31
v2 16 resting tremor extrapyramidal disorder of unknown cause (18) 31
   extrapyramidal disorder and anterior horn disease 
   of unknown cause (29) 
v3 34 resting tremor    37*
v4 1 chorea-athetosis chorea-athetosis of unknown cause (11) 30
   friedreichs ataxia (16) 
v5 1 chorea-athetosis chorea-athetosis of unknown cause (14) 32
   friedreichs ataxia (19)
   spinocerebellar ataxia (31)
v6 0.5 chorea-athetosis familiair chorea (early childhood) after death
   familiair dystonia (adolescence) 
v7 0.5 chorea-athetosis familiair chorea (1)  26
   familiar dystonia (16)
v8 4 chorea-athetosis mild hyperkinetic syndrome and general motor  30
   retardation (9)
v9 12 resting tremor and  dystonia of unknown cause (28) 36
  dysarthria
v10 0.5 chorea-athetosis chorea-athetosis of unknown cause (7) 45
   myoclonus-dystonia (42)
v11 1.5 chorea-athetosis dystonic cerebral palsy (44) 47
v12 32 gait disturbance and  functional tremor (35)  38
  resting tremor
v13 6 distal muscle  early onset pyramidal syndrome of unknown cause (6) 44
  weakness
* the brothers of patient v3 (v1 and v2) were already diagnosed with A-T 
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nine patients (v4-v8, v10-v13), a mild to severe resting tremor in eight patients (v1-v3, v5, v7-
v9, v12), even as mild to moderate dystonia (v5-v12), a mild to severe oculomotor apraxia in 
seven (v4, v5, v7, v8, v10, v12, v13), and nystagmus in five patients (v4, v5, v7, v12, v13). Overall, 
patient v4, v5 and v13 were clinically more severely affected than the other patients.
Electrophysiological studies were performed in 10 patients and were dominated by either 
anterior horn cell involvement (v1-v3, v7, v8, v11, v12) (ages 29 to 47 years) or axonal sensorimotor 
polyneuropathy (v4-v5, v9 from the age of 31, 19 and 36 years) or the combination of both. 
In v13 no electrophysiological studies were performed, although, the clinical picture was 
compatible with a sensorimotor polyneuropathy with additional anterior horn involvement. 
Cerebral images were available of 12 patients. A normal cerebellum was demonstrated in eight 
patients (v2, v3, v6, v7, v9-v12) at ages between 19 and 46 (median 35.5) years. Cerebellar 
atrophy, particular of the vermis, was found in patients v1, v4, v5 and v8, at ages of 29, 31, 19 
and 29 years. In v6 a temporal lobe brain tumor was demonstrated at age 23. 
Non-neurological features (Table 4)
Endocrine function
Classical A-T: five patients (c2-c6) had a distinct growth retardation with adult heights below 
the 3rd percentile, while the height of c1 was between p10 and p25. All six patients lacked the 
puberty-associated growth spurt. Diminished secondary sexual characteristics were noted in 
three patients (c2, c5, c6). Diabetes mellitus type II, documented in four patients (c1, c2, c4, c6), 
started at ages between 19 to 28 (median 24) years.
Variant A-T: although the exact height of three patients (v3, v6, v11) was never documented, 
the remaining 10 patients reached normal height. Only one patient (v6) had delayed secondary 
sexual characteristics. In the third decade of life two women (v11, v12) had offspring. Diabetes 
mellitus did not occur.
Eye and skin abnormalities
Classical A-T: in all patients ocular telangiectasia was noted in childhood. Cutaneous 
telangiectasia was documented in four patients (c1, c3, c4, c6). 
Variant A-T: minimal ocular telangiectasia was observed in seven (v1-v3, v5, v10, v12, v13) and 
cutaneous telangiectasia in one patient (v13).
Pulmonary function
Classical A-T: in five patients pulmonary function tests (c1-c4, c6) revealed severe and 
progressive restrictive lung function at ages between 14 and 33 years. The mean vital capacity 
was 12 to 58% of normal. 
Variant A-T: lung function was normal in all tested patients (v5, v7, v8, v12) at ages between 30 
and 49 years. 
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Malignancies
Classical A-T: three patients developed a malignancy: epipharyngeal B-cell non-Hodgkin 
lymphoma was diagnosed in c2 at age 16; mixed cellularity Hodgkin’s lymphoma in c3 at age 
25, and c5 died from breast cancer at the age of 27. 
Variant A-T: four patients developed a malignancy. At age 51, v3 died of acute lymphoblastic 
leukemia. Patient v6 deceased of an ectopic pituitary tumor at the age of 23. In v9 and v10 
breast cancer was diagnosed at age 32 and 43.
Laboratory features (Table 4)
α-fetoprotein levels
Classical A-T: all patients had elevated serum α-fetoprotein levels. Concentrations, measured at 
the age of 19 to 28, varied between 258 and 980 μg/L (reference value < 10 μg/L).
Variant A-T: α-fetoprotein serum concentrations were increased in all patients (reference value 
< 10 μg/L) (p = 0.001, Student’s t-test against 10) and varied between 102 and 496 μg/L. These 
results were obtained between ages of 26 and 52. The serum concentrations of α-fetoprotein 
were lower than in classical A-T patients (p=0.009, Mann-Whitney).
Table 4: Clinical and laboratory features in 6 classical and 13 variant A-T patients
  classical  variant
demographic features
offspring 0/ 6 2/ 13
died 5/ 6 2/ 13
non-neurological features
endocrine function 
adult height <p3 5/ 6 0/ 10
delayed secondary sexual characteristics 3/ 5 1/ 7
diabetes mellitus type II 4/ 6 0/ 13
eye and skin abnormalities
ocular telangiectasia 6/ 6 7/ 13
cutaneous telangiectasia 4/ 4 1/ 8
pulmonary function 
restricted respiratory function 5/ 5 0/ 4
malignancies 
haematological tumors 2/ 6 1/ 13
breast cancer 1/ 6 2/ 13
brain tumor 0/ 6 1/ 13
laboratory features
elevated serum α-fetoprotein concentration 6/ 6 12/ 12
immunology    
complete IgA deficiency 3/ 6 0/ 10
complete IgG2 and IgG4 deficiency 5/ 6 0/ 10
cytogenetic features 
rearrangements in chromosomes 7 and 14 6/ 6 8/ 8
radiation hypersensitivity 4/ 4 6/ 8
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Immunodeficiency
Classical A-T: IgA deficiency was demonstrated in three (c2, c5, c6) and IgG2 - and IgG4- deficiency 
in five patients (c1-c4, c6). 
Variant A-T: one patient (v5) had slightly decreased IgG2 and IgG4 levels. None of the patients 
had IgA-, IgG2- or IgG4-deficiency. 
Cytogenetic features
Classical A-T: all patients showed rearrangements of chromosomes 7 and 14. Radiation 
hypersensitivity was assayed in four patients (c1-c4): all showed severe radiation hypersensitivity 
as demonstrated by the occurrence of a large number of, often complex, chromosome 
aberrations in a high percentage (>70%) of their cells.
Variant A-T: in eight patients tested (v1-v3, v5-v8 and v12) typical rearrangements of 
chromosomes 7 and 14 were demonstrated. In eight patients radiation hypersensitivity was 
studied: severe hypersensitivity was observed in one (v5), intermediate X-ray sensitivity in four 
(v1, v8, v12, v13) and no hypersensitivity in three patients (v2, v4, v7). 
mutation analysis of the ATM gene (Table 1)
Classical A-T: mutation analysis revealed mutations in 9/12 alleles. All mutations would be 
predicted to result in loss of the function of the ATM protein. 
Variant A-T: mutations were identified in 24/26 alleles. Five unrelated patients had the same 
c.8147T>C (p.Val2716Ala) missense mutation in exon 57. Ten patients carried at least one 
missense mutation and the remaining three a splice site mutation. 
ATM expression levels and ATM kinase activity 
Classical A-T: ATM protein studies were only performed in patient c3. Cell lines of this patient 
showed some ATM protein expression without ATM kinase activity.
Variant A-T: cell lines from seven patients (v1, v2, v4, v5, v7, v8, v12) were shown to have some 
ATM protein expression, all with residual ATM kinase activity as measured by phosphorylation 
of ATM targets. The ATM kinase activity was only slightly decreased in the cell lines derived 
from patients v1, v2 and v12,15 all with missense mutations (Table 1). Cells from patient v7 (with 
missense mutation 2909T>G) and v8 (with missense mutation c.8147T>C), showed similar 
levels of residual ATM protein with a clearly measurable kinase activity (figure 1). Interestingly, 
cells from v4 and v5 (with the homozygous c331+5G>A splice site mutation) expressed the 
lowest level of ATM kinase activity.
Discussion 
Classical A-T is characterized by cerebellar ataxia, ocular telangiectasia, immunodeficiency, 
rearrangements of chromosome 7 and 14, X-ray hypersensitivity and elevated α-fetoprotein 
levels. All our adult classical A-T patients showed these hallmarks in an early stage of the 
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disease. In contrast, in variant A-T patients some of these features were absent and some 
became apparent only later in life (Table 2-4). 
In our experience, variant A-T patients present with extrapyramidal symptoms: most patients 
presented with chorea-athetosis in early childhood and five others with a resting tremor in 
childhood or young adulthood (Table 3). A cerebellar ataxia developed only years later in the 
course of disease. Remarkably, in the literature by far the majority of variant A-T patients are 
reported to present with ataxia in childhood.6,9,10 Eye movements can be normal in variant A-T 
patients, even at adult age, while oculomotor apraxia always develops in childhood in classical 
A-T patients (Table 2).8,10,11,16 In line with the literature, polyneuropathy was found both in 
classical and variant A-T patients. 
Figure 1. Western blot of different proteins in 4 variant A-T patients and a classical A-T patient 
There are two lanes for each cell line; - is absence of ATM kinase activation and + is activation of ATM 
kinase by exposure of cells to 5Gy gamma rays. The normal cells show activation of ATM kinase by 
autophosphorylation of ATM ser 1981, and phosphorylation of downstream targets, SMC1ser966, 
Nbs1ser343 and p53ser15 measured 30 minutes after irradiation. In the classical A-T patient (lane 
4) there is no ATM and no ATM kinase activity. The variant A-T patients have reduced levels of ATM 
in their cells with v4 and v5 having less ATM than v7 and v8. Cell lines from v7 and v8 have higher 
levels of ATM kinase activity than lines from patients v4 and v5, which correlates with the severity 
of the clinical picture
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All classical A-T patients have ocular telangiectasia, endocrinopathy – i.e. stunted growth in 
puberty and infertility – and immunological defects. Only 7/13 of our variant A-T patients and 
13/18 of the reported patients had ocular telangiectasia.6-9,11,12,16,17 Two of our patients and one 
published patient had offspring.16 Immunodeficiency of any clinical importance was not found 
in our variant A-T patients, neither described in the literature.8,9,11,12,16,17 Diabetes mellitus type 
II develops frequently in classical A-T as illustrated in this paper, however, it did not occur in 
our variant A-T patients and has not been reported until now. Importantly, both classical and 
variant A-T patients have an increased risk of malignancy.
Generally, the clinical diagnosis A-T is difficult to establish in patients who do not present with 
the characteristic classical phenotype, as clearly illustrated in this study. Variant A-T was often 
only diagnosed more than two decades after its onset (Table 3). A-T was finally considered when 
new neurological features (v1, v2, v4, v5, v7, v8, v11, v12) or the occurrence of a malignancy 
(v9, v10) complicated the clinical picture. In one patient (v10) A-T was diagnosed because 
of severe side effects, namely extensive dermatitis and brachial plexopathy, after radiation 
therapy for breast cancer, similar to what has been described previously for another patient 
with a mild form of A-T.16 Three patients (v3, v6 and v13) were diagnosed because of affected 
family members. In all our patients the finding of an elevated α-fetoprotein concentration 
strongly indicated the correct diagnosis. The α-fetoprotein serum concentrations in variant 
A-T were significantly less increased than in classical A-T. In the literature even borderline 
increased or normal α-fetoprotein levels in adult variant A-T patients have been described.12,16 
Rearrangements of chromosome 7 and 14 appeared to be present in all variant A-T patients 
tested (Table 4). Interestingly, the same was true for all variant A-T patients reported in the 
literature.6,8,9,11,12,16 Although so never emphasized, routine karyotyping would therefore be a 
very sensitive method to screen for A-T. In contrast with literature, the majority of our patients 
had a normal cerebellum on neuro-imaging studies around the age of diagnosis.7,11,12,14,16,17
It has previously been suggested that the phenotypic variability in A-T can be explained by 
differences in genotype. Mutations leading to even small amounts of active residual ATM 
protein can rescue the patient from classical A-T.4 In line with the literature, we did not find 
homozygosity or compound heterozygosity for two truncating mutations normally associated 
with classical A-T in variant A-T (Table 1). Three of our patients (v8, v11 and v13) were compound 
heterozygotes for a mutation previously described in classical A-T 19,24 and either a missense 
or splice site mutation, which – obviously – leads to the milder phenotype. Although some 
variability in neurological and non-neurological features exists between patients with the same 
genotype, we are not aware of any family in whom classical A-T and variant A-T co-occur. 
Even within the group of variant A-T patients phenotypic heterogeneity was noted. Siblings 
v4 and v5 and patient v13, all with a splicing mutation, had a more severe phenotype than the 
other variant A-T patients with missense mutations. Remarkably, the genotype of patient v13 
was identical to that of a earlier described (non-related) German patient with a comparable 
“intermediate phenotype”.6 The five unrelated patients, v8-v12, with the c.8147T>C mutation, in 
the presence of different truncating mutations in two cases, had a rather mild phenotype (Table 
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1). Patient v12 with a splice site mutation on the second allele had a less severe neurological 
phenotype than the patients (v8 and v11) with the truncating mutations on the second allele. 
The 8147T>C mutation appears a founder mutation in the Netherlands for variant A-T.
The clinical features of patients v8-v12, which are associated with expression of the p.Val2716Ala 
protein are similar to those associated with the earlier described p.Val2424Gly mutant ATM (due 
to the c.7271T>G mutation).16 Both mutations are associated with onset of some neurological 
features in childhood but with slower than usual progression of neurodegeneration, the 
retained ability to bear children and the occurrence of breast cancer. Analysis of cells from 
patient v8, that only expressed the p.Val2716Ala mutant protein, showed expression of some 
residual ATM protein with a significant level of kinase activity (figure 1). A similar level of ATM 
kinase activity was found to be associated with presence of the c.2909T>G mutation (v7). This 
is consistent with the similarity of their milder clinical features. Additionally, we were able to 
show that cells from the more severely affected patients with the homozygous c.331+5G>A 
splice site mutation (v4 and v5) had a lower level of ATM kinase activity compared with the 
protein expressed from the missense mutations described above. Another splice site mutation, 
c.5762ins167, was also reported to lead to a lower level of ATM kinase activity compared with 
a missense mutation, c.7271T>G, and a less milder variant phenotype.21 In contrast to our 
findings and all reports in the literature, recently two siblings with mild A-T were described, in 
whom ATM was fully absent in their cells. It was suggested that modifying genes might explain 
this intriguing finding.14 
As a progressive multisystem disorder, A-T shares many features with mitochondrial disorders. 
In-vitro experiments have provided some evidence for mitochondrial dysfunction as an 
additional pathogenic mechanism in A-T.25-27 We speculate that the milder clinical pattern in 
variant A-T, may be explained by better conserved mitochondrial function due to less oxidative 
stress as a result of residual ATM kinase activity.
Based on our experience added to previous reports in the literature, we conclude that some 
of the hallmarks (i.e. ataxia, oculocutaneous telangiectasia and immunodeficiency) of classical 
A-T become present only later in life or even remain absent in variant A-T. Extrapyramidal 
signs, instead of cerebellar ataxia, appear to be the dominating presenting features in variant 
A-T patients, and ocular telangiectasia are often absent in these patients. Second, the milder 
course of variant A-T is likely to be explained by mutations in the ATM gene, that leave some 
residual ATM protein with some residual kinase activity: a higher level of residual ATM kinase 
activity leads to a less severe phenotype. 
In children and adults with otherwise unexplained extrapyramidal or cerebellar signs A-T should 
be suspected. We recommend to determine serum α-fetoprotein in these patients. Additionally 
routine chromosomal analysis can be helpful in diagnosing (variant) A-T. Subsequent ATM 
protein studies and ATM gene mutation analysis should finally prove the diagnosis.
Early recognition of classical as well as variant A-T is a prerequisite for providing a correct 
prognosis and appropriate rehabilitation and support, including the avoidance of diagnostic 
X-ray procedures (because of radiosensitivity). Diagnosing A-T is of particular importance given 
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the increased risk of malignancies and the higher risk for side effects of subsequent cancer 
treatment. 
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Abstract
Ataxia-telangiectasia (A-T) is an autosomal recessive neurodegenerative disorder with 
multisystem involvement and cancer predisposition, caused by mutations in the A-T mutated 
(ATM) gene. To study genotype-phenotype correlations, we evaluated the clinical and 
laboratory data of 51 genetically proven A-T patients, and additionally measured ATM protein 
expression and kinase activity. Patients without ATM kinase activity showed the classical 
phenotype. The presence of ATM protein, correlated with slightly better immunological 
function. Residual kinase activity correlated with a milder and essentially different neurological 
phenotype, absence of telangiectasia, normal endocrine and pulmonary function, normal 
immunoglobulins,  significantly lower X-ray hypersensitivity in lymphocytes and extended 
lifespan. In these patients, cancer occurred later in life and generally consisted of solid 
instead of lymphoid malignancies. The genotypes of severely affected patients generally 
included truncating mutations resulting in total absence of ATM kinase activity, while patients 
with milder phenotypes harbored at least one missense or splice site mutation resulting in 
expression of ATM with some kinase activity. Overall, the phenotypic manifestations in A-T 
show a continuous spectrum from severe classical childhood-onset A-T to a relatively mild 
adult-onset disorder, depending on the presence of ATM protein and kinase activity. Each 
patient is left with a tremendously increased cancer risk.
Key Words: Ataxia-telangietasia, AT, genotype-phenotype, cancer,  ATM
22451_Mijke Verhagen binnenwerk.indd   102 10-07-2012   11:45:54
103
ATM PROTEIN AND RESIDUAL KINASE ACTIVITy 
4.2
Introduction
Ataxia-telangiectasia (A-T; MIM#208900) is an autosomal recessive multisystem disorder caused 
by mutations in the A-T mutated (ATM) gene (MIM# 607585). The estimated incidence is 1:40.000 
to 1:300.000 live births.1,2 Characteristic findings are early-onset cerebellar ataxia, oculocutaneous 
telangiectasia and susceptibility to pulmonary disease.1 In addition, A-T patients have an 
increased risk of cancer, especially hematologic malignancies.3,4 Other associated features are 
immunodeficiency, growth retardation and diabetes mellitus.1 Typical laboratory hallmarks are 
increased serum α-fetoprotein (AFP) levels, chromosomal instability and radiosensitivity.1
The ATM gene is localized on chromosome 11q22-23 and contains 66 exons.5,6 The encoded 
ATM protein is a serine/threonine protein kinase involved in cell cycle control and repair of 
DNA double-strand breaks.7 Worldwide, more than 400 different, mostly truncating ATM gene 
mutations have been reported in patients with A-T (Leiden Open Variation Database). Most 
mutations are private and there are no mutational hotspots in the ATM gene. 
In recent years, it has become increasingly clear that the clinical phenotype of A-T varies from 
the severe, early-onset classical phenotype as described above to an adult-onset disorder 
with milder neurological impairment and less systemic symptoms.8-14 It has been postulated 
that the presence of some residual ATM kinase activity may protect the patient from the most 
severe, i.e. ‘classical’ disease course.13,15 
In this study, we describe a relatively large series of A-T patients and focus on genotype - 
phenotype correlations. 
Subjects and Methods
In 1995, mutations in the ATM gene were shown to cause A-T. In the Netherlands, ATM mutation 
analysis studies have been performed in one single center, The Netherlands Cancer Institute, 
since that year. Based on the available clinical and molecular genetic data in the database, 
we could easily discriminate between patients with A-T (with one or two pathogenic ATM 
mutations being identified), healthy carriers of one single ATM mutation (parents or non-
affected siblings of patients), and patients without any pathogenic abnormality in the gene. In 
this way, we were able to identify 51 patients with genetically confirmed A-T. 
For all patients, ATM mutation analysis was performed using methods as previously 
described.16-18 Large genomic deletions and insertions were assessed by MLPA (kit P041 and 
P042, MRC-Holland). Reference sequence used is NM_000051.3, and exon numbering is 
according to the ATM database at the Leiden Open Variation Database: www.LOVD.nl/ATM. 
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in exon 4 in the reference sequence, according to journal 
guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. For the purpose of this 
study, we additionally measured ATM protein and ATM kinase activity, in lymphoblast cell lines, 
as described previously.19 Studies to demonstrate chromosomal rearrangements and X-ray 
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hypersensitivity were performed in different laboratories, generally situated in the referring 
hospital, but always according to standard procedures.20-21 
Clinical and laboratory data were collected retrospectively from the medical records of the 
patient’s primary hospital until January 2009. The follow-up period was defined as starting at 
birth and continuing until death, loss of contact or January 2009. The study was approved by 
the ethics committee of the Radboud University Nijmegen Medical Centre, The Netherlands. 
For the genotype-phenotype correlation analysis, patients were divided into 4 groups: patients 
without any ATM protein (group 1), patients with ATM protein but without residual ATM kinase 
activity (group 2), and patients with ATM protein with residual ATM kinase activity (group 3). 
Data from patients in whom we were not able to study the disorder at the protein level were 
pooled in group 4. 
In the statistical analysis, the clinical and laboratory findings were compared between groups 
1, 2, and 3 using Fisher exact tests. For time-dependent variables, Kaplan Meier curves were 
constructed and differences were tested with the log-rank test. All comparisons were made for 
group 1 versus groups 2 and 3 (absence versus presence of ATM protein), group 1 versus group 
2 (absence of ATM protein versus presence of ATM protein but without kinase activity) and 
for groups 1 and 2 versus group 3 (absence versus presence of residual ATM kinase activity). 
A P-value below 0.05 was considered statistically significant. No adjustment was made for 
multiple comparisons. Statistical analysis were performed with SPSS 18 software.
Results
The study included 51 genetically confirmed A-T patients, 24 males and 27 females, in the age 
range of 4 to 51 years (median age 17 years) and belonging to 38 families (Table 1). Thirty-
two patients were alive at the last moment of follow-up (median age 20.5, range 4-50). The 
deceased patients (n=19) died at ages between 9 and 27 years (median age 15), except for one 
man who died at age 51 (patient 21.I). Most patients deceased due to a malignancy (n=14), the 
second cause of death was respiratory failure (n=4) and 1 patient had died from  hemorrhagic 
cystitis as late complication of cytostatic treatment. The median age at diagnosis of A-T was 7 
years (range 0.5-after death). 
Onset of cerebellar ataxia was reported in 50 of 51 patients, at a median age of 19 months 
(range 7 months-39 years). Ocular telangiectasia were present in 43 of 48 patients (median 
age 5, range 2-48 years). AFP was elevated in 41 of 44 patients at the time of diagnosis (mean 
159, range 20-980 µg/L) (reference value <10 µg/L).  At the time of diagnosis, serum IgA 
deficiency was found in 46%, IgG deficiency in 16% and IgG2 deficiency in 61% of the patients. 
Immunoglobulin replacement was given in 14 patients, the details are shown in Supp. Table S1. 
Opportunistic infections were not observed. Nineteen patients (37%) developed a malignancy 
(mean 15 years, range 4-51), 13 of them suffered from hematologic malignancies (mean 12, 
range 4-51 years) and six from solid tumors (mean 25, range 10-43 years), i.e. breast cancer 
(n=3), hepatocellular carcinoma, dermatofibrosarcoma, and ectopic pituitary tumor. 
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ATM mutations, ATM protein expression levels and ATM kinase activity
Pathogenic mutations were detected in 95 of the 102 alleles. Table 1 shows the results for all 
51 patients. Forty-two different mutations were observed, including 11 frameshift mutations 
in 19 out of the 95 alleles, 10 nonsense mutations in 20 alleles, 10 splice site mutations in 
22 alleles, nine missense mutations in 19 alleles, one double missense mutation in 13 alleles, 
and one trinucleotide deletion leading to loss of one single amino acid in the protein in two 
alleles. Most of the mutations were found only once, but the c.7875_7876delTGinsGC mutation 
was observed in nine patients from seven families (13/95 alleles), the c.8147T>C mutation 
was found in five unrelated patients and the c.1563_1564delAG mutation occurred in five 
patients of four families. Homozygosity was quite common: 18 patients from 12 families had 
homozygous mutations. Ten mutations had not been described previously (see marked alleles 
in Table 1). 
Determination of ATM expression and kinase activity was possible in 22 families, consisting 
of 34 patients. In most families with multiple affected siblings, we were able to study all 
individuals and always found identical results. In families in which we were able to study only 
the index patient, we assumed the same results for the other sibling(s). In 11 patients, ATM 
was completely absent (group 1); in 14 patients, we were able to demonstrate the presence 
of ATM protein, but without detectable kinase activity (group 2); nine patients exhibited ATM 
protein expression as well as residual ATM kinase activity (group 3). Figure 1 illustrates ATM 
expression and residual ATM kinase activity of a representative set of patients. Importantly, the 
patients in group 3 could be ranked according to the level of residual ATM kinase activity: the 
cell-lines of family 18 showed the lowest activity, whereas the cell lines of patient 20 and family 
21 showed by far the most residual ATM kinase activity. The level of signal varied between 
phospho-specific antibodies. The phospho-SMC1 and phospho-KAP-1 antibodies are known 
to be strong/robust antibodies as reflected in the relatively high dilutions employed when 
using them (phospho-SMC1 is used at 1:5000 and phospho-KAP-1 at 1:10.000) and by the 
relatively short exposure time required to get a good signal (just a few seconds). However, 
the phospho-CREB antibody is used at a lower dilution (1:1000) and requires super signal ECL 
and an exposure time of at least a few minutes in order to detect it. The phospho-CREB signal 
is seen better in Supp. Figure S1, the same lysates run in a different order. Reproducibility was 
good; variability, between western blots, was not a problem in our well-defined assay where as 
stated above, we use a panel of phospho-specific antibodies, that should all register a signal to 
indicate unambiguous presence of ATM kinase activity in a particular lysate.
Clinical phenotypes in patients of groups 1, 2, and 3 
The clinical data of the 34 patients in whom we were able to assay ATM protein and ATM 
kinase activity are summarized in Tables 1– 4, described below, and used for further genotype-
phenotype correlation studies. The clinical features of the patients in group 4 are described in 
a separate paragraph. 
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Demographic features 
Survival rates did not differ significantly between group 1 and 2, while patients with residual 
ATM kinase activity became much older (log-rank test P=0.003) (Fig. 2 and Table 2). The majority 
of patients (10/13) died due to malignancies or late complications of chemotherapy; the other 
three patients, all in group 2, died from respiratory failure. 
The median age at diagnosis of A-T was 4 and 6.5 years in group 1 and 2, respectively, whereas 
A-T was diagnosed later in life in group 3 (median 31.5 years, P=<0.001).
Neurological features
Table 3 outlines the most relevant neurological features of the patients of groups 1, 2 and 
3. Cerebellar ataxia manifested around similar ages in patients from group 1 and 2, with a 
Figure 1: Western blot showing retained levels of ATM kinase activity in lysates from different A-T 
patients 
There are two lanes for each cell line, dependent on the absence (-) or presence (+) of  ATM kinase 
activation by exposure of cells to 5Gy gamma rays. Normal cells show activation of ATM kinase by 
autophosphorylation of ATM Ser1981, and phosphorylation of downstream targets, SMC1ser966, 
KAP-1ser824, Nbs1ser343 and CREBser121 measured 30 minutes after irradiation. Cell lines of the 
classical A-T patient (lane 3 and 4) show no ATM neither ATM kinase activity. The patients of group 
3, patients 18.1, 19.1, 21.1 and 20 (lane 5 to 12), have reduced levels of ATM and ATM kinase activity 
in their cells.
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median age of 1.5 (range 1-3 years) and 1.25 year (range 1-6 years), respectively. In group 3, 
cerebellar ataxia developed later (P=<0.001): patients 18.I and 18.II suffered from ataxia since 
the age of 15, patients 19.I and 22 from their twenties, patients 20 and 21.I-21.III from their 
thirties. Instead, patients from group 3 presented with chorea(-athetosis) (patient 18.I-19.II, 
22) in childhood (median 1 year, range 0.5-4) or a resting tremor (patients 20-21.III) at ages 
between 16 and 34 years. In patient 20, chorea-athetosis was only mild, while it was absent 
in patients from family 21. In groups 1 and 2, extrapyramidal signs started in all patients at a 
Figure 2: Survival, loss of mobility, and occurrence of malignancies and diabetes mellitus by age for 
patients with and without the presence of ATM protein and residual ATM kinase activity.
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young age. The ability to walk was lost early in patients of group 1 (mean 9, range 7-11 years) 
and 2 (mean 10, range 9-15 years), while independent walking was generally preserved during 
the whole follow-up in patients from group 3 (Figure 2) (P=<0.001). In group 3, only patient 
18.I and 18.II became wheelchair bound, both in their twenties. In groups 1 and 2, nystagmus 
and oculomotor apraxia were present in most patients in childhood. In patients of group 3, the 
onset of these symptoms was, if presented at all, in adulthood.
Polyneuropathy was present in all patients from groups 1 and 2 in childhood, but in only half 
of the patients from group 3 in adulthood (P=0.023). Motor neuron disease predominated in 
patients with large amounts of residual kinase activity. 
Swallowing difficulties only emerged in two patients from group 3, but in all patients from 
groups 1 and 2 (P= 0.009). In group 3, swallowing difficulties did not correlate with age.
Table 2: Nonneurological features of 34 A-T patients 
  Group 1 Group 2 Group 3
 no ATM protein residual ATM residual ATM
  protein without protein with
  kinase activity kinase activity
 (n=11) (n=14) (n=9)
 frequency P-value% frequency P-value0 frequency P-value^
Demographic features
male/female 5/6 0.500 7/7 0.570 5/4 0.500
alive at last follow-up 7/11  7/14  7/9
median age alive (range) (years) 12 (7-38) 0.061x 15 (4-29) 0.653x 36 (33-50) 0.003x
median age of death (range) (years) 10.5 (9-23)  21 (9-27)  37 (23-51)
median age at diagnosis (range) (years) 4 (1-9) 0.010x 6.5 (0.5-12) 0.532x 31.5 (26-†) <0.001x
Telangiectasia
ocular telangiectasia  11/11 0.179 13/13  5/9 0.003
ocular telangiectasia (age < 18 years) 10/10 0.018 13/13  0/9 <0.001
cutaneous telangiectasia 7/7 0.026 8/11 0.202 0/5 0.002
Endocrine function
before puberty height <P3 3/9 0.257 3/13 0.477 0/7 0.157
adult height <P3 3/3 0.055 3/4 0.571 0/7 0.002
diabetes mellitus type II (age > 18 years) 2/2 0.011x 2/4 0.364x 0/9 0.009x
delayed secondary sexual characteristics 2/3 0.176 1/6 0.226 1/5 0.545
offspring (age ≥ 16 years) 0/4 0.800 0/7  1/9 0.450
Malignancies
haematological 3/11 0.243x 4/14 0.973x 1/9 0.012x
non-haematological 1/11  2/14  1/9
Pulmonary function
restricted respiratory function 7/7 0.054 6/7 0.500 0/4 0.002
Treatment for immunodeficiency
immunoglobulin replacement 8/11 0.005 4/12 0.070 0/9 0.006
antibiotic prophylaxe 5/8 0.298 9/12 0.455 0/9 <0.001
Others
kyphoscoliosis 4/5 0.185 7/9 0.725 0/7 0.001
% no ATM protein (group 1) versus ATM protein (groups 2 and 3); 0 no ATM protein (group 1) versus ATM protein 
without kinase activity (group 2); ^ no ATM kinase activity (groups 1 and 2) versus ATM protein with kinase 
activity (group 3); x Log-rank test.
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Nonneurological features 
The main nonneurological  findings of the patients of groups 1, 2 and 3 are summarized in 
Table 2. 
Ocular telangiectasia were noted in patients from groups 1 and 2 at a median age of 5 (range 
2-15 years). In group 3, telangiectasia were only observed in 56% of the patients in adulthood 
(median age 34). In addition, fewer patients of the latter group had cutaneous telangiectasia 
compared to groups 1 and 2 (P=0.002). 
Malignancies occurred in all three groups, but more frequently and at a younger age in patients 
without ATM kinase activity (P=0.012) (see also Fig 2). In group 1, three of 11 of the patients 
developed a hematologic malignancy at a young age, i.e. an epi-pharyngeal non-Hodgkin 
B-cell lymphoma in patient 2 at age 16, a nasopharyngeal B-cell lymphoma in patient 5.II at age 
11, and Hodgkin disease in patient 3 at age 9. Patient 7.I died from a hepatocellular carcinoma 
at age 10. In group 2, four of 14 of the patients suffered from a lymphoid malignancy. Patient 
14.II was treated for T-cell acute lymphocytic leukemia at age 4. Patient 15.II died from a 
lymphoma at age 10. Patient 17.I died of Hodgkin disease at age 26 and his sister (patient 
Table 3: Neurological features of 34 A-T patients 
 Group 1 Group 2 Group 3
 no ATM protein residual ATM residual ATM
  protein without protein with
  kinase activity kinase activity
 (n=11) (n=14) (n=9)
 frequency P-value% frequency P-value0 frequency P-value^
cerebellar ataxia
onset ≤ age 5 years 11/11 0.009 13/14 0.560 0/9 <0.001
onset ≥ age 6 years 0/11 0.009 1/14 0.560 9/9 <0.001
nystagmus (age ≥ 6 years) 5/7 0.501 7/11 0.572 4/7 0.499
oculomotor apraxia (age ≥ 6 years) 8/9 0.593 10/11 0.711 5/7 0.269
extrapyramidal signs 8/8  13/13  9/9
choreo(athethosis) 6/6 0.455 12/12  6/9 0.029
 since childhood 5/5 0.605 11/11  5/7 0.083
resting tremor unknown  2/2  7/9
myoclonus 5/5 0.737 7/7  6/7 0.368
dystonia 6/6 0.403 10/10  5/8 0.028
 since childhood 5/5 0.510 9/9  2/4 0.039
wheelchair-bound since
 age of >8 and <12 years 7/7 0.002x 9/10 0.172x 0/9 <0.001x
 age of >12 years 0/7  1/10  2/2
polyneuropathy (age >6 years) 3/3 0.446 7/7  4/8 0.023
neuronopathy of anterior horn cells unknown  unknown  6/8
swallowing problems 7/7 0.251 8/8  2/5 0.009
 since childhood 7/7 0.192 4/4  0/2 0.013
dysarthria 10/10  12/12  9/9
 since childhood 9/9 0.667 12/12  5/6 0.222
% no ATM protein (group 1) versus ATM protein (groups 2 and 3); 0 no ATM protein (group 1) versus ATM protein 
without kinase activity (group 2); ^ no ATM kinase activity (groups 1 and 2) versus ATM protein with kinase 
activity (group 3); x Log-rank test.
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17.II) died of a relapse of Hodgkin disease at age 13. In addition, patient 11.I developed a 
dermatofibrosarcoma protuberans at age 15 and at age 24, while patient 16 died from breast 
cancer at age 27. In group 3, patient 19.II died from an ectopic pituitary tumor at age 23 and 
patient 21.I from acute lymphoblastic leukemia at age 51. 
Restrictive pulmonary function was demonstrated in all patients of groups 1 and 2, with the 
exception of patient 9. In group 3, pulmonary function was normal in all (P=0.002). 
In patients of groups 1 and 2, growth velocity gradually slowed down during the first decade 
of life, while the physiologic growth acceleration in puberty was lacking. As a result, final 
height was often below the third percentile. In contrast, all patients from group 3 reached a 
normal adult height. Besides, diabetes mellitus, diagnosed by two increased plasma glucose 
concentrations (fasting >7  mmol/L or random >11.1 mmol/L), occurred in all adults of group 
1 and in half of the adults of group 2. None of the patients of group 3 suffered of diabetes 
mellitus. These differences in endocrine problems between groups 1 and 2 versus group 3 
were statistically significant (see also Fig. 2).
Laboratory findings 
Serum AFP was elevated in all patients from all three groups (Table 4), varying from 20 to 980 
µg/L. Patients 10 and 11.I, both from group 2, had only AFP levels of 20 and 38 µg/L, respectively, 
Table 4: Laboratory findings in 34 A-T patients
 Group 1 Group 2 Group 3
 no ATM protein residual ATM residual ATM
  protein without protein with
  kinase activity kinase activity
 (n=11) (n=14) (n=9)
 frequency P-value% frequency P-value0 frequency P-value^
AFP 
elevated in childhood 9/9  6/6  unknown
elevated in adulthood 2/2  3/3  8/8
Immunological studies
IgG deficiency 4/11 0.012 0/11 0.045 0/8 0.267
IgA deficiency 8/11 0.035 6/11 0.330 0/8 0.002
IgG2 deficiency 7/7 0.007 4/8 0.051 0/4 0.018
decreased CD3 absolute 2/5 0.191 0/6 0.182 1/6 0.728
decreased CD4 absolute 2/5 0.074 0/6 0.182 0/6 0.404
decreased CD4CD45RA/RO ratio 5/5  7/7  7/7
decreased CD8 absolute 4/5 0.439 3/7 0.247 5/6 0.306
decreased CD19 absolute 4/5 0.490 6/7 0.682 6/6 0.431
decreased NK-cellen 0/5 0.722 0/7  1/6 0.333
Cytogenetic studies
rearrangements in chromosomes 7 and/ or 14 9/10 0.370 9/9 0.526 8/8 0.704
X-ray hypersensitivity 
 fibroblasts 2/2  4/4  2/2
 lymphocytes 8/8 0.193 5/5  4/7 0.031
% no ATM protein (group 1) versus ATM protein (groups 2 and 3); 0 no ATM protein (group 1) versus ATM protein 
without kinase activity (group 2); ^ no ATM kinase activity (groups 1 and 2) versus ATM protein with kinase 
activity (group 3).
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while all other values were > 57 µg/L. AFP levels were not systematically monitored during the 
course of the disease in any of the patients in this study.
At the time of diagnosis, IgG deficiency was found in 36% of the patients from group 1, but 
not in patients from groups 2 and 3. IgA deficiency was demonstrated in slightly more patients 
from group 1 than 2, but not in group 3 (P=0.002). IgA deficiency was only observed in one 
of the two sibs of family 12 and 15. IgG2 subclass deficiency was found in all patients from 
group 1 and in 50% of the patients from group 2. Agammaglobulinaemia with normal IgM, 
also designated as a ‘’hyper-IgM’’ phenotype, was found in all patients from family 7. These 
patients developed increased IgM levels in the course of the disease.
B-cells counts were below the fifth percentile in 16 of 18 patients (Fig. 3). T-cells counts,  CD4+, 
as well CD8+, were normal to decreased. Naïve CD4+ T-cells were decreased in all patients. The 
amounts of NK cells were within normal ranges.
Figure 3: B- and T-cell counts in 18 A-T patients.
Number of B- and T-cells in A-T patients, depending on protein status (J group 1; j group 2; i group 
3).
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Rearrangements of chromosomes 7 and/or 14 were found in  cultured peripheral lymphocytes 
of all but one patient in all three groups. In one patient of group 1 (5.I), rearrangements were 
not observed in 50 GTG-banded metaphases. 
Radioresistant DNA synthesis, (RDS), as measured by incorporation of radioisotopes,20 was found 
to be present in fibroblasts of all A-T patients. In lymphocytes, clearly increased radiosensitivity 
was detected (either via RDS or induced chromosome aberrations) in all patients of groups 1 
and 2, except patient 9 who exhibited intermediate radiosensitivity. In group 3, radiosensitivity 
of lymphocytes, measured by radiation induced chromosome aberrations, was quite variable: 
lymphocytes of patient 18.I were severely radiosensitive, patients 20 and 22 displayed 
intermediate radiosensitivity, and in patients 18.II, 19.I, 21.II radiosensitivity was not observed. 
Radioresistent DNA synthesis  in lymphocytes was intermediate in patient 21.III and normal in 
21.II. Remarkably, intermediate and severe radiation resistant DNA synthesis was observed in 
fibroblasts of patients 18.II and 19.I in contrast to their lymphocytes.
Clinical phenotypes in patients of group 4 
In 17 patients from 16 families, we were not able to assay ATM protein and ATM kinase activity 
(Table 1), mostly because there were no cell cultures available and the patients had already 
passed away before the start of our study.
The neurological features were essentially similar to those in groups 1 – 3, that is, all patients 
had neurological abnormalities and none of them suffered from a neurological disorder that 
we had not yet encountered in groups 1 – 3. As for the neurological features, the prevalence 
and clinical characteristics of telangiectasia, endocrine abnormalities, malignancies, and 
pulmonary disease were also found as documented in groups 1 – 3. Interestingly, a 34-year-old 
patient was recognized based on the combination of an extrapyramidal movement disorder, 
i.e. torticollis and tremor capitis, a continuous rest and intention tremor of the limbs but also 
the trunk, and breast cancer at the age of 32 (patient 36) (patient v9)13. She did not suffer from 
cerebellar ataxia and telangiectasia at all. In addition, patient 37, also with a relatively mild 
neurological disorder at breast cancer diagnosis at age 43, suffered from severe side effects 
of radiotherapy. The occurrence of severe “radiosensitivity” was the trigger that led to the 
diagnosis of A-T (patient v10 in Verhagen et al., 2009).13,22
The only peculiar laboratory observations in group 4 were normal AFP levels in three patients. 
Patient 28, with a classical phenotype of A-T, was reported to have a serum AFP concentration 
of 3 µg/L at age 4. Unfortunately, AFP was never remeasured. In patients 32.1 (at age 9) and 
32.II (at age 10), the initial serum AFP levels were reported “normal” (absolute values unknown) 
while later measurements revealed clearly increased levels of 108 and 40 µg/L at ages 42 and 
43 years, respectively. Importantly, two patients (patients 30 and 33) who died at age 13 and 
14, respectively, had the so-called ‘’hyper-IgM’’ phenotype.
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Discussion
The group of A-T patients we studied was relatively large, which allowed us to pool patients 
with similar protein characteristics in different groups. This enabled us to disclose distinctive 
molecular genetic as well as clinical characteristics between patients from different groups.
In line with the literature, we found private mutations in the ATM gene in most families while 
a few mutations, that is, c.7875_7876delTGinsGC, c.8147T>C, 1563delAG and c.3576G>A, 
occurred relatively frequently. We identified 10 novel mutations of which six were predicted to 
lead to a deleterious effect on the protein, because they were frameshift or nonsense mutations. 
The novel splice site mutation demonstrated in family 32 predicts also truncation of the ATM 
protein. In patient 28 (compound-heterozygous for two novel missense mutations) and patient 
29 (compound-heterozygous for one novel splice site mutation and the known double missense 
mutation), we demonstrated total absence of ATM protein kinase activity in cultured skin 
fibroblasts and considered this indirect proof of the pathogenic effect of these mutations.  
The genotypes of the patients in groups 1, 2 and 3 differed fundamentally. In group 1, almost 
all alleles (19/22 alleles) were affected by truncating mutations, whereas group 2 harbored 
only one truncating mutation in addition to the founder mutation c.7875_7876delTGinsGC 
(10/28 alleles) and three different splice site mutations (9/28 alleles). In group 3, more than half 
of the mutations were missense mutations (10/18 alleles). 
Remarkably, patient 9 (group 2) was heterozygous for the splice site mutation c.331+5G>A 
and the c.7875_7876delTGinsGC mutation. The third cousins of this patient, patients 18.I and 
18.II, were homozygous for the c.331+5C>A mutation and have some residual kinase activity 
(see also Fig. 1). We expected to find some residual ATM kinase activity in patient 9 as well, 
but were unable to demonstrate any kinase activity above the detection level of our assays, 
probably because any kinase activity in this patient’s cells was reduced, as it was derived from 
only one allele compared with two alleles in patients 18.I and 18.II. Regarding the phenotype, 
patient 9 was the only patient in group 2 (and 1) with normal pulmonary function, and with 
intermediate radiosensitivity of lymphocytes. He was wheelchair bound at the age of 15, thus 
suffering from a somewhat milder phenotype. 
Neurological features were present in every A-T patient in this study, irrespective of the overall 
severity of the phenotype. The neurological phenotype in patients without residual ATM kinase 
activity was in line with that reported in the literature for classical A-T patients.1,23,24 Interestingly, 
cerebellar ataxia was not the dominating manifestation and sometimes even absent in patients 
with some residual ATM kinase activity. The presence of residual kinase activity mainly resulted 
in extrapyramidal instead of cerebellar signs, milder or absent polyneuropathy, predominance 
of anterior horn cell degeneration in most patients, and adult-onset or absence of oculomotor 
apraxia and swallowing problems. Apparently, the more residual ATM kinase activity, the 
milder the neurological features seems to be. Patient 20 and family 21, who presented with an 
isolated tremor in adulthood, without any other hallmark of classical A-T, and with the highest 
amount of residual kinase activity, clearly illustrates how mild the phenotype can be.  
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The finding that all A-T patients showed an extrapyramidal movement disorder during the course 
of the disease, while cerebellar ataxia was only found in the most severely affected patients 
(groups 1 and 2), suggests that the basal ganglia are more vulnerable to the pathophysiologic 
mechanisms that underlie A-T than the cerebellum is. Our present study substantiate previous 
recommendations to consider A-T not only in the differential diagnosis of childhood onset 
cerebellar ataxia, but also in children with extrapyramidal movement disorders without 
other clinical hallmarks of A-T. Adults with unexplained extrapyramidal movement disorders 
or anterior horn cell disease, as well as adults with mild neurological features and cancer or 
unexpectedly severe side effects of cancer treatment (see below), may also suffer from A-T. 
The nonneurological features observed in patients from group 1 and 2, that is, onset of 
ocular telangiectasia in childhood, growth retardation in puberty, diabetes mellitus in young 
adulthood, restrictive lung disease, and an increased risk of developing (hematologic) 
malignancies, were similar to those reported in classical A-T patients in previous reports.1,13,24 
In contrast, none of the patients of group 3 developed diabetes mellitus or pulmonary disease 
during the study period. Importantly, the risk of developing cancer during childhood was 
much lower in group 3 than in groups 1 and 2, but still greatly increased compared to the 
general Dutch population in this age range.25 Patients in group 3, and patients in group 4 with 
predicted residual ATM kinase activity (patients 36 and 37) who suffered from malignancies, 
were older at the onset of cancer than patients of groups 1 and 2 and had predominately solid 
tumors. In the literature the cancer risk is around 20%, while 37% of the patients of our cohort 
developed a malignancy.3,26-28 In contrast to what has been reported in the literature, we found 
that malignancies instead of respiratory failure were the primary cause of death.1,28 Survival in 
group 3 was much longer than in groups 1 and 2, but still diminished compared to the healthy 
population.
Our study suggests that there is an ameliorated immunological phenotype in patients with ATM 
protein, irrespective of the presence or absence of residual kinase activity. Namely, patients 
of group 2 had normal total IgG levels and were less often treated with immunoglobulin 
substitution than patients of group 1. In patients of group 3, immunoglobulin deficiency was 
not encountered at all. In the literature, only one patient with a milder A-T phenotype has 
been described with decreased IgA, IgG2 and IgG4 levels.12 Our observations, that a low level 
of residual ATM kinase activity leads to a less severe immunological phenotype than seen in 
patients without ATM kinase activity, are in line with data reported by Staples et al.29. Normal 
to high IgM levels with IgG and IgA deficiency, the so-called “hyper-IgM” phenotype, was only 
found in patients of group 1 and in two patients of group 4, who were homozygous for a 
truncating mutation predicting absence of ATM protein.
Patients without ATM kinase activity mainly developed lymphoid malignancies. This 
corresponds with the impaired repair of double strand breaks during V(D)J recombination in 
B- and T-lymphocytes and also during somatic hypermutation and class switch recombination 
processes in B-cells.30-32 Genetic instability of Ig/TCR genes during lymphoid development may 
result in the formation of lymphoid-specific oncogenic chromosome translocations involving 
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Ig/TCR loci.33 It might be that more normal B and T cells survive in patients with residual ATM 
kinase activity as suggested by Staples and colleagues.29 However, B-cell counts were below 
normal values in all patients of all groups in our study. Also, naïve CD4-cell counts were very 
low in all groups, pointing to a skewed repertoire of lymphocytes. 
An alternative explanation for the development of hematologic malignancies in A-T comes 
from a recent study of Mazan-Mamczarz et al. who showed a role for the ATM protein in the 
interaction of HuR.34 This protein binds to and regulates many mRNAs involved in the stress 
response, tumorigenesis and irradiation. Ionizing radiation modulates the dynamic association 
of the RNA-binding protein HuR with target mRNAs in an ATM dependent manner, potentially 
coordinating the genotoxic response as an RNA operon. ATM has a critical role in this process. 
The authors suggested that dysregulation of the DNA damage response RNA operon may 
be relevant to lymphoma development in A-T.34 Interestingly, most patients of group 3 had 
a normal or only intermediate increased radiosensitivity in their lymphocytes. None of our 
patients developed lymphomas. In the literature, lymphomas have also not been described in 
patients with a milder A-T phenotype.
Remarkably, there was discrepancy between the radiosensitivity of fibroblasts and 
lymphocytes in two patients of group 3. The lymphocytes of patients 18.II and 19.I showed 
normal radiosensitivity whereas their fibroblasts were intermediate and severely radiosensitive. 
This might fit in with the observation of severe side effects with skin ulceration and plexus 
brachialis neuropathy after radiotherapy for breast cancer in the patient with otherwise mild 
A-T (patient 37).13,22 The discrepancy between in-vitro radiosensitivity measured in B-cell lines 
and fibroblasts has been described before35 and suggests that the B-cell lines that are used in 
the lymphocyte assays are composed of a selection of B-cells with better preserved ATM kinase 
activity. It may also reflect why lymphomas have not been described in patients with residual 
ATM kinase activity to date.
Altogether this study demonstrates that A-T is not a dichotomous but rather a continuous disease 
phenotype, with childhood-onset “classical A-T” versus the relatively mild adult-onset “variant 
A-T” at the outer ends of the spectrum. Each A-T patient suffers from neurological abnormalities 
and an increased cancer risk, but the severity as well as the precise nature of the neurological 
manifestations and cancer types that occur depend on the absence or presence of residual 
ATM kinase activity. Not all patients with A-T exhibit telangiectasia and suffer from pulmonary 
disease and endocrine disturbances: the presence of some residual ATM kinase activity seems 
to protect against these systemic features. Remarkably, we found that the presence or absence 
of immunodeficiency was defined by the presence or absence of ATM protein rather than its 
kinase activity. There are many reasons, among which the increased cancer risk, that plead in 
favor of an early and correct diagnosis in every patient with A-T, irrespective of the severity of 
the phenotype. The recognition of “variant A-T” is difficult, as illustrated by the long diagnostic 
delay in many patients with mild A-T phenotypes.13 We think that, as a consequence, milder A-T 
phenotypes might easily be missed, and consider it extremely difficult to predict the “minimal 
A-T phenotype”. With respect to ATM kinase activity in A-T patients a remaining task is to try 
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to determine if there is a pro rata improved overall clinical presentation with increased kinase 
activity expressed in the patient’s cells or, alternatively, whether there is a threshold of kinase 
activity above which, no further incremental improvement in clinical presentation can be seen. 
This information could then be used to build up a database, probably for each country- as 
they tend to have their own spectrum of ATM mutations – which could be helpful in advising 
parents, at a specialized clinic, about the likely progress the A-T will take in their child.
So far, curative treatment strategies are not available for A-T. Our observations strongly support 
the development of novel therapeutic approaches, such as compound-induced read through 
of premature termination codons, which aim to induce at least a minimal amount of (functional) 
ATM protein.36 Restoration of some residual ATM kinase activity would potentially make the 
difference between a devastating neurodegenerative disorder with death in the first decades 
of life and a far less severe neurological disease course without the burden of childhood cancer 
and without additional pulmonary, endocrine, and immunological complications.
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Supplementary
Supplementary Figure 1
Figure S1:  Whole cell lysates in Figure 1, run on a different gel and in a different order to show 
reproducibility of kinase acitivity using phospho specific antibodies.
Lysates  from patients 18.1, 21.1, 20 and 19.1 showing similar signal intensities as in Figure 1, for 
autophosphorylation of ATM Ser1981, and phosphorylation of downstream targets, SMC1ser966, 
KAP-1ser824, Nbs1ser343 and CREBser121 measured 30 minutes after irradiation. Cell lines of the 
classical A-T patient (lane 3 and 4) show no ATM neither ATM kinase activity. There are two lanes for 
each cell line, dependent on the absence (-) or presence (+) of  ATM kinase activation by exposure 
of cells to 5Gy gamma rays.
22451_Mijke Verhagen binnenwerk.indd   121 10-07-2012   11:46:05
122
CHAPTER 4.2
Supplementary Table 1
Table 1: Immunoglobulin replacement in 34 A-T patients 
patient gender,  IVIg from age till age indication
 age (yr)   (yrs) (yrs)
Group 1: ATM protein absent
1 M,13 yes 8  present IgG2 deficiency
2 F,23 yes 18 † IgG deficiency after cancer treatment
3 F,9 yes 9 † recurrent pneumonia
4 M,38 yes 19 20 temporary IgG deficiency
5.I  F,17 no
5.II F,11 no
6 M,16 yes 13 15 IgG2 deficiency
7.I  F,10 yes 5 present hyper IgM phenotype
7.II  M,10 yes 1 present hyper IgM phenotype
7.III  F,7 yes 9 † hyper IgM phenotype
8 M,6 no
Group: 2 ATM protein present, without ATM kinase activity
9 M,15 no
10 F,16 no
11.I  M,29 no
11.II F,22 ?
12.I  M,27 no
12.II  M,14 no
13 F,6 yes 6.5 present recurrent pneumonia
14.I  M,8 no
14.II F,4  yes 0.5 2 temporary agammaglobulinemia
15.I  F,21 yes 14 † late-onset agammaglobulinemia
15.II M,10 no
16 F,27 no
17.I  M,26 yes 18 † late-onset agammaglobulinemia
17.II  F,9  ?
Group 3: ATM protein present, with residual kinase activity
18.I  F,36 no
18.II  M,33 no
19.I  F,33 no
19.II M,23 no
20 F,50 no
21.I  M,51 no
21.II  M,46 no
21.III  M,45 no
22 F,34 no
† until death; ? unknown
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SUMMARy
5.1
In this thesis we describe in detail the clinical features and laboratory abnormalities of ataxia 
telangiectasia (A-T) and we explore genotype-phenotype relationships for mutations in the 
ATM-gene. The main findings are summarized below. 
Part I – Neurological abnormalities in Ataxia-Telangiectasia
The phenotype of A-T is dominated by neurological abnormalities. However, since the 1980s, 
there has been remarkably little literature concerning the neurological features of A-T. With 
regard to the neuromuscular abnormalities, both axonal polyneuropathy and anterior horn cell 
disease have been described. In Chapter 2.1 clinical, electrophysiological and ultrasonographic 
findings are evaluated in 13 classic A-T patients, whose ages vary from 1 to 25 years old, in order 
to gain more insight into the development and spectrum of neuromuscular abnormalities in 
A-T. As the most prominent finding, a progressive axonal sensorimotor polyneuropathy was 
observed, which was detectable by means of electromyography and muscle ultrasound from 
as early as the age of 8 onwards and clinically at around the age of 12. Due to the existing 
polyneuropathy it was impossible to decide in living patients whether or not additional motor 
neuron disease is part of the classic phenotype. 
In Chapter 2.2 this question was resolved by the demonstration of anterior horn cell degeneration 
as a disease feature of both classic and variant A-T. In this chapter the neuropathological 
findings of two classic A-T patients, who died at age 19 and 22, and a 33-year-old patient with 
a milder phenotype are described. For the first time, the autopsy findings of patients with a 
genetically proven diagnosis of milder and classic A-T are reported. The neuropathological 
findings of all these patients were comparable to the previously described abnormalities 
in classic A-T patients, i.e. cerebellar atrophy, less pronounced degeneration of the dentate 
nucleus and inferior olive, degeneration of the posterior columns and neurogenic muscular 
atrophy. Degenerative changes were visible in the anterior horn cells of all three patients. In 
the variant case the degenerative changes were generally somewhat milder, except for more 
prominent anterior horn cell degeneration. 
Chapter 2.3 deals with cognitive and speech-language functioning in A-T. Eight individuals (age 
range 3 – 15 years old) with classic A-T were tested. Confounding effects of motor functioning 
were taken into account in relation to test performance. Cognitive and language functioning 
appeared to level off starting from school age onwards, but did not deteriorate.  
Part II – Non-neurological problems in Ataxia-Telangiectasia
In this part, currently underexposed or unrecognized health problems in A-T are discussed.
In Chapter 3.1 the clinical characteristics and ICU course of three adolescent patients with 
classical A-T who died during mechanical ventilation due to hypercapnic respiratory failure 
are presented. Restrictive pulmonary function was indicated as a new, but common, disease 
feature of classical A-T, which may seriously complicate ventilator treatment in such patients. 
Pathophysiological mechanisms which could underlie the restrictive pulmonary function are 
discussed.   
22451_Mijke Verhagen binnenwerk.indd   127 10-07-2012   11:46:08
128
CHAPTER 5.1
Chapter 3.2 deals with cutaneous granulomas as found in four children with classic A-T. 
Decreased IgG and IgA concentrations with normal IgM levels, the so-called hyper IgM 
phenotype, was found as a common immunological denominator in these patients with 
cutaneous granulomas. Furthermore, all displayed a marked decrease in B-cells and naive 
T-cells coinciding with the appearance of the cutaneous granulomas, similar to published 
patients with other primary immunodeficiencies with skin granulomas. We postulate that the 
etiology of these granulomas is related to immune dysregulation of macrophages due to the 
absence of naive T-cells with an appropriate T-cell receptor repertoire in the presence of γδ 
T-cells and/or NK-cells.
Part III – Genotype/phenotype relationship in Ataxia-Telangiectasia
In the literature some patients, designated as variant A-T patients, are described who exhibit 
milder clinical features and have an extended lifespan. It has been suggested that this milder 
phenotype is associated with mutations that leave some residual ATM kinase activity, whereas 
in classic A-T patients ATM kinase activity is completely absent. For the first time, we analyzed 
the clinical spectrum and genotype/phenotype relationships in a relatively large series of 
classic and variant A-T patients.
In Chapter 4.1 the clinical, cellular and genetic data from 13 patients with variant A-T are 
compared with those of six adults with classic A-T. We were able to demonstrate that almost 
all of the variant cases presented with an extrapyramidal movement disorder, rather than 
cerebellar ataxia. Ataxia appeared later and progressed more slowly. Some individuals with 
variant A-T presented with choreoathetotic movements as early as infancy, whereas others 
presented with a resting tremor, distal muscle weakness or chorea-athetosis in childhood or 
adulthood. In contrast, all patients with classic AT presented with ataxic gait in early childhood. 
Furthermore, mild to moderate telangiectasias were only found in approximately half of the 
variant cases in adulthood. Patients with a variant phenotype were only correctly diagnosed 
an average of 25 years after disease onset. Measurement of serum alpha-fetoprotein and 
chromosomal instability precipitates the correct diagnosis. In this chapter a clear genotype/
phenotype relationship was suggested for A-T, since the severity of the phenotype appeared 
to depend on the amount of residual kinase activity as determined by the genotype.
In Chapter 4.2 this putative phenotype/genotype relationship was further examined. Fifty-
one genetically proven A-T patients were described, taking into account their ATM protein 
status. In line with the literature, the absence of ATM kinase activity resulted in the classic 
phenotype. For the first time, we demonstrated that the presence of ATM protein leads to a 
slightly better immunological function. Furthermore, we demonstrated that the amount of 
residual ATM kinase activity correlates with the severity of the neurological phenotype. The 
presence of residual kinase activity, irrespective of the amount thereof, protects against 
endocrinopathy, immunoglobulin deficiency, childhood cancer, lymphomas and pulmonary 
disease. Importantly, the cancer risk remains hugely increased in each A-T patient.
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In conclusion, in this thesis the clinical spectrum of A-T is expanded. We demonstrate that 
A-T patients with a variant phenotype show a milder and essentially different neurological 
phenotype than classic A-T patients. Cerebellar ataxia as well as telangiectasia may be absent 
in variant A-T, which may strongly hamper the clinical diagnostic process. 
However, a correct diagnosis of A-T is important, particularly because of the increased risk of 
developing malignancies and of dreadful complications after treatment with radiotherapy and 
radiomimetic drugs. Importantly, we have demonstrated that even minimal amounts of ATM 
protein with kinase activity greatly improve the length and quality of life of A-T patients.
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The first descriptions of ataxia-telangiectasia (A-T) date from the 1920s and 1940s.4,5 However, 
A-T was recognized as a separate disease entity in 1957 independently by Biemond in the 
Netherlands and Sedgwick and Boder in the United States.1 Both descriptions reported a familial 
syndrome that was characterized by progressive cerebellar ataxia, onset in infancy, progressive 
oculocutaneous telangiectasia and proneness to sinopulmonary disease.1,6,7 In those days, the 
respiratory tract problems were attributed to infections secondary to an immunodeficiency.2
For many years, the descriptions in the literature were mainly of patients with the severe 
classic phenotype. From the 1970s onwards, a few reports of patients with a milder phenotype 
appeared.2,8,9 A major step forward was made in 1995, with the discovery of the ATM-gene.10 
Soon thereafter, many patients with a milder phenotype previously not recognized as A-T 
could be identified as having A-T.11-19
In the present thesis the clinical features and laboratory abnormalities of both classic A-T 
and milder A-T patients are described in detail, using a large cohort of A-T patients in the 
Netherlands. The availability of extended clinical data and cell lines from many patients, and the 
collaboration with many colleagues at home and abroad, allowed us to study the relationship 
between the clinical picture, the type of mutation, the amount of ATM protein and its kinase 
activity. 
Phenotype of patients with ‘classic A-T’ and ‘variant A-T’
During recent years, several patients with a milder phenotype have been classified as having 
A-T. Recently, Hiel et al. described A-T patients in whom cerebellar ataxia was not the initial 
or dominating feature.16 Outlining the phenotype of these A-T patients will facilitate the 
identification of even more variant A-T patients and improve our understanding of the 
pathophysiological mechanisms. Therefore we decided to analyze the phenotypic variation 
in A-T. 
Neurodegeneration is the most prominent and debilitating disease hallmark of A-T. Classic A-T 
patients present with cerebellar ataxia in early childhood and show a complex extrapyramidal 
movement disorder and oculomotor apraxia at an early stage in the course of the disease. 
Generally, patients are confined to a wheelchair from around the age of 10. Later in the course 
of the disease, both axonal polyneuropathy and motor neuron disease have been described.1 
Cognitive function remains relatively intact, although mild deficits have been reported. 
To date, the above mentioned description is still largely applicable to patients with a classic 
phenotype. However, we have demonstrated that a progressive axonal sensorimotor 
polyneuropathy is of greater clinical importance than was previously thought (Chapter 2.1). Signs 
of the peripheral neuropathy became discernible, both clinically and electrophysiologically, 
around the age that classical A-T patients became wheelchair-bound and this is therefore likely 
to contribute to losing the ability to walk. We felt that, due to the existing polyneuropathy, it 
was impossible to decide whether or not additional motor neuron disease may be part of the 
classical phenotype. The complexity of motor abnormalities in A-T hampered the determination 
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of the relative contribution of the abnormalities in the peripheral nervous system to respiratory 
failure. In contrast to the severe deterioration of motor functioning, we found no identifications 
of cognitive deterioration in the A-T patients studied in this cohort (Chapter 2.3). The patients 
were tested systematically, for the first time taking into account their complex movement 
disorder and oculomotor impairments. This study allowed us to demonstrate that cognitive 
and language functioning did not deteriorate, but that they were certainly not normal and 
leveled off at school age.
Moreover, in this thesis we demonstrated that patients with a milder phenotype often show a 
milder and essentially different neurological phenotype than classic A-T patients (Chapter 4). 
In patients with a milder phenotype, extrapyramidal signs, i.e. chorea-athetosis and a resting 
tremor, are commonly the presenting and dominating clinical sign. The disease onset ranges 
from as early as in classic A-T, to adulthood. Interestingly, we showed that a cerebellar syndrome 
either may be lacking or could develop years later in the course of disease. In some patients, 
anterior horn cell degeneration is predominant. This suggests that the basal ganglia, and 
possibly the anterior horn cells, may be more vulnerable to the pathophysiologic mechanisms 
that underlie A-T than the rest of the central nervous system, including the cerebellum. 
The neuropathological abnormalities observed in A-T patients are fairly stereotypical from 
patient to patient, although there is individual variation. Characteristic neuropathological 
findings include cerebellar atrophy, particularly of the cortex, degeneration of the posterior 
columns, specially of the gracile fascicle, and axonal degeneration of the peripheral nerves 
with subsequent muscle atrophy by the end of the first decade of life.1 With advancing age, 
neuropathological abnormalities progress and become more advanced and prominent. How 
the loss of ATM results in the neurodegenerative phenotype remains unclear.
The neuropathological abnormalities of two of our classic A-T patients, who died at the age of 
19 and 22 years old, are in line with the literature (Chapter 2.2). Interestingly, in both patients 
there was some neuronal loss of the anterior horns in the lumbar spinal cord. 
The neuropathological findings of the variant case, the first patient in the literature with 
a genetically confirmed diagnosis of variant A-T, were in general comparable with those 
reported in patients who survived into their fourth decade. The degenerative changes were 
somewhat milder, except for the anterior horn cell abnormalities. Apparently, anterior horn cell 
degeneration is a disease feature of both classical and variant A-T. It may be assumed that the 
muscle weakness due to anterior horn cell degeneration is clinically more impressive in milder 
A-T patients, as compared with classic patients in whom the earlier and more pronounced 
cerebellar and extrapyramidal symptoms may partly mask their muscle weakness.
Despite the presence of extrapyramidal symptoms and the long lifespan, no abnormalities 
were observed in the basal ganglia of all three patients. To date, only in mice studies has 
the loss of dopaminergic neurons in the substantia nigra and striatum been noted in ATM 
deficient animals.20 The mechanisms that contribute to the extrapyramidal symptoms remain 
unknown. 
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Besides telangiectasia, the non-neurological problems in A-T include pulmonary problems, 
immune dysfunction, the absence of a pubertal growth spurt, diabetes mellitus and the 
increased risk of malignancies.1 Survival is clearly decreased; classic A-T patients generally die 
in the second or third decade of life. The main causes of death are malignancy and respiratory 
failure.1,21 
This pattern is confirmed in our series of patients with classic A-T. Remarkably, established 
sinopulmonary infections in our A-T patients were relatively rare and opportunistic infections 
did not occur, despite their immune deficiency state. These observations raised the question 
of the extent to which infections contribute to the pulmonary problems. We observed classic 
A-T patients without any history of severe recurrent sinopulmonary infections, but with a 
progressive restrictive pulmonary function, which complicated mechanical ventilation and 
contributed to death (Chapter 3.1). The etiology of the restrictive pulmonary function is unclear. 
Some authors mention bronchiectasis and scarring due to recurrent pulmonary infections as 
possible causes.22,23 Although these conditions may contribute to the pulmonary restriction, 
they are in our opinion not the main cause. For example, in patients with cystic fibrosis who 
suffer from frequent lung infections, the majority develops primarily obstructive lung disease, 
whereas only 6% will develop a purely restrictive lung problem.24 Mechanical factors that lead 
to decreased chest wall compliance, e.g. scoliosis, dysfunction of the intercostal muscles and 
neuromuscular weakness, may also contribute to the restrictive lung function. The relevance 
of structural mechanical factors is supported by the presence of a small bell-shaped thorax in 
our patients, which impairs rib expansion and therefore contributes to restriction of the lungs. 
We hypothesize that intercostal muscle atrophy and growth retardation may contribute to this 
bell-shaped thorax deformity.
Unlike classic A-T, the non-neurological features are virtually absent in variant A-T patients. 
Only rarely do such features become apparent later in life (Chapter 4). Immunodeficiency, 
pulmonary problems or growth retardation of any clinical importance did not occur in any 
of our variant A-T patients. Diabetes mellitus type 2 (DM-2) was seen in only one extremely 
obese patient. The cancer risk is severely increased in variant A-T patients as compared with 
the general population, with a cancer incidence rate of 6.5 (95% CI 3.5-10.8) per 1000 person-
years.37 However, the cancer risk is significantly lower than in classical A-T (p=0.001); in this 
population the cancer incidence rate is 15.7 (95% CI 11.7-20.6) per 1000 person-years.37 In 
childhood, patients with classical A-T develop, almost exclusively, lymphoid tumors. It is less 
common for patients with variant A-T to develop lymphomas. The incidence rate for non-
lymphoid tumors is comparable (p=0.91) in classic and variant A-T patients, with an incidence 
rate of respectively 3.4 (95% CI 1.7-6.0) and 3.7 (95% CI 1.6-7.3) per 1000 person-years. In 
general, breast cancer is the most common solid tumor in A-T patients. They have a thirty 
fold increased risk of developing breast cancer.37 Notably, treatment of malignancies in A-T 
patients remains a challenge due to defective DNA repair in all somatic cells and consequently 
radiosensitivity of all organ systems. 
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Genotype-phenotype correlation for mutations in the ATM gene 
In 1996, Lakin et al. demonstrated that a high proportion of ATM-mutations, all non-sense 
and frame-shift mutations and some missence or splice-site mutations, result in the complete 
absence of ATM protein.25 Other, less frequent, missense as well as splice site mutations result 
in some residual ATM kinase activity remaining and therefore a milder phenotype.26
In the present thesis, we confirm that the complete absence of ATM protein results in the 
classical A-T phenotype. In addition, for the first time we show that the presence of some ATM 
protein, without kinase activity as detected in our assay, leads to lesser impairment of the 
immune system. The mechanism behind this has not been elucidated. We hypothesize that 
in-vivo the residual ATM protein still might show some kinase activity. Barone et al. reported 
variable levels of serine 1981 phosphorylation, but not of the down-stream targets in 50% of 
A-T patients with ATM protein but without detectable kinase activity.27 This suggests a subtle 
residual function of various mutant forms of ATM protein which might result in a somewhat 
better performance of the immune system. These protein do not improve the functioning of 
the nervous system.
The presence of some ATM protein with residual kinase activity as assessed in our assay 
definitely results in a milder A-T phenotype. We demonstrated that the neurologic phenotypic 
manifestations in these patients show a spectrum ranging from a childhood-onset disorder, 
with chorea-athetosis or cerebellar ataxia as the presenting symptom and loss of mobility 
from the end of the second decade of life, to a relatively mild adult-onset disorder, with a 
resting tremor as the main presenting symptom and preserved ability to walk (Chapter 2.2 
and Chapter 4). Moreover, we have shown that the severity of the neurological phenotype 
depends on the measured amount of residual ATM-kinase activity: a higher level of measured 
residual ATM-kinase activity leads to a less severe phenotype. Until now, none of the variant 
A-T patients displayed pulmonary dysfunction, immunodeficiency or growth retardation. This 
strongly suggests that residual ATM kinase activity, irrespective of the amount thereof, prevents 
the development of these features. However, we do not know wheter these features could 
become apparent later in life, whereas only one patient has been described who survived into 
the seventh decade of life.11 Our oldest patients are in their sixth decades of life. Unfortunately, 
long-term follow-up data on A-T patients are not available in the literature.   
The presence of particular mutations did not correlate with specific phenotypic features, e.g. 
the severity of the immunodeficiency, granulomas or malignancy. For example, IgA deficiency 
was only observed in one of the two sibs of two Dutch families (Chapter 4.2). 
Diagnosis
Recognizing A-T is difficult, particularly in patients with a milder phenotype. This is  illustrated 
by the long delay between the onset of symptoms and diagnosis in our patients with variant 
A-T (Chapter 4.1). However, an early diagnosis is important. Ignorance of the correct diagnosis 
may put the patient at risk, particularly because of the increased radiosensitivity, the possible 
22451_Mijke Verhagen binnenwerk.indd   136 10-07-2012   11:46:09
137
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
5.2
risk of developing cancer after radiodiagnostic procedures and the dreadful complications 
that may evolve after radiotherapy and radiomimetic drugs.
When to suspect A-T
Evidently, A-T has to be considered in children who present with cerebellar ataxia and 
telangiectasia. However, A-T should also be suspected in:
O  patients with unexplained evident or slowly progressive cerebellar ataxia that starts during 
childhood or in adulthood (Chapter 2.2);11,12,14,15,17
O  patients with otherwise unexplained young- or adult-onset extrapyramidal symptoms, i.e. 
resting and postural tremor, chorea-athetosis, dystonia, and myoclonic jerks (Chapter 4);13,17-19 
O  adults showing unexplained motor neuron disease (Chapter 4);16 
O  patients with unexplained sensory-motor axonal neuropathy;19
O  infants with IgA- and IgG-deficiency and normal or elevated IgM levels;28-32
O  infants with hematological malignancies, in particular lymphoid neoplasms;33
O  adults with mild neurological abnormalities and hematological or solid tumors, in particular 
leukemia, breast cancer (Chapter 4),27 hepatocellular carcinoma, thyroid carcinomas, and 
carcinomas of the parotid gland, stomach or ovarian;34-37
O  patients with mild neurological features who suffer unexpectedly severe side effects 
following cancer treatment (Chapter 4).11,38-41
We would like to stress that A-T should not be excluded when the classic characteristics, such as 
oculocutaneous telangiectasia, cerebellar ataxia, and immunoglobulin deficiency, are lacking. 
Screening for A-T is not difficult, because an elevated serum AFP level appears to be a highly 
sensitive and fairly specific diagnostic biomarker for this disease.
Differential diagnosis
The differential diagnosis of cerebellar ataxia, extrapyramidal syndromes and motor neuron 
diseases is broad. In this paragraph we highlight the diseases which mimic A-T most. Diseases 
which, at presentation, show some resemblance to (variant) A-T are other autosomal recessive 
cerebellar ataxias (ARCAs) for which Friedreichs ataxia is prototypical (reviewed in Manto and 
Marmolino, 2009)42.
The neurological phenotype of oculomotor apraxia type 2 (AOA2), a form of autosomal 
recessive cerebellar ataxia, resembles ‘variant’ A-T to a high degree. AOA2 patients usually 
present with a cerebellar syndrome in the second decade of life.43 In addition, the vast 
majority of AOA2 patients will develop a sensorimotor peripheral neuropathy. Oculomotor 
apraxia and extrapyramidal signs are occasionally present.43 Similar to A-T, AOA2 patients may 
have increased serum AFP levels at the time of diagnosis. Patients with AOA2 and patients with 
variant A-T do not have an immunodeficiency. In contrast to A-T patients, AOA2 patients are not 
susceptible to malignancies, and telangiectasia and increased radiosensitivity are lacking.43
The clinical features of the very rare disease ataxia-telangiectasia like disorder (ATLD), also 
known as MRE11 deficiency, are also similar to those of A-T. Patients with ATLD present with a 
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progressive cerebellar ataxia and oculomotor apraxia in early childhood.44 Later in the course 
of the disease, extrapyramidal symptoms may develop.44 However, disease onset is later and 
disease progression is slower than in classical A-T. As is the case with A-T, the peripheral blood 
shows an increased level of chromosome translocations involving chromosomes 7 and 14, 
and hypersensitivity to ionising radiation is present at the cellular level.45 ATLD patients show 
normal AFP and normal concentrations of total IgG, IgA and IgM.45 Other extra-neurological 
features such as telangiectasia and an increased cancer risk are also missing.44,45  
Work-up
When A-T is clinically suspected, ancillary testing should be performed to make the diagnosis 
more probable and finally to prove it. We propose the following diagnostic evaluation (Figure 
1).
Ancillary testing should start with an assay of serum AFP. AFP is increased in practically every 
symptomatic A-T patient; there are only a few (n = 5) reported cases with normal levels.11,46,47 If 
there is a (borderline) increase in AFP, chromosomal analysis involving at least 50 GTG-banded 
metaphases should be performed on lymphocytes. Until now, all A-T patients, even those 
with a milder phenotype, have shown spontaneous rearrangements of chromosome 7 and 
14 (Chapter 4).11,13,15,17,18,48 Testing of in-vitro radiosensitivity in lymphocytes or fibroblasts is a 
good alternative for the rearrangement studies, although it is good to note that in variant A-T, 
this test performed in lymphocytes may be normal. In the case of persistent clinical suspicion, 
the next test should be a Western blotting of ATM protein. Almost all classic and variant A-T 
patients show abnormal intensity of the ATM band on a Western blot.49 The final proof of the 
diagnosis, preferably should be ATM-gene mutation analysis combined with Western blotting 
of the ATM protein and measurement of ATM kinase activity. It is important to note that ATM-
gene mutation analysis is laborious and available only in dedicated centers.
Implications for follow-up and treatment
A-T is a complex, multisystem disorder. Therefore, we recommend follow-up and treatment of 
pediatric and adult A-T patients by a multidisciplinary team of specialists who are familiar with 
the problems encountered by A-T patients. Ideally, the multidisciplinary team should consist 
Table 1. Suggested annual ancillary diagnostics in patients with the classic A-T phenotype 
O blood count and smear
O glucose level
O lactate dehydrogenase measurement
O measurements of total IgG, IgG2, IgG4, IgA and IgM
O protein electrophoresis
O pulmonary function testing*
O sonography of the abdomen
O breast MRI** 
**from the age of four onwards
**from the age of 25 onwards
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of a (pediatric) neurologist, immunologist, pulmonologist, oncologist, and a rehabilitation 
specialist supported by a speech therapist, ergotherapist and physiotherapist. 
The suggestions for an annual follow-up program are summarized in Table 1 and 2 and Box 1.
In children, a periodic assessment of neuropsychological and language functioning is 
recommended. The complex movement disorder, including oral motor and oculomotor 
impairments, should be taken into account during the assessment. The crucial time points for 
such an assessment are the time of entry to nursery school, primary school and secondary 
education (Chapter 2.3). 
Figure 1. Flow chart for the diagnostic evaluation of patients with clinical suspicion of A-T
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At the time of diagnosis pulmonary function testing should be performed. If these results 
are abnormal it is recommended that this test should be repeated annually. By means of 
serial pulmonary function testing, subtle progression of pulmonary disease can be detected, 
even in the absence of clinical symptoms. Recent studies show that forced spirometry gives 
reproducible results in A-T patients when minor adjustments are made, i.e. stabilizing the 
patient’s head and watching for leakage around the mouthpiece.22,23 Mortality due to respiratory 
failure after mechanical ventilation of A-T patients is high (Chapter 3.1).50 In most A-T patients 
mechanical ventilation will be considered during life, because of respiratory distress or surgical 
interventions. Therefore, information about pulmonary function is essential before the start of 
mechanical ventilation as part of general anaesthesia during surgery or treatment at the ICU. If 
mechanical ventilation is unavoidable, forced weaning and early extubation is essential.
In patients with classic A-T, immunoglobulin levels should be checked at least once a year, 
since variability in immunodeficiency is common during the course of the disease. In our 
experience, a sudden abnormal increase or decrease in one or more of the immunoglobulines, 
or the appearance of a monoclonal gammopathy, could be the first signs of an evolving 
hematological malignancy. The rise of IgM also appears to be a poor prognostic sign. 
Table 2. Suggested annual ancillary diagnostics in patients with the milder A-T phenotype 
O blood count and smear
O lactate dehydrogenase measurement
O protein electrophoresis
O sonography of the abdomen
O breast MRI*
*from the age of 25 onwards
Box 1. Recommendations for follow-up and treatment of classical A-T patients
1.  Check the patient in an outpatient clinic every 6 to 12 months, preferably in a 
multidisciplinary A-T team.
2.  Perform a valid assessment of neuropsychological and language functioning from 
infancy; crucial time points are the time of entry to nursery school, primary school and 
secondary education. 
3.  Perform a pulmonary function test at the time of diagnosis and annually in classic 
A-T patients. Be aware of respiratory complications during intercurrent illnesses and 
operative procedures.
4. A hyper IgM phenotype is a poor prognostic sign.
5.  Changes in serum electrophorese pattern and immunoglobulin concentrations may 
indicate the development of lymphomas. 
6.  Screen for malignancies at least once a year i.e. history, physical examination and ancillary 
testing (see Table 1 and 2).
7.  Avoid examination through ionizing radiation and tailor-made radiomimetic 
chemotherapeutics and radiotherapy.
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Treatment with immunoglobulin replacement may be considered in patients with recurrent 
sinopulmonary infections and persistent hypogammaglobulinaemia. 
In patients with a classic phenotype, the development of DM-2 should be monitored by 
measuring blood glucose levels. So far, DM-2 seems not to develop more often in patients with 
residual ATM-kinase activity. 
Because of the increased risk of developing malignancies, A-T patients should be subjected to 
lifelong periodic screening for malignancies. Radiographic examinations should be avoided 
as much as possible. Physical examination should include palpation of the thyroid gland, 
breasts, liver and lymph nodes. Recommended ancillary laboratory testing consists of a blood 
count and smear, monitoring of lactate dehydrogenase and protein electrophoresis. An 
annual sonography of the abdomen should detect intra-abdominal lymphomas and primary 
or metastatic malignant liver disease. Because of the increased risk of breast cancer,37 we 
recommend – based on the National Comprehensive Cancer Network (NCCN) guidelines – an 
annual breast MRI for females from the age of 25 onwards. 
Treatment of malignancies is difficult in A-T due to the increased susceptibility to DNA-
damaging agents and radiotherapy, resulting in increased toxicity. Furthermore, treatment is 
complicated by the underlying immunodeficiency and the progressive impaired pulmonary 
function. When an A-T patient is diagnosed with cancer, we recommend consulting a member 
of the European I-BFM workgroup for DNA-repair disorders and cancer, or an oncologist who is 
familiar with this treatment in A-T. 
Future perspectives
Novel phenotypes?
As the number of variant A-T patients grows, it has become increasingly clear that A-T is a 
disease with a more widespread clinical spectrum than was originally assumed. The common 
denominator recognized so far in all patients seems to be the presence of neurological 
symptoms, i.e. extrapyramidal signs, a cerebellar syndrome or motor neuron disease (Chapter 
4.1). 
We presume that ‘the mildest A-T phenotypes’ have not yet been described. It may well be the 
case that patients with other movement disorders resembling Parkinson’s disease, or anterior 
horn cell degeneration, actually have A-T. It would be valuable to screen these patients for A-T 
by measurements of serum AFP or chromosomal analysis.
With more refined and more accessible diagnostic tools, it may even appear that malignancy 
may be the only symptom of an ATM-gene defect. In-vitro and in-vivo radiosensitivity is one 
of the disease characteristics of A-T. Therefore, it would be worthwhile to test all patients 
who develop severe complications after DNA-damaging drugs or radiotherapy, starting with 
measurements of AFP or chromosomal analysis.
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Identification of such milder A-T patients and studies of their genotypes and phenotypes 
may further increase the understanding of the spectrum of A-T and the functions of the 
ATM-protein. Furthermore, genotype-phenotype correlation studies might offer clues to the 
identification of possible modifier mechanisms that compensate for ATM-deficiency. In the 
literature, two sibs have been described who showed a milder neurological A-T phenotype, 
despite homozygosity for a truncating ATM mutation and the absence of ATM protein and 
kinase activity on immunoblotting and phosphorylation studies.49 Identifying comparable 
cases could be helpful in the identification of modifier  mechanisms which influence the 
phenotype and which could be important ta,rgets for therapeutic intervention.
Novel findings in ‘old disease’
Malignancies in A-T
Around 20 – 35 percent of A-T patients develop a malignancy, particularly non-Hodgkin’s 
lymphomas and leukemia in childhood or epithelial tumors at an older age.51,52 The influence 
of modifier genes and environmental factors has been suggested. 
Epstein-Barr Virus (EBV) is a well-known oncogenic virus, which is associated with tumor 
development including Hodgkin’s disease and non-Hodgkin’s lymphomas.53 EBV has also 
been implicated in carcinomas of the breast54,55 and thymus53,56. It has been reported that EBV 
infection plays a significant role in many, though not all, of the malignant lymphomas occurring 
in patients with primary immune deficiencies.57 Loss of immunological control of EBV-infected 
lymphocytes allows ongoing proliferation and malignant transformation, possibly promoted 
by defective immune regulation and chronic immune stimulation.57 Recently, an ATM/Chk2-
mediated DNA damage response has been identified as a major component of the EBV-induced 
innate tumor suppressor pathway.58 Therefore, EBV infection could be an important cofactor in 
the heterogeneity of developing malignancies in A-T patients. 
Pulmonary problems in A-T
Although pulmonary problems belong to the oldest disease hallmarks of A-T, the restrictive 
pulmonary function that we observed in patients without any residual ATM kinase activity is a 
novel finding (Chapter 3.1 and 4). Until now, the etiopathogenesis of the pulmonary problems 
in A-T, including the restrictive pulmonary function, has not been fully understood. We also 
demonstrate that neuromuscular problems develop in classic A-T patients at the end of the 
first decade of life (Chapter 2.1). It would be interesting to assess the neuromuscular function 
of the respiratory muscles and nerves, for example by means of electromyography, in order to 
evaluate the contribution of neuromuscular disease to the pulmonary problems.
We assume that respiratory muscle strength training improves the pulmonary function, and 
therefore the survival, of A-T patients. Recent studies showed improvements in inspiratory 
muscle strength, exercise performance and health-related quality of life in non-A-T patients with 
a restrictive pulmonary function after a period of respiratory muscle strength training.59,60
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A-T and progeric changes
Progeric changes are well known disease features of classic A-T.1 This makes the association 
of A-T with early ageing of increasing interest. It is not known if variant A-T patients have a 
predisposition to develop diseases of the elderly at a younger age, such as cataract, glaucoma, 
cardiovascular disease and Alzheimer’s disease. Therefore, we recommend to monitor even 
young A-T patients for these so called diseases of the elderly.
Novel therapies and prevention
To date, no curative strategy for A-T exists. Therefore, the greatest challenge will be the 
development of curative therapies. In this thesis it has been demonstrated that the presence 
of minimal amounts of residual kinase activity protects the patient against the most dreadful 
sympyoms. Therefore, the measurement of ATM protein and its kinase activity is an excellent 
diagnostic test for distinguishing between classic and variant A-T. Increased awareness of A-T 
is critical for a correct diagnosis and subsequently for proper patient care. An early diagnosis 
of A-T will protect the patient against complications of mechanical ventilation and against 
catastrophic side effects of radiomimetic chemotherapy or radiotherapy. The next challenge is 
to find therapies to restore (minimal) amounts of ATM kinase activity.
Mutation-targeted therapies
Perhaps the most promising therapy for A-T is mutation-targeted therapy. Shuch therapy may 
be of help in compound heterozygote A-T patients. The in-vitro restoration of some functional 
ATM protein has been reported in cell lines of patients with specific non-sense and splice site 
mutations.61,62 A similar approach has shown to be promising in a phase 1-2a study in patients 
with Duchenne’s muscular dystrophy.63 Hopefully comparable results can be achieved with this 
approach in relation to A-T. The fact that we have demonstrated that even minimal amounts of 
ATM protein with kinase activity greatly improve the length and quality of life strongly support 
further development of these approach. 
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(adapted from/bewerkt naar) Ataxia teleangiëctasia: het klinische spectrum. Tijdschrift voor 
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Inleiding
AT is een zeldzame autosomaal recessieve multisysteemaandoening, met in Nederland een 
incidentie van ongeveer 1 op de 180.000. De ziekte wordt gekenmerkt door neurodegeneratie, 
met name van het cerebellum, oculocutane teleangiëctasieën, immuundeficiëntie en 
predispositie voor maligniteiten. De aandoening wordt veroorzaakt door mutaties in het 
‘AtaxiaTelangiectasia Mutated’ (ATM)-gen, dat codeert voor het eiwit ATM kinase (ATM).6,10 
Dit eiwit speelt een belangrijke rol bij de reparatie van DNA-schade en bij controle van de 
celcyclus.3 Patiënten met klassieke AT presenteren zich rond de leeftijd van anderhalf jaar met 
een cerebellaire ataxie en hebben een ernstig progressief ziektebeeld dat rond het tiende 
levensjaar leidt tot rolstoelafhankelijkheid en altijd de oorzaak is van vroegtijdig overlijden. 
De laatste jaren is er een kleinere groep patiënten beschreven, de zogenoemde variant AT 
patiënten, met een minder ernstig ziektebeloop met een minder ernstig fenotype, langzamere 
ziekteprogressie en een beduidend langere overlevingsduur.11,13-16,18,48,49,64-66 
Kliniek
Klassiek fenotype
De 3 zogenoemde ‘hallmarks’ van AT zijn een cerebellaire ataxie, oculocutane teleangiëctasieën 
en recidiverende luchtweginfecties.1 Klassieke AT patiënten presenteren zich rond de leeftijd 
waarop ze gaan lopen met een gang- en rompataxie. De ataxie is langzaam progressief, 
maar wordt vaak tot het vijfde levensjaar gemaskeerd door een initieel normale motorische 
ontwikkeling.1 Vanaf de leeftijd van ongeveer 6 jaar toont de MRI-scan afwijkingen in de zin van 
een progressieve cerebellaire atrofie. Klassieke AT patiënten worden rond de leeftijd van 10 jaar 
rolstoelafhankelijk. Neuropathologisch onderzoek toont dan onder meer ernstige cerebellaire 
atrofie, met vooral aantasting van de vermis en verlies van een groot deel van de Purkinje cellen 
en in mindere mate van de korrelcellen. Oculaire teleangiëctasieën ontstaan typisch tussen 
het 2de en 8ste levensjaar (zie Figuur 1, Hoofdstuk 1). Daarnaast kunnen cutane teleangiëctasieën 
ontstaan op de aan zon blootgestelde huidgebieden.1 De derde ‘hallmark’, recidiverende 
luchtweginfecties, is in 1957 door Boder en Sedgwick aan het ziektebeeld toegevoegd, maar 
dit kenmerk geldt niet voor iedere AT patiënt. De meeste klassieke AT patiënten hebben 
stoornissen in de humorale en/of cellulaire afweer. Tussen de ernst en frequentie van de 
infecties en de ernst van de afweerstoornis is echter geen relatie aangetoond.67
Het neurologische beeld van AT patiënten is complex. De meeste klassieke patiënten 
hebben naast een cerebellair syndroom ook extrapyramidale bewegingsstoornissen, met 
name progressieve choreo-athetose, dystonie en myoclonieën.1,68 Alle patiënten hebben 
progressieve oculomotore apraxie. Verder is vanaf de leeftijd van 8 jaar een progressieve 
axonale sensomotore polyneuropathie waarneembaar (Hoofdstuk 2.1). Deze polyneuropathie 
kan zodanig ernstig zijn dat er geen uitspraken kunnen worden gedaan over additioneel 
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voorhoornlijden (Hoofdstuk 2.1). Bij neuropathologisch onderzoek zijn er aanwijzingen dat de 
voorhoorncellen tevens degenereren (Hoofdstuk 2.2).
Ten slotte is in de eerste publicaties over AT regelmatig mentale retardatie beschreven. 
Bij neurocognitief onderzoek, waarbij rekening gehouden werd met de complexe 
bewegingsstoornissen van de patiënten en de oculomotore beperkingen, vonden wij geen 
aanwijzingen voor cognitieve achteruitgang. Echter, vanaf de schoolleeftijd werd er ‘levelling 
off’ van de cognitieve functie en de spraak-taalontwikkeling waargenomen (Hoofdstuk 2.3). 
Andere belangrijke niet-neurologische kenmerken zijn een verhoogd risico op maligniteiten, 
een progressieve restrictieve longfunctiestoornis (Hoofdstuk 3.1) en endocriene stoornissen.1 
AT patiënten hebben een 50 tot 100 maal verhoogd risico op het krijgen van kanker in 
vergelijking met leeftijdsgenoten; 10-30% van hen zal gedurende het leven een maligniteit 
ontwikkelen.67,68 Meestal betreft dit T- celleukemieën of lymfomen.67 Opvallende endocriene 
stoornissen zijn het ontbreken van een groeispurt tijdens de puberteit, het optreden van 
ovariële dysgenesie en het ontwikkelen van diabetes mellitus als jong volwassene. 
De meeste patiënten overlijden in de tweede of derde decade ten gevolge van maligniteiten 
en/of respiratoire insufficiëntie. 
Variant fenotype
Sinds het ATM-gen in 1995 bekend is geworden, zijn er meerdere AT patiënten in de literatuur 
beschreven met een meer gematigd fenotype.11,13-16,18,49,66 
In dit proefschrift wordt voor het eerst beschreven, dat het klinische beeld van patiënten met 
variant AT, in tegenstelling tot klassieke AT, vaak niet gedomineerd wordt door een cerebellaire 
ataxie, naar door extrapyramidale verschijnselen, eventueel in combinatie met voorhoornlijden 
16 (Hoofdstuk 4.1 en 4.2). De meeste patiënten presenteren zich op de kinderleeftijd met 
een choreo-athetose of als (jong) volwassenen met een rusttremor. De ataxie ontbreekt of 
ontstaat pas jaren later: vaak op jongvolwassen leeftijd (Hoofdstuk 4.1). De ziekteprogressie 
is langzaam, de meerderheid van de variant AT patiënten kunnen nog zonder hulpmiddelen 
lopen op volwassen leeftijd (Hoofdstuk 4.1 en 4.2). Bij de meeste volwassen patiënten zijn 
dyskinesieën, oculomotore apraxie, nystagmus, een rusttremor en voorhoornlijden aanwezig. 
Verder kan een axonale sensomotore polyneuropathie voorkomen, eventueel in combinatie 
met voorhoornlijden (Hoofdstuk 4.1 en 4.2). Bij de meeste volwassen variant AT patiënten 
worden geen afwijkingen op een MRI-scan van het cerebrum gezien (Hoofdstuk 4.1). De 
bevindingen bij neuropathologisch onderzoek van één variant AT patiënt waren vergelijkbaar 
met de gevonden neurodegenerative afwijkingen bij klassieke AT patiënten, echter milder van 
aard, behoudens de afwijkingen in de voorhoorncellen (Hoofdstuk 2.2). 
Ten slotte valt op dat deze patiënten geen longfunctie, endocriene of afweerstoornissen 
hebben. Tot op heden is geen verhoogd risico op het ontwikkelen van diabetes mellitus of 
groeiretardatie gevonden. Bovendien wordt op volwassen leeftijd bij circa de helft van de 
patiënten maar een lichte vorm van oculaire teleangiëctasiëen gezien (Hoofdstuk 4.1 en 4.2). 
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Voorts is de overlevingsduur beduidend langer, in het Nederlandse cohort werd een mediane 
overleving van 36 jaar gevonden (Hoofdstuk 4.2). 
Patiënten met variant AT hebben een ernstig verhoogd risico op het ontwikkelen van 
maligniteiten in vergelijking met de algehele populatie, de kanker incidentie ratio bedraagt 
6.5 (95% BI 3.5-10.8) per 1000 levensjaren.37 Het risico op het ontwikkelen van een maligniteit 
is echter significant lager dan bij klassieke AT patiënten (p=0.001).37 In tegenstelling tor 
klassieke AT patiënten ontwikkelen variant AT patiënten voornamelijk solide tumoren. De 
meest voorkomende vorm van kanker is borstkanker: variant AT patiënten hebben een 30 
maal verhoogd risico op het krijgen deze vorm van kanker in vergelijking met de algehele 
populatie.37
Pathogenese
AT ontstaat ten gevolge van mutaties in het ATM-gen. Dit is een groot gen, dat bestaat uit 
66 exonen. Tot op heden zijn meer dan 400 verschillende mutaties beschreven, die verspreid 
liggen over het gehele gen, er zijn geen zogenaamde ‘mutatie hotspots’.69
Het ATM-gen behoort tot de groep van phosphatidylinositol-3-kinase (PI3K)-gerelateerde 
genen, die van belang zijn bij DNA reparatie en celcycluscontrole.67 Het ATM-eiwit is betrokken 
bij het herkennen van dubbelstrengs-DNA breuken en wordt geactiveerd als er breuken in het 
DNA zijn ontstaan.69
Klassiek versus variant fenotype
Zowel AT patiënten met een klassiek als met een variant fenotype zijn zogenoemd compound 
heterozygoot of homozygoot voor een mutatie in het ATM-gen. Klassieke AT wordt echter 
veroorzaakt door mutaties in het ATM-gen die grotere functionele consequenties hebben voor 
het ATM-eiwit: bij deze patiënten is de ATM-kinaseactiviteit geheel afwezig3 (Hoofdstuk 4.2). 
Variant AT wordt geassocieerd met missense en splice-sitemutaties die leiden tot expressie van 
resteiwit met nog enige restactiviteit.3 Hoe meer resteiwit c.q. restactiviteit, hoe minder ernstig 
het (neurologische) klinische beeld lijkt te zijn3 (Hoofdstuk 4.1 en 4.2). 
Wanneer dient aan AT gedacht te worden?
Bij kinderen met een cerebellaire ataxie en teleangiëctasieën wordt vaak al snel aan de 
daignose AT gedacht. Echter, er dient ook aan AT gedacht te worden bij:
O  patiënten met een onverklaarde (langzaam) progressieve cerebellaire ataxie onafhankelijk 
van de debutleeftijd.11,12,14,15,17 
O  patiënten met een onverklaarde extrapyramidale bewegingsstoornis.13,17-19
O  volwassenen met onverklaard voorhoornlijden16 (Hoofdstuk 4.1 en 4.2) 
O  patiënten met een onverklaarde sensomotore axonale polyneuropathie.19
O  zuigelingen met een IgA- en IgG- deficiëntie en een normale of verhoogde IgM 
concentraties.28-32
O  zuigelingen met een hematologische maligniteit, in het bijzonder lymfoide tumoren.33
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O  volwassenen met milde neurologische afwijkingen en een hematologische of solide tumor, 
in het bijzonder leukemie en borst kanker27 (Hoofdstuk  4.1 en 4.3).
O  patiënten met milde neurologische afwijkingen en onverwacht ernstige complicaties 
tijdens of na de behandeling van een maligniteit (Hoofdstuk  4.1 en 4.2).11,38-40
AT dient toch overwogen te worden als klassieke ziektekenmerken zoals oculocutane 
teleangiëctasieën, cerebellaire ataxie en immunoglobuline deficiëntie ontbreken (Hoofdstuk 
5.2).  
Diagnostiek
Het diagnostische traject dat doorlopen dient te worden bij klinische verdenking op AT 
(Hoofdstuk 5.2) is samengevat in Figuur 1.
Bij verdenking op de diagnose AT is het bepalen van de serum AFP-concentratie de eerste keus 
voor aanvullend onderzoek. Bij een atactisch kind is een verhoogde AFP-concentratie vanaf 
de leeftijd van 8 maanden vrijwel bewijzend voor de diagnose ‘klassiek AT’.70 AFP is tevens een 
betrouwbare marker gebleken bij (symptomatische) variant AT patiënten (Hoofdstuk 4.1). In 
geval van een normale AFP-serumconcentratie dient ‘ataxie met oculomotore apraxia type 1 
(‘ataxia-ocular apraxia type 1’; AOA1)’ in de differentiaaldiagnose te staan. Bij patiënten met 
een variant fenotype, waarbij een verhoogde AFP-waarde wordt gevonden, dient naast AT 
ook de diagnose ‘ataxie met oculomotore apraxia type 2 (AOA2)’ overwogen te worden. Het 
achterliggende mechanisme van de verhoogde AFP-serumconcentratie in AT is tot op heden 
onbekend.71 In afwezigheid van AT, kan AFP ook een marker zijn voor leveraandoeningen, zoals 
het hepatocellulair carcinoom of chronische hepatitis, en kiemceltumoren. 
Naast bepaling van de concentratie AFP in het serum kan cytogenetisch onderzoek worden 
verricht. Aanvullend cytogenetisch onderzoek verdient sterke aanbeveling bij een hoge 
klinische verdenking op variant AT, onafhankelijk van de gevonden AFP-waarde. Zowel 
bij patiënten met een klassiek als variant fenotype worden in lymfocyten karakteristieke 
rearrangements, translocaties en inversies, in chromosoom 7 en/of 14 gevonden (Hoofdstuk 
4.1 en 4.2). Bovendien hebben lymfocyten van klassieke AT patiënten een hogere 
stralingsgevoeligheid dan cellen van gezonde personen. Daardoor tonen deze cellen na 
blootstelling aan ioniserende straling in vitro duidelijk meer chromosomale afwijkingen dan 
Tabel 1. Aanbevolen jaarlijks aanvullend onderzoek bij patiënten met klassiek AT 
O Volledig bloedbeeld met differentiële witte bloedceltelling
O Serum glucose waarde
O Lactaat dehydrogenase 
O Totaal IgG, IgG2, IgG4, IgA en IgM
O Eiwitelektroforese
O Longfunctieonderzoek*
O Echo abdomen
O MRI van de mammae**
*’vanaf de leeftijd van 4 jaar
**’vanaf de leeftijd van 25 jaar 
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gezonde cellen. Deze stralingsovergevoeligheid is in lymfocyten bij variant AT patiënten 
minder uitgesproken en kan bij hen zelfs geheel afwezig zijn (Hoofdstuk 4.2). Daarnaast bestaat 
een verhoogde stralingsgevoeligheid in fibroblasten van AT patiënten met zowel een klassiek 
als variant fenotype. Bovenstaande afwijkingen bij cytogenetisch onderzoek worden niet bij 
AOA1 en AOA2 patiënten gevonden.65
Bij klassieke AT patiënten is het vinden van afwijkingen in het immuunsysteem ondersteunend 
voor de diagnose. De meest voorkomende humorale afweerstoornissen zijn verlaagde of niet-
detecteerbare serum concentraties van IgG2, IgA en/ of IgE in combinatie met normale of 
verhoogde IgM-waarden.1 
Figuur 1: stroomdiagram voor aanvullend onderzoek bij patiënten met verdenking op AT
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De diagnose AT kan bewezen worden met behulp van ATM-mutatieanalyse; dit onderzoek wordt 
in het Antoni van Leeuwenhoek ziekenhuis/ het Nederlands Kanker Instituut verricht. Gegeven 
de grootte van het gen (66 exonen) en het ontbreken van ‘hotspots’ kan ATM-mutatieanalyse 
redelijkerwijs niet screenend gebruikt worden. Eventueel kan in buitenlandse laboratoria de 
hoeveelheid ATM-eiwit en de kinaseactiviteit bepaald worden op onderzoeksbasis.
Therapie  
De behandeling van AT richt zich momenteel met name op symptomatische behandeling, 
omdat curatieve behandeling niet mogelijk is. Gezien de complexiteit van het ziektebeeld is 
het aan te bevelen AT patiënten te vervolgen in een multidisciplinair team. 
De aanbevelingen voor jaarlijks aanvullend onderzoek zijn samengevat in Tabel 1 en 2.
Bij kinderen met AT wordt aanbevolen periodiek neurocognitief onderzoek te verrichten, 
hierbij dient rekening gehouden te worden met de motore en oculomotore beperkingen. 
Belangrijke tijdstippen om een dergelijk assessment uit te voren zijn: voor start op de kleuter-, 
basis- en middelbare school (Hoofdstuk 2.3).
Indien een patiënt recidiverende infecties heeft, kan antibioticaprofylaxe gegeven worden. 
In geval van hypogammaglobulinemie kan immunoglobulinesubstitutie gestart worden. De 
immuunglobuline concentraties dienen bij voorkeur jaarlijks gecontroleerd te worden. Snelle 
daling of stijging van immuunglobuline kunnen de eerste tekenen van een hematologische 
mailigniteit zijn. Een hyperIgM-syndroom is een slecht prognostische factor. Deze patiënten 
hebben een grotere kans op het ontwikkelen van huidgranulomen (Hoofdstuk 3.2).
Blootstelling aan ioniserende straling (onder andere ten behoeve van diagnostiek, zoals 
X-thorax en CT-scans) moet tot het minimum beperkt worden.
Voor vroege opsporing van maligniteiten bij AT patiënten is goede follow-up van  belang. In 
geval van maligniteiten moet een aangepaste behandeling gestart worden met gereduceerde 
doseringen radiotherapie (eventueel zelfs zonder radiotherapie) en met aangepaste doseringen 
chemotherapeutica. 
Een belangrijke doodsoorzaak bij patiënten met klassiek AT is respiratoir falen. Aanbevolen 
wordt jaarlijks longfunctieonderzoek te verrichten. Indien de longfunctie ernstig restrictief 
gestoord blijkt te zijn, dient hiermee rekening gehouden te worden als kunstmatige beademing 
overwogen wordt, bijvoorbeeld in geval van een voorgenomen operatie of bij respiratoire 
insufficiëntie. Vroege extubatie en geforceerde ‘weaning’ is dan van belang (Hoofdstuk 3.1). 
Tabel 2. Aanbevolen jaarlijks aanvullend onderzoek bij patiënten met variant AT
O Volledig bloedbeeld met differentiële witte bloedceltelling
O Lactaat dehydrogenase 
O Eiwitelektroforese
O Echo abdomen
O MRI van de mammae*
  *’vanaf de leeftijd van 25 jaar
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Conclusie
De diagnose ‘AT’ moet niet alleen bij kinderen met een cerebellaire ataxie en eventueel 
teleangiëctasieën overwogen worden, maar ook bij patiënten met onverklaarde extrapiramidale 
verschijnselen, onafhankelijk van de debuutleeftijd. Nu wordt de diagnose ‘AT’ bij patiënten 
met een variant fenotype vaak laat – en soms helemaal niet – gesteld door het mildere en 
atypische ziektebeloop. 
Indien de diagnose ‘AT’ overwogen wordt, verdient het aanbeveling om de AFP- 
serumconcentratie te bepalen; dit is zowel bij klassieke als variant AT patiënten een belangrijke 
ziektemarker.  Bij een hoge klinische verdenking op de diagnose AT, maar een variant fenotype 
en/ of een (rand)normale AFP-serumconcentratie, verdient het aanbeveling cytogenetisch 
onderzoek te verrichten voordat mutatieanalyse wordt aangevraagd. 
Een vroege en correcte diagnose van klassiek en variant AT is van belang voor adequate 
begeleiding, herhaaldelijke oncologische screening, erfelijkheidsadvies en therapie. Bij AT 
patiënten dient onder meer rekening gehouden te worden met het verhoogde risico op 
maligniteiten en de stralingsovergevoeligheid. Vanwege dit laatste moet blootstelling aan 
ioniserende straling tot het minimum beperkt blijven. Daarnaast moet bij klassieke AT patiënten 
rekening gehouden worden met de restrictief gestoorde longfunctie, welke behandeling met 
kunstmatige beademing ernstig kan compliceren.
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Patients in this thesis
patient family gender year age pheno- chapters in this thesis
   of  of type
   birth death  2.1 2.2 2.3 3.1 3.2 4.1 4.2
1 I M 1957 51 variant      v3 21.III
2 I M 1962  variant      v2 21.I
3 I M 1963  variant      v1 21.II
4 II F 1958  variant      v12 20
5 III F 1958  variant      v11 26
6* IV M 1959 33 variant  pt 2
7 V F 1960  variant      v13 24
8* VI M 1962 19 classical  pt 1
9 VII F 1962 27 classical      c5 16
10 VII F 1962 47 variant      v10 37
11 VIII M 1964 14 classical       12.II
12 VIII M 1972 27 classical P13   A  c4 12.I
13 IX F 1964  classical?**       32.II
14 IX F 1965  classical?**       32.I
15 X M 1969 23 variant      v6 19,II
16 XI F 1975  variant      v7 19.I
17 XI M 1970 40 classical      c6 4
18 XII M 1971 10 classical       15.II
19 XIII F 1979 21 classical P12     c1 15.I
20 XIII F 1971  variant      v9 36
21 XIV F 1972  variant      v5 18.II
22 XV M 1975  variant      v4 18.I
23 XV F 1974  variant      v8 22
24 XVI F 1979 11 classical       5.II
25 XVI F 1985 n.a. classical       5.I
26 XVII M 1979  classical       11.II
27 XVIII F 1986  classical       11.I
28 XVIII M 1979 17 classical       31
29 XIX M 1980 26 classical P11     c3 17.II
30 XX F 1994 9 classical       17.I
31 XXI M 1980 n.a. classical       35
32 XXII F 1982 15 classical       25
33 XXIII F 1983 23 classical P10 pt3  B  c2 2
34 XXIV M 1983 9 classical       27
35 XXIV M 1985 17 classical       28
36 XXIV M 1989 10 classical       7.III
37 XXV F 1998  classical       7.II
38 XXVI F 2001 10 classical     Pt 3  7.I
39 XXVII F 1989  classical       29
40 XXVIII M 1992  classical P7  No 2    6
41 XXIX F 1992  classical P9  No 1    10
42 XXX F 1992 14 classical P8    Pt 1  33
43 XXXI M 1993  classical   No 3    9
44 XXXII M 1993 13 classical P6   C Pt 2  30
45 XXXIII M 1994  classical P5  No 4    1
46 XXXIV M 1994 16 classical       38
47 XXXV M 1996  classical P4  No 5    23
48 XXXVI F 1998  classical       34
49*** XXXVI F 1998  classical     Pt 4
50 XXXVII F 1999 9 classical       3
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Patients in this thesis  continued
patient family gender year age pheno- chapters in this thesis
   of  of type
   birth death  2.1 2.2 2.3 3.1 3.2 4.1 4.2
51 XXXVIII M 1999  classical P3  No 7    14.I
52 XXXIX F 2004 4 classical P1  No 8    14.II
53 XXXX M 2001  classical P2  No 6    8
54 XXXXI F 2001  classical       13
* patients from Belgium
** phenotype cannot be determined with certainty, not enough data available
*** patients from Iceland
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kindergeneeskunde, neurologie en huisartsgeneeskunde. 
Beste leden van de manuscriptcommissie, Prof. dr. Ronald de Groot, prof. dr. Oebo Brouwer, dr. 
Ineke van der Burgt, prof. dr. Asgeir Haraldsson en dr. Bart van de Warrenburg, hartelijk dank voor 
het beoordelen van dit proefschrift.
Anne, Ellen, Henke, Jolanda, Karien, Loes, Marjolein, Mirjam, Nicole, Renate en Yvet. Bedankt 
dat jullie altijd voor mij klaar stonden. Als ik even zin had in een kop thee, samen lunchen of 
dineren, was er altijd wel één van jullie die tijd had! 
Ellen, ik voel me vereerd dat jij op deze bijzondere dag mijn paranimf wilt zijn.
Mijn ouders. Guido en Heleen, bedankt voor de mogelijkheden die jullie ons altijd gegeven 
hebben! Jullie staan altijd voor mij klaar en altijd kan ik bij jullie terecht, veel dank hiervoor. 
Luke, mijn paranimf, super dat je aan mijn zijde wilt staan. Jij bent mijn oudere broer met altijd 
wijze adviezen. Heidi, altijd even attent. Bedankt voor alle lieve kaartjes en gezellige afspraken. 
Ook Sjoerd, Wim, Jeanne, Tom, Willem, Lisan en Kim, bedankt voor alle steun en interesse. 
Koen, altijd probeerde je mij te stimuleren om toch dat leerboek te pakken of even aan mijn 
onderzoek te werken. Altijd sta je met raad en daad voor mij klaar. Bedankt voor je steun, 
begrip en liefde. Ik ben stapelgek op jou…
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DANKWOORD
Tot slot wil ik de A-T stichting bedanken voor de steun. Dankzij jullie kon ik mij gedurende 
bijna één jaar volledig op het onderzoek naar A-T richten. Jullie inzet voor de patiënten en hun 
familie is bewonderenswaardig. Met hart en ziel zetten jullie je in om het ziektebeeld betere 
herkenning en bekendheid te geven in Nederland. Daarnaast steunen jullie zowel nationaal 
als internationaal onderzoek naar A-T. Petje af hiervoor en ga zo door! Hartelijk dank voor het 
vertrouwen die jullie mij/ ons geschonken hebben.
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